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Abstract
Psychiatric illnesses are debilitating conditions for those affected and place a
significant burden on the National Health Service, the social services and the family.
Here I describe genetic analysis, physical mapping and transcript mapping of a
region of chromosome 4p that is linked to psychiatric illness, including bipolar and
unipolar affective disorders and schizophrenia.
I have studied four families that show linkage of psychiatric illness to chromosome
4p. Linkage was first observed in a large family, F22, segregating bipolar affective
disorder (BPAD) and recurrent major depression (RMD). Subsequently, a smaller
family, F59, segregating affective disorders (Blackwood et al, 1996a), and two
families (F50 & F48) segregating schizophrenia (SCZ), schizoaffective disorder and
BPAD confirmed this linkage.
Previously, comparison of the haplotypes inherited with illness in each family
allowed prioritisation of two sub-regions for detailed study. Minimal Region One
(MR1) is defined by overlap of the disease chromosomes from three Celtic families
(F22, F59 & F50). Minimal Region Two (MR2) is defined by the two largest
families F22 and F48, as well as F50. The sequence available from the human
genome sequencing project for these two regions is largely complete. Here, I
describe an extension to the BAC map in the repetitive telomeric end ofMR1. The
telomeric end ofMR1 is defined by a recombination event in an individual from F50.
I mapped clones, designed markers and refined the position of the recombination
breakpoint. I also refined the position of the recombination breakpoint at the
centromeric end ofMR1, as defined by a member of F59.
I describe construction of a transcript map ofMR land 2 using bioinformatics
methods, RT-PCR and cDNA library screening. I then selected two candidate genes
from this region: orphan g-protein-coupled receptor 78 (GPR78) and superoxide
dismutase 3 (SOD3), for further study. Firstly, I identified SNPs in the genes from
the linked families, and then carried out a preliminary association study on 95 SCZ
in
patients, 93 BPAD patients 95 controls. The linkage disequilibrium (LD) between the
markers was measured and, using a low stringency significant p-value cut off,
revealed a positive association in GPR78. SNPs were then tested on a larger
population for association. This work adds to the case for studying the role of
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1.1. Psychiatric Illness: The Clinical Picture
1.1.1. Phenotypes and Diagnosis
Attempts to distinguish and classify psychosis and disorders ofmood extend back
several thousand years to Hippocrates (ca 460-377 B. C.). However, it wasn't until
the late nineteenth century and the early twentieth century that the discipline of the
diagnosis ofmental illness established itself. Emil Kraepelin, regarded as the founder
of the discipline, distinguished four different sub-types of 'dementia praecox', or
schizophrenia, from 'manic-depressive insanity', which grouped together single
episode depression, recurrent major depression (RMD) and bipolar affective disorder
(BPAD) (Shean, 2004). Classification systems have changed and evolved over the
years and are still open to debate even today.
Today, the most commonly used diagnostic criteria are the Diagnostic and Statistical
Manual ofMental Disorders (DSM) (American Psychiatric Association, 2000), the
Research Diagnostic Criteria (RDC) (Spitzer et al, 1978) and the Classification of
Mental and Behavioural Disorders (ICD) (World Health Organisation, 1992). DSM is
currently revising its 4lh edition (DSM-IV-RT), and ICD has published its 10th. The
reliability of the current diagnostic systems is open to debate since diagnosis can vary
between psychiatrists, countries and measures used (Janca, 2001; Bertelsen, 2002;
Benazzi, 2003b). Figures 1-1, 1-2 and 1-3 detail the core diagnostic criteria used to
diagnose RMD, BPAD and schizophrenia using the DSM-IV-RT manual.
Bipolar affective disorder is characterised by episodes of mania and depression. The
pervading effect is on mood, not cognition. However, the manic phase ofBPAD can
disturb cognitive processes such as decision making and reasoning. DSM-IV-RT
(American Psychiatric Association, 2000) classifies BPAD into four categories.
Patients with BPAD I disorder have had a full manic episode and usually major
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depression, where as patients with BPAD II disorder have a milder form ofmania
with episodes ofmajor depression. A mixed disorder consists of symptoms that meet
the criteria for both a manic episode and a major depressive episode nearly every day.
Finally, cyclothymic disorder is distinguished by the absence of depression, but
bipolar I or II will eventually develop in 15-30 % ofpatients (Manning et al, 1998).
The life time population prevalence of BPAD is 1.2% (Weissman, 1991), although
higher rates of -4% have been observed (Angst, 1995). The age of onset for BPAD is
generally ten years earlier than RMD, usually between adolescence and 30 years
(Angst and Sellaro, 2000). Episodes of un-medicated mania and depression have
been estimated to last from six months to a year and the median cycling is 18 months.
Residual symptoms are common between cycles and the proportions ofmania and
depression remain stable into old age (Angst and Sellaro, 2000).
DSM-IV-RT Diagnostic criteria for major recurrent depressive disorder
A. Presence of two or more major depressive episodes.
Note: To be considered separate episodes, there must be an interval of at least 2
consecutive months in which criteria are not met for a major depressive episode.
B. The major depressive episodes are not better accounted for by schizoaffective disorder
and are not superimposed on schizophrenia, schizophreniform disorder, delusional disorder,
or psychotic disorder Not Otherwise Specified.
C. There has never been a manic episode, a mixed episode, or a hypomanic episode. Note:
This exclusion does not apply if all of the manic-like, mixed-like, or hypomanic-like episodes
are substance or treatment induced or are due to the direct physiological effects of a general
medical condition.
Figure 1-1: The diagnostic criteria for recurrent major depression. Adapted from The
Diagnostic and Statistical Manual of Mental Disorders, (American and Psychiatric




DSM-IV-RT Diagnostic criteria for bipolar I disorder
At least one Manic or Mixed episode, but there may be Hypomania or Major Depression as
well.
Manic episode:
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood,
lasting at least 1 week.
B. Three (or more) of the following symptoms have persisted:
(1) inflated self-esteem or grandiosity
(2) decreased need for sleep (e.g., feels rested after only 3 hours of sleep)
(3) more talkative than usual or pressure to keep talking
(4) flight of ideas or subjective experience that thoughts are racing
(5) distractibility (i.e., attention easily drawn to unimportant or irrelevant stimuli)
(6) increase in goal-directed activity or psychomotor agitation
(7) excessive involvement in pleasurable activities that have a high potential for painful
consequences (e.g. buying sprees, sexual indiscretions, foolish investments)
Major depressive episode:
A. Five (or more) of the following symptoms have been present for 2-weeks and at least one
of the symptoms is either (1) or (2).
(1) Depressed mood most of the day, nearly every day, as indicated by either subjective
report (e.g., feels sad or empty).
(2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day,
nearly every day.
(3) Significant weight loss or weight gain, or decrease or increase in appetite nearly every
day.
(4) Insomnia or hypersomnia nearly every day.
(5) Psychomotor agitation or retardation nearly every day.
(6) Fatigue or loss of energy nearly every day.
(7) Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
(8) Diminished ability to think or concentrate, or indecisiveness, nearly every day.
(9) Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a
suicide attempt or a specific plan for committing suicide
Figure 1-2: The diagnostic criteria for bipolar affective disorder I. Adapted from The
Diagnostic and Statistical Manual of Mental Disorders, (American and Psychiatric
Association, 2000, 4th edition, text revision).
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DSM-IV-RT diagnostic criteria for schizophrenia
A. Characteristic symptoms:
Two (or more) of the following. Only one Criterion A symptom is required if delusions are
bizarre or hallucinations consist of a voice keeping up a running commentary on the person's
behaviour or thoughts, or two or more voices conversing with each other.
(1) delusions
(2) hallucinations
(3) disorganized speech (e.g., frequent derailment or incoherence)
(4) grossly disorganized or catatonic behaviour
(5) negative symptoms, i.e., affective flattening, alogia, or avolition
B. Social/occupational dysfunction:
For a significant portion of the time since the onset of the disturbance, one or more major
areas of functioning such as work, interpersonal relations, or self-care are markedly below
the level achieved prior to the onset (or when the onset is in childhood or adolescence, failure
to achieve expected level of interpersonal, academic, or occupational achievement).
C. Duration:
Continuous signs of the disturbance persist for at least 6 months. This 6-month period must
include at least 1 month of symptoms (or less if successfully treated) that meet Criterion A
(i.e., active-phase symptoms) and may include periods of prodromal or residual symptoms.
D. Schizoaffective and mood disorder exclusion:
Schizoaffective Disorder and Mood Disorder With Psychotic Features have been ruled out
because either (1) no major depressive, manic, or mixed Episodes have occurred
concurrently with the active-phase symptoms; or (2) if mood episodes have occurred during
active-phase symptoms, their total duration has been brief.
E. Substance/general medical condition exclusion:
The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of
abuse, a medication) or a general medical condition.
F. Relationship to a pervasive developmental disorder:
If there is a history of autistic disorder or another Pervasive Developmental Disorder, the
additional diagnosis of Schizophrenia is made only if prominent delusions or hallucinations
are also present for at least a month.
Figure 1-3: The diagnostic criteria for schizophrenia. Adapted from The Diagnostic and




Recurrent major depression is the most common of the psychiatric illnesses.
Prevalence ratings have been estimated from 7.8% (Weissman, 1991), to -17%
(Angst, 1995). In DSM-IV-RT (American Psychiatric Association, 2000), RMD is
diagnosed after at least two separate episodes and by the absence of any manic or
schizophrenic features. Core symptoms ofRMD include a depressed mood for most
of the day, nearly every day, and a marked loss of interest or pleasure in all or almost
all activities. Cognitive deficits are due to a lack of energy and/or motivation, or the
toxic effects of stress hormones rather than an active and specific defect.
Schizophrenia has a lifetime risk of ~1% in the population, and an average age of
onset between early adolescence to 35 years (Frangou and Murray, 1997). In DSM-
IV-RT (American Psychiatric Association, 2000) symptoms of schizophrenia are
positive or negative. Positive symptoms include delusions, hallucinations,
disorganized speech, and disorganized or catatonic behaviour. Negative symptoms
include affective flattening, alogia (a lack of fluency and productivity of thought and
speech) and avolition (absence of initiative or motivation to begin or maintain a
behaviour). Symptoms must seriously interfere with day to day functioning and be
present for at least six months. A well characterised set of cognitive impairments are
also observed, involving verbal memory and learning and attention-vigilance (Saykin
et al, 1994). There are a number of other disorders classified under the schizophrenia
spectrum, including schizoaffective disorder. This has a phenotype that is a mix of
BPAD and schizophrenia. It is characterised by a period of illness which corresponds
to a major depressive episode, a manic episode, or both, with concurrent symptoms
that meet the criteria for schizophrenia (American Psychiatric Association, 2000).
1.1.2. Pharmacological Treatments
1.1.2.1. Schizophrenia
Traditional treatments for schizophrenia are pharmacologically simple, targeting only
one or two brain neurotransmitter systems. Typical antipsychotics (e.g. reserpine)
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have an affinity for dopamine (DA) D2 receptors, reducing DA release. They relieve
positive symptoms, but have little effect on cognitive impairments and negative
symptoms (Thaker and Carpenter, 2001). The atypical antipsychotics (e.g. clozapine)
block DA D2 receptors, but also block DA Di and D4 receptors and seretonergic
(5HT) receptors, whilst newer atypical antipsychotics (e.g. olanzapine) also have an
affinity for acetylcholine (ACh) receptors (Frangou and Murray, 1997). Drugs that
enhance glutamatergic transmission via the N-methyl-D-aspartate (NMDA) receptor
have had some success at reducing negative symptoms (Thaker and Carpenter, 2001).
Thus, symptoms can be relieved by targeting several brain neurotransmitter systems.
1.1.2.2. Bipolar Affective Disorder
The two commonest pharmacological treatments for BPAD are lithium (Li) and the
anticonvulsant valproate (VPA). These stabilise mood by reducing the incidence of
severe depression and mania. A variety of other medications, for example
antipsychotics and antidepressants, can be used and multiple medications are
common (Lloyd et al, 2003). Few studies directly address the efficacy of
antidepressants since it is often assumed that the results of studies ofRMD are
generalizable (Thase and Sachs, 2000).
The effects of Li and VPA in the brain are diverse. For example, Li alters the activity
ofDA, 5HT, ACh, noradrenalin (NA), y-aminobutyric acid (GABA), glutamate and
various neuropeptides (Lenox and Hahn, 2000). Such diverse effects could be
mediated by an effect on cellular signalling cascades, for example, neuronal inositol
(1,4,5) tri-phosphate (IP3) (Berridge et al, 1989; Williams et al, 2002), protein kinase
C (PKC) and glycogen synthase kinase-3 (GSK-3) (Coyle and Manji, 2002). The
PKC and GSK-3 signalling cascades regulate gene transcription of the immediate
early genes, DNA binding transcription factors that in turn regulate a wide range of
gene transcription (Ikonomov and Manji, 1999). A bimodal mechanism of action has
been proposed where Li raises baseline cellular activity and attenuates peak activity,
thereby reducing extremes and stabilising fluctuation (Jope, 1999a; Jope, 1999b).
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1.1.2.3. Recurrent Major Depression
Introduction
Most efficacious drugs for depression affect brain neurotransmitter systems, by either
reducing their catabolism (e.g. monoamine oxidase (MAO) inhibitors) or blocking
synaptic reuptake (e.g. trycyclic antidepressants). Most trycyclic antidepressants (e.g.
imipramine) act upon both NA and 5HT, but more selective antidepressants (e.g. the
serotonin selective reuptake inhibitor fluoxetine) are safer and easier to use (Skolnick
et al, 2003). Broad spectrum antidepressants (e.g.DOV 216,303) inhibit the reuptake
ofDA in addition to NA and 5HT and single dopamine reuptake inhibitors are also
antidepressant (Skolnick et al, 2003).
1.2. Environmental Aetiology
A number of environmental risk factors have been identified for schizophrenia and
affective disorders, such as maternal malnutrition, maternal viral infection, foetal
hypoxia and winter births (Bromet and Fennig, 1999; Moller, 2003). However, it is
the pathological role of stress that has received considerable attention.
It is widely believed that a biological or genetic predisposition for psychiatric illness
is pushed past a resistance threshold by environmental factors (McGue et al, 1985).
The Holmes and Rahe Social Readjustment Rating Scale (Holmes and Rahe, 1967)
rates common life events, such as the death of a loved one, for stressfulness. Findings
suggest that, compared to controls, symptom onset in psychiatric illness is preceded
by an increased number of life events (Brown and Birley, 1968; Fowles, 1992;
Norman and Malla, 1993). However, no specifically psychiatric environmental
factors can be identified (Walker and Diforio, 1997), and some of the increase in
stressful life events may be bought on by illness itself (Frangou and Murray, 1997).
Therefore, the precipitate role of environmental stress is unclear.
The hypothalamic-pituitary-adrenal (HPA) axis is the primary system involved in the
regulation of the physiological stress response. In response to stress, corticotrophin
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releasing hormone (CRH) and arginine-vasopressin (AVP) are released into the
circulation from the hypothalamus. This causes the release of adrenocortico trophic
hormone (ACTH) from the anterior pituitary which in turn promotes the secretion of
Cortisol from the adrenal cortex. Cortisol has a catabolic action on a variety of
physiological systems. Negative feedback via glucocorticoid receptors (GR) and
mineralocorticoid receptors (MR) in the hippocampus ensures that Cortisol secretion
occurs within a narrow time window of immediate need (Herman et al, 1996).
Animal studies provide evidence for the role of the HPA axis in the response to
environmental stress, and also its role in the manifestation of stress related behaviour.
In rats, stress results in significant increases in corticosterone (the Cortisol equivalent
in rats) (Lopez et al, 1998). Prenatal stress leads to an increased baseline
corticosterone level and greater, prolonged and non-habituating corticosterone levels
in response to stress in adult rats and monkeys (Weinstock, 1997). Adult prenatally
stressed rats have fewer hippocampal GR and MR receptors compared to controls
(Weinstock, 1997). Behavioural abnormalities have been observed in rats and
monkeys that have been exposed to various forms of prenatal stress. These include
reduced play and social interaction (Clarke and Schneider, 1993), attentional deficits
(Schneider, 1992) and an increase in defecation and a reduction in ambulation
(Thompson, 1957; Wakshlak and Weinstock, 1990). An injection of CRH results in
many of these behavioural measures, providing a link between the response of the
HPA axis to stress and the behavioural consequences of stress (Weinstock, 1997).
Increases in baseline urinary Cortisol, CRH and ACTH levels have been observed in
BPAD, RMD and schizophrenic patients (Thakore, 1998; Altamura et al, 1999;
Pariante and Miller, 2001). In addition, depressed patients have been shown to
exhibit enlarged pituitary and adrenal glands and an enhanced response to ACTH
(Pariante and Miller, 2001). Elevation ofCRH may be due to impaired negative
feedback at GR since repeated stress results in a failure of negative feedback in the
brain and antidepressants enhance GR function (Pariante and Miller, 2001).
9
Chapter One Introduction
In line with animal studies, maternal stress during pregnancy leads to delays in motor
development and behavioural abnormalities in children such as clinging, crying,
hyperactivity, unsociable behaviour (Stott, 1973; Meier, 1985) and a higher incidence
of attention deficit hyperactivity disorder (Clements, 1992). Mothers suffering
bereavement of spouses during pregnancy have children with a higher incidence of
psychiatric disorders (Huttenen and Niskanen, 1978).
1.3. Biological Aetiology
1.3.1. Neuropathology
The lack of available living neural tissue from patients has hindered the elucidation
ofpathological mechanisms in psychiatric illness. Post-mortem studies represent one
way to analyse neural tissue. However, sample preservation, post-mortem cellular
changes and medication effects can complicate the interpretation of results.
An often reported finding from post-mortem studies ofmood disorders is the loss of
glial cells (Harrison, 2002) and increased activity of the cAMP and phosphoinositol
signalling pathways (Vawter et al, 2000). Differences between BPAD and RMD
patients are also observed. For example, the basal ganglia is smaller in RMD patients
and BPAD patients show increased neuronal number in the locus coeruleous (LC)
(Baumann and Bogerts, 2001). The most common pathology in schizophrenia
appears to be enlarged ventricular volume and a reduction in grey matter, accounted
for by changes in myelination rather than cell loss (Harrison, 1999; Halliday, 2001).
However, similar changes are also observed in patients suffering from alcohol abuse
and schizophrenics are more likely to abuse alcohol than controls (Halliday, 2001).
1.3.2. Theories of Aetiology
Theories of the aetiology abound, virtually every neurotransmitter has been studied
and much attention has been devoted to receptors and other components of
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neurotransmitter pathways. However, a full understanding of the pathological
mechanisms of psychiatric illness remains elusive.
1.3.2.1. The Pathogenesis of Mood Disorders
The role ofNA in mood disorders is well established. NA containing cell bodies in
the LC in the brainstem receive input from other brainstem nuclei and project to most
areas of the cortex, subcortex and the spinal chord (Cooper et al, 1996). Drugs that
cause a decrease in NA (e.g. AMPT) cause depression, whilst elevated NA can cause
manic symptoms (Ressler and Nemeroff, 1999). The NA transporter is inhibited by
many antidepressants, thus increasing synaptic NA concentrations. However, a
complimentary decrease in the (3-adrenergic post-synaptic receptor is observed after
chronic antidepressant treatment. Thus, the net effect of this is unclear (Ressler and
Nemeroff, 1999). Some studies have shown a decrease in cell number in the LC in
suicide victims (Arango et al, 1996), and chronic stress in rats decreases axonal
density in the LC that is reversible by antidepressants (Kitayama et al, 1997). Thus,
although dysregulation ofNA systems occurs in depression, a simple increase or
decrease ofNA is not sufficient to explain findings (Ressler and Nemeroff, 1999).
Increasing evidence points to the role of glutamate and GABA. Several studies report
altered glutamatergic function in depressed patients and the antidepressant activities
of antagonists of the glutamate receptor NMDA (Sancora et al, 2003). Both animals
and humans show decreased GABAergic transmission in response to stress (Petty,
1995), and the mood stabiliser VPA is a GABA agonist (Petty, 1995). Furthermore,
the blockade ofGABAa receptors results in learned helplessness, an animal model of
depression, in non-stressed rats (Sancora et al, 2003).
Astrocytes are the main source of glutamate and GABA synthesis, taking up
glutamate from the synapse to synthesise glutamine. Glutamine is then used to re-
synthesise glutamate and synthesise GABA. Impaired glial function, as inferred from
post-mortem studies, would result in decreased glutamate uptake and increased extra-
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synaptic levels. Thus, NMDA antagonists may exert an anti-depressive action by
blocking the increased activation that increased levels of extra-synaptic glutamate
would cause. However, increased levels of extra-synaptic glutamate might decrease
presynaptic glutamate release via negative feedback. A decrease in glutamate
synthesis in astrocyctes and decreased presynaptic glutamate release would also
decrease the amount of glutamine available for GABA synthesis (Sancora et al,
2003). As with NA, a simple explanation of altered glutamate and GABA
functioning in mood disorders is not forthcoming.
Other neurotransmitters are implicated in the pathogenesis ofmood disorders. For
example, 5HT neurons in the raphe nucleus innervate hypothalamic areas and
stimulate the release ofACTH and Cortisol. Hyper-reactivity of 5HT and the related
HPA axis pathways has been observed in RMD and BPAD (Pariante and Miller,
2001). Nitric oxide (NO), a soluble gas that can act as an atypical neurotransmitter,
has been implicated in numerous behaviours including depression (Papageorgiou et
al, 2001; Suzuki et al, 2001) and the regulation of the HPA axis (Bernstein et al,
1998; Shan and Krukoff, 2001).
It is clear that a wide variety of neurochemical changes are involved in the
pathogenesis ofmood disorders. Consequently, there is increasing interest in
fundamental molecular changes. For example, there is some interest in the role of
circadian rhythms in the pathogenesis ofmood disorders (Sher, 2003). Circadian
rhythms are biological rhythms (e.g. the sleep/wake cycle and hormone secretion)
with a period close to 24 hours that are regulated by cells in the hypothalamus.
Abnormalities in the sleep/wake cycle are observed in winter seasonal affective
disorder (SAD). Patients show increased winter nocturnal melatonin secretion
compared to controls and propanol, that shortens this secretion, alleviates symptoms
(Schlager, 1994). Light treatment, increasing the light part of the day-night cycle,
also alleviates symptoms (Lewy et al, 1982). Disruption also exists in non-seasonal
mood disorders (Wehr et al, 1983; Reimann et al, 2001). For example, blunting of
circadian rhythm amplitude, advanced phase and doubling of the sleep-wake cycle
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are observed in BPAD patients (Reimann et al, 2001). The cyclic pattern of relapse
may be linked to circadian disruption (Wehr et al, 1983), and evidence suggests that
sleep alterations precede the onset of depression and mania (Sher, 2003).
Recent attention has also focused on possible common cellular signalling pathways
underlying mood disorders, such as impairments in neuroplasticity and cellular
resilience (Duman et al, 1997; Manji et al, 2000). Numerous neuroplastic events
could be involved, such as alterations in dendritic function, synaptic remodelling,
long term potentiation, axonal sprouting, neurite extension, synaptogenesis and
neurogenesis (Manji and Lenox, 2000). The cell loss and/or atrophy observed post¬
mortem might indicate neuroplastic impairment. A possible mediator might be stress.
Stress can cause cell atrophy and reduce neurogenesis in the hippocampus and reduce
cellular resilience to insults such as glutamate excitotoxicity, possibly by the
inhibition of neurotrophic factors (Manji et al, 2000). Lithium and VPA have been
found to have significant neuroprotective properties after various cytotoxic insults in
vitro and in vivo in rats, and Li, VPA and antidepressants increase neurogenesis in
the hippocampus (Manji et al, 2000). Furthermore, Li or VPA treated patients exhibit
less prefrontal cortex volume loss than untreated patients (Drevets et al, 1997).
1.3.2.2. The Pathogenesis of Schizophrenia
The hyper-dopaminergic hypothesis of schizophrenia has been widely studied. An
excess of DA is thought to cause psychotic symptoms since DA agonists (e.g.
cocaine and amphetamine) have marked psychotic effects (Thaker and Carpenter,
2001). Amphetamine causes excess synaptic DA release in schizophrenic patients
compared to controls, and correlates with a worsening ofpsychotic symptoms (Breier
et al, 1997). However, the theory does not explain the negative symptoms of
schizophrenia. Chronic phencyclidine (PCP) administration, which reduces glutamate
transmission at the NMDA receptor, induces psychotic symptoms, negative
symptoms and cognitive impairment (Tamminga, 1998).
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Other neurotransmitters with altered function in schizophrenia include 5HT, markers
of the HPA axis (Pariante and Miller, 2001) and ACh (Araki et al, 2002). As with
mood disorders, a wide range of systems appear to be involved and focus on
molecular mechanisms will arguably be more informative. For example, there is
some evidence for a decreased neuronal density in the prefrontal and occipital
corticies and reduced brain volume in schizophrenic patients, possibly due to
decreased neuronal branching and connectivity (Selemon and Goldman-Rakic, 1999).
There are three main hypotheses of schizophrenia: neurodegenerative, early
developmental and progressive (De Haan and Bakker, 2004). The neurodegenerative
hypothesis, a progressive loss of tissue, is generally unsupported since gliosis, an
important marker of neurodegeneration, has not been confirmed in schizophrenic
brains (De Haan and Bakker, 2004). The prenatal and early developmental hypothesis
states that neuronal migration may be disturbed during pregnancy due to, for
example, stress or viral infection. Evidence to support this includes abnormalities in
the positioning of neurons in the cortex in schizophrenics, increases of schizophrenia
after complications during pregnancy and the alterations observed in brain
asymmetry and brain volume in schizophrenics and young individuals at risk (De
Haan and Bakker, 2004). The long latency between damage and symptoms may be
explained by the maldevelopment in utero of a late maturing system such as
connectivity (Weinberger and Lipska, 1995). In early development, abnormal
neuronal migration, cytoarchitecture and synapse formation occur in those
predisposed to developing schizophrenia. Subsequently, the time at which
schizophrenia develops in early adolescence is when pruning of neuronal connections
reaches a significant phase (Lieberman et al, 1997).
1.4. Genetic Aetiology
The vast numbers of biological studies, some ofwhich have been discussed, have
failed to identify a unifying theory of the pathological mechanisms underlying
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psychiatric illness. Genetics is a hypothesis free approach with perhaps more hope for
identifying the genes and the cellular pathways involved.
1.4.1. Family Studies
Over the years, it has become widely accepted that there is a substantial genetic
component in the liability to developing psychiatric illness. This was first indicated
by an increased risk to relatives of probands with schizophrenia, BPAD or RMD. For
example, Kendler and Diehl (1993) revealed an increased risk for schizophrenia
(4.8%) compared to controls (0.5%) in a meta-analysis of seven studies. A review of
21 studies also suggested an increased risk ofBPAD in the relatives of BPAD
probands (Craddock and Jones, 1999). Fewer studies have looked specifically at
RMD, but in five that did there was evidence for a genetic component (Sullivan et al,
2000). Only a couple of studies, for example Pope et al (1982), have failed to show a
similar increased familial risk.
1.4.2. Twin Studies
Twins provide important evidence for a genetic component to psychiatric illness. By
comparing monozygotic (MZ) and dizygotic (DZ) twins it is possible to distinguish
the role of genetics from non-shared environment. In addition, incomplete
concordance between MZ twins provides evidence for variable penetrance.
In a study ofUK twin pairs, concordance rates for schizophrenia, schizoaffective
disorder, mania and other related disorders were found to be between 10 and 44% for
MZ twins and 0 and 11.6% for DZ twins (Cardno et al, 1999). Craddock and Jones
(1999) reviewed six twin studies ofBPAD. All showed an increased probandwise
concordance rate in MZ compared to DZ twins and a pool of the data gave an MZ
concordance of 50%. A meta-analysis of six studies ofRMD identified concordance
rates of 14-37% in DZ twins and 23-67% in MZ twins (Sullivan et al, 2000).
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Concordance rates for schizophrenia and BPAD are often higher than for RMD,
suggesting greater genetic heterogeneity in RMD. For example, a meta-analysis of all
the major twin studies ofBPAD and RMD revealed higher MZ twin concordance
rates for BPAD (72%) than for RMD (40%), although concordance rates for BPAD
and RMD were more similar in DZ twins (Allen, 1976). The variation of
concordance with study design reveals further insight into the underlying genetics.
Higher concordance rates observed with a broader diagnostic criterion provide
evidence for variable penetrance. A narrow, vs a broad, diagnosis of schizophrenia
revealed concordance rates of 36 and 56% in MZ twins and 18 and 26% in DZ twins
respectively (Fischer et al, 1969). Bertelsen et al (1977) observed a concordance in
MZ twins of 58% with a strict illness definition ofBPAD and 84% with a broad
definition, and a concordance of 17 and 35% respectively for DZ twins.
1.4.3. Adoption Studies
Family and twin studies cannot completely distinguish between concordance as a
result of shared genetics or shared environment. Adoptee studies, where the genetic
family is distinct from the environment shared with the adopted family, represent a
key way of demonstrating a genetic component to psychiatric illness.
Studies have consistently shown that adopted children, whose biological mothers are
diagnosed with schizophrenia, show an increased occurrence of schizophrenia or
related disorders compared to controls (Kety et al, 1971; Kety, 1988; Tienari, 1991;
Tienari et al, 1994). Mendlewicz and Rainer (1977) found that BPAD, RMD,
schizoaffective disorder and cyclothymia in the biological parents of BPAD adoptees
was in excess of that seen in the adoptive parents, and was the same as the rate of
psychopathology in the parents of non-adopted BPAD individuals. Furthermore, the
rate of psychopathology in the adoptive parents was the same as in the adoptive
parents of normal offspring. Two studies using the modern diagnosis ofBPAD
showed a trend towards the increased risk of biological parents ofBPAD probands
16
Chapter One Introduction
for affective disorder (Craddock and Jones, 1999). Adoptee studies ofRMD also
provide qualitative evidence for a genetic component to RMD (Sullivan et al, 2000).
1.4.4. Mode of Transmission
Family data shows that psychiatric illness is not inherited in a Mendelian manner, but
the actual mode of inheritance is not immediately clear. Using large data sets, McGue
et al (1985) assessed the pure genetic forms (i.e. no account taken of environmental
factors) of a single major locus model (GSL) and a multiple genes model (MT) for
the genetic transmission of schizophrenia. Only the MT model fitted the data, but it
only narrowly achieved significance. Whilst their analysis rejects the idea that a
single gene could account for all of the schizophrenia phenotype, it does not exclude
the possibilities of a major gene contributing to the liability or polygenic bilinear
inheritance (Mynett-Johnson and McKeon, 1996).
Genes can interact multiplicatively or additively. The best fit to morbid risk data is
seen with a multiplicative model of 3-4 loci (Risch, 1990). Multiple additively
interacting genes would predict a decrease in the risk to relatives by a factor of 0.5
for each degree of relationship. Family data does not fit this model and therefore
suggests multiplicative interaction (Mynett-Johnson and McKeon, 1996). A
combination of inheritance patterns seems likely, with major gene inheritance in
some families, multiplicative polygenic inheritance in others and environmental




Linkage analysis was designed to identify genes for monogenic disorders but it has
been applied to complex disorders with some success. Linkage measures whether a
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marker allele is inherited more often than would be expected by chance with a
phenotype. The method relies on the principles of recombination. Alleles on different
chromosomes are randomly assorted during meiosis and alleles on the same
chromosome are assorted depending upon recombination whereby the chance of a
recombination event separating the marker and disease allele increases with distance.
The distance between two alleles is measured by the recombination fraction (RF): the
number of recombinant genotypes per 100 meioses. RFs of <0.5 (50%) and >0.50
mean that two loci are on the same or different chromosomes respectively.
In families, the small numbers of progeny mean that the RF may not be reliable.
Therefore, linkage measures the probability of obtaining a set of results in a family
on the basis of independent assortment and a specific degree of linkage. The odds of
these two probabilities (independent assortment versus linkage) are divided to
calculate the ratio and the results are expressed as a logarithm (a Lod score). For
example, in a family of two parents and six offspring, one parent and three offspring
have disease X (non-diseased = x) and all are genotyped for a biallelic marker (M/m).
Four offspring have the parental genotype (XM or xm) and two have the recombinant
genotype (Xm or xM). The expected frequencies of parental and recombinant
genotypes are calculated for a range ofRFs. For example, for independent assortment
(RF: 0.5), the probability of a parental genotype is 0.25 and the probability of a
recombinant genotype is 0.25. Thus, the probability of four parental and two
recombinant genotypes is 0.25 x 0.25 x 0.25 x 0.25 x 0.25 x 0.25 = 0.00024. For a
RF of 0.30, the probability of a parental genotype is 0.35 and the probability of a
recombinant genotype is 0.15. Thus, the probability of four parental and two
recombinant genotypes is 0.35 x 0.35 x 0.35 x 0.35 xO. 15x 0.15 = 0.00034. The
odds ratio of these two probabilities is 0.00034/0.00024 = 1.42. This means that a RF
of 0.30 is 1.42 times more likely than independent assortment. The Lod score is the
logarithm of this ratio (0.15). The odds of obtaining the result are tested under
different values ofRF to see which value gives the highest probability. Since
logarithms are exponents, Lod scores from different matings can be accumulated to
support or not support a linkage value.
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Odds for linkage of 1000:1 gives a Lod score of 3, the traditional threshold for a
significant result. However, this does not correspond to a p-value of 0.001 (or 10~3)
since a Lod score is a ratio of two probabilities and a p-value is an absolute
probability. A Lod of 3 means that the data is 103 fold more likely to occur under a
hypothesis of linkage than under a null hypothesis of independent assortment. A p-
3 • *3value of 10" means that the probability of the observed data is 10" under the null
hypothesis. In fact, a Lod of 2.1 equals a p-value of 10" and a Lod of 3 equals a p-
value of 10"4 (Lander and Kruglyak, 1985). However, the corresponding p-value of a
Lod score can vary depending on the linkage method used (Elston, 1998).
1.5.1.2. Methodological Considerations
Linkage analysis is a parametric method because it requires the strict definition of
parameters such as mode of inheritance and therefore is best suited to monogenic
disorders. Since psychiatric illnesses have uncertain inheritance patterns, incomplete
penetrance and diagnostic ambiguity, they do not lend themselves easily to linkage
(Mynett-Johnson and McKeon, 1996). However, there are a number of factors that
enhance the power to detect susceptibility loci. For example, a number of phenotypes
can be tested, bilinear inheritance can be ruled out and clinical diagnosis can be
reviewed regularly to capture new and changed diagnoses (Mynett-Johnson and
McKeon, 1996). There are, however, lower limits to the power to detect linkage. For
example, allelic association identified the APO*E4 susceptibility allele for late onset
Alzheimer's disease. Whilst the E4 allele was estimated to account for -17% of the
population variance, a linkage study of 32 pedigrees found only modest evidence for
linkage to this locus (Mynett-Johnson and McKeon, 1996).
In the absence of an alternative strategy, linkage analysis has become a standard tool
for identifying genomic susceptibility regions for psychiatric illness. The result has
been vast numbers of suspected false positives and many genomic regions have been
implicated. In order to make sense of the huge amount of data, Fander and Kruglyak
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(1995) propose four levels of significance: A Lod of 2.2 for suggestive linkage, a Lod
of 3.6 for significant linkage, a Lod of 5.4 for highly significant linkage and
replication of an original result with a p-value of <0.01 for confirmed linkage.
To circumvent the problem of specifying the mode of inheritance, alternative model-
free nonparametric linkage methods have been devised. In general, they rely on
detecting the fact that affected subjects share marker alleles more often than would
be expected by chance. Nonparametric methods differ in terms of the types of
pedigree structure they are applied to, whether they rely on identity-by-descent (if
parents are included) or identity-by-state (siblings only) information and the methods
of analysis used (Elston, 1998). Results are analysed using the Chi-square statistic to
determine the probability that alleles are shared greater than would be expected by
chance, or a Lod score that, rather than being maximised over the RF, is maximised
over the expected probability of allele sharing (0.25 versus 0.5) (Elston, 1998).
1.5.1.3. Findings
Linkage studies have implicated many genomic regions in the genetic susceptibility
to schizophrenia, BPAD and RMD, but not all have been replicated. For example, the
significant linkage ofmood disorders to chromosome 1 lp reported by Egeland et al
(1987) failed to be replicated in most subsequent studies (Tsuang et al, 2004). The
regions of greatest interest are these which have been independently confirmed. As
replication studies are conducted, several separate genomic regions are consistently
emerging, such as those on 8p 13q and 22q for schizophrenia and 4p, 13q and 22q for
BPAD (Berry et al, 2003; Tsuang, 2004). This provides evidence for substantial
locus heterogeneity in psychiatric illness.
Some of the more consistent findings for schizophrenia include chromosomes 1, 6, 8,
13 and 22. Linkage evidence supported by a second type of genetic evidence, such as
the chromosomal abnormalities observed on chromosomes 1 and 22 and the




Linkage has been observed to schizophrenia on chromosome 1, in the region of a
chromosomal (1:11) translocation which is associated with schizophrenia in a large
family (Berry et al, 2003). The translocation directly disrupts the DISCI gene on
chromosome 1 (Millar et al, 2000). The gene is expressed in multiple regions of the
brain and is possibly involved in brain development and function (Millar et al, 2003).
There are positive linkage results for both arms of chromosome 6, but most interest is
focused on the 6p21 -24 region, containing several candidate genes, including the
spinocerebellar ataxia gene, the HLA region, NOTCH4 and dysbindin (Berry et al,
2003). The linkage to schizophrenia on chromosome 8p is especially compelling in
the light of corresponding association results and haplotype analysis (Stefansson et
al, 2002). This is discussed in more detail in Section 1.5.2.4. Linkage to
Chromosome 15 is interesting since the a-7 nicotinic cholinergic receptor subunit
gene is positioned here. This gene is implicated in the P50 sensory gating deficit, an
attention deficit marked by an inability to filter out irrelevant stimuli, that is observed
in schizophrenic patients (Freedman et al, 1983). Linkage of the P50 sensory gating
deficit to markers within the a-7 nicotinic cholinergic receptor subunit gene has been
replicated a number of times (Berry et al, 2003). Linkage to chromosome 22 has been
identified by several studies in the region of the velo-cardio-facial syndrome (VCFS)
deletion on 22ql 1 (Berry et al, 2003). Patients with VCFS show an elevated risk for
schizophrenia and major affective disorders (Tsuang et al, 2004). COMT and proline
dehydrogenase are two candidate genes in this region (Collier and Li, 2003).
Consistent evidence for linkage has been identified to BPAD on chromosomes 4, 12,
13, 18, 21 and 22. Significant linkage ofBPAD and RMD to chromosome 4p, with a
maximum Lod score of 4.8, was identified in a large Scottish pedigree (Blackwood et
al, 1996), and independent confirmation was obtained from several studies (Asherson
et al, 1998; Ewald et al, 1998; Detera-Wadleigh et al, 1999; Williams et al, 1999).
These findings are discussed in greater detail in Section 1.7.1. Barden et al (1988;
cited in Berrettini, 2000b) identified significant linkage to BPAD on chromosome
12q, with a Lod score exceeding 8, in a sub-population of French origin from Quebec
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(Berrettini, 2000b). This locus has been confirmed by studies of Danish and
American pedigrees (Detera-Wadleigh et al, 1999; Ewald et al, 1998). The confirmed
susceptibility locus for schizophrenia on chromosome 13q has also been linked to
BPAD in two independent reports (Berrettini, 2000a; Berrettini, 2000b). Linkage has
been observed to both arms of chromosome 18 and the pericentromeric regions
(Baron, 1997). Interestingly, the linkage observed for BPAD to the q ann of
chromosome 18 by Stine et al, (1995) provides evidence for paternal inheritance
(Baron, 1997; Berretinni, 1998). Linkage ofBPAD to chromosome 21q22 has also
been observed by several independent investigators (Baron, 1997; Aita et al, 1999).
Interestingly, this is the same region as the Downs syndrome critical region and they
may share common gene variants (Aita et al, 1999). The linkage to schizophrenia and
VCFS on chromosome 22q, described above, has also been linked to BPAD by
several independent investigators (Berrettini, 2000a; Berrettini, 2000b).
The range of chromosomal regions implicated in schizophrenia and BPAD from
linkage studies may reflect both Type 1 (incorrect rejection of null hypothesis) and
Type 2 (incorrect acceptance of null hypothesis) errors. Type 1 errors can arise from
inappropriate study design, for example small sample sizes and incorrect disorder
specification. Type 2 errors can arise for the same reason, but also as a result of locus
heterogeneity (Tsuang et al, 2004).
1.5.1.4 Linkage Overlap in Bipolar Affective Disorder and Schizophrenia
Schizophrenia and BPAD share certain epidemiological characteristics such as age of
onset, lifetime risk, worldwide distribution and risk of suicide (Berrettini, 2000a).
Both exhibit similar risk factors, including an excess of perinatal complications and
winter births (Torrey, 1999). The clinical entity of schizoaffective disorder, an
intermediate phenotype between BPAD and schizophrenia, adds support for a
continuum theory between these illnesses (Moller, 2003). Benazzi (2003a) found
evidence to support the continuity between the symptoms ofRMD and BPAD and
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the psychotic symptoms more usually associated with schizophrenia can occur in
both BPAD (Potash et al, 2001), and RMD (Carpenter et al, 1973).
The evidence for a continuum manifests itself in biological studies. Most
neurochemical systems that are dysfunctional in schizophrenia, for example, brain
catecholamine and HPA axis functioning, are also dysfunctional in BPAD (Moller,
2003). A common post-mortem characteristic of schizophrenia, the reduced activity
of genes responsible for producing myelin, has recently been confirmed in BPAD
(Tkachev et al, 2003). Furthermore, some medications for schizophrenia, such as the
antipsychotic olanzipine, are approved as treatment for bipolar mania (Moller, 2003).
Schizophrenia and BPAD can occur together in single families (Detera-Wadleigh et
al, 1999) and the risk for illness crosses diagnostic boundaries, although family
studies cannot differentiate the role of shared environment from shared genetics.
Relatives of schizophrenic probands have an increased risk ofRMD and
schizoaffective disorder (Gershon et al, 1988) whilst relatives ofBPAD probands
have been shown to have an increased risk of schizoaffective disorder (Maier et al,
1993) and RMD (Craddock and Jones, 1999). Concordance has also been observed
between MZ twins for BPAD and RMD (Bertlesen et al, 1977; Allen et al, 1974).
On the basis of this evidence, it is not surprising that linkage studies highlight similar
susceptibility regions. For example, the linkage to chromosome 4p in families
segregating BPAD and RMD was supported by independent investigators in families
segregating both schizophrenia (Detera-Wadleigh, 1999; Williams et al, 1999) and
schizoaffective disorder (Asherson et al, 1998). The confirmed loci for BPAD on
18p 11 and 22ql 1-13 have been observed in schizophrenia and the confirmed loci for
schizophrenia on 13q32 has been observed in BPAD (Berrettini, 2000a; Berrettini,
2000b). Chromosome lOp is another region where positive linkage to both BPAD and
schizophrenia has been observed (Berrettini, 2000a).
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Direct evidence for overlapping susceptibility loci comes from a meta-analysis of all
published whole genome scans for BPAD and schizophrenia. The strongest evidence
for linkage to BPAD lies on chromosomes 13q and 22q whilst the strongest evidence
for linkage to schizophrenia lies on chromosomes 8p, 13q and 22q (Badner and
Gershon, 2004). The emergence of common susceptibility loci might reflect the
phenotypic similarities. For example, a subset ofBPAD pedigrees with a high
incidence ofpsychotic symptoms (hallucinations and delusions) showed the strongest
linkage to chromosomes 13q and 22q, but no linkage was observed if this subset was
included in a larger sample (Potash et al, 2003). The region of linkage reported to
BPAD and schizophrenia on chromosome 22ql 1 includes several candidate genes,
including COMT. Association between a COMT haplotype and schizophrenia has
recently been replicated in BPAD. In addition, for both BPAD and schizophrenia, the
haplotype relative risk was greater in women (Shifman, 2004).
Despite this, there are several genomic regions that appear to be unique. Evidence for
linkage ofBPAD to chromosome 12q has been identified, but there are no reports of
linkage of schizophrenia to this region (Berrettini, 2000a; Tsuang et al, 2004) and
several studies report linkage of schizophrenia to chromosome 6p and 8p, but there
are no reports of linkage ofBPAD to these regions (Berrettini, 2000; Berry et al,
2003). In conclusion, the evidence for shared susceptibility is convincing, justifying
the combination of linkage findings from BPAD and schizophrenia to help define
susceptibility alleles. However, it cannot be assumed that linkage to one is applicable




Since recombination events are relatively rare and occur once or rarely twice per
chromosome per generation, studying one or even several families means that linkage
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regions will be large, containing many candidate genes. A higher resolution mapping
technique is the association study. This measures allele frequency in populations of
unrelated individuals and therefore effectively utilises hundreds of recombination
events. Consequently, alleles that are inherited with the phenotype will be much
closer to the susceptibility allele. The method is non-parametric because no
assumptions are made about the mode of inheritance.
Chi-squared contingency table tests can be used to test whether there is a significant
difference in allele frequency between two groups. For example, values in a 2x2
contingency table could be the number of occurrences of allele 'M' vs allele'm' in
well vs unwell individuals. The null hypothesis is: no association between allele and
mental health, and therefore the cells of the table would reflect the allele frequency of
each allele observed in a group of controls. Each of the obtained values in the cells is
compared to the values under the null hypothesis. The significance of this difference,
accounting for type 1 errors (a false positive result when the null hypothesis is
incorrectly rejected) and degrees of freedom (the number of cell entries required
before the values of the rest are fixed, i.e. 1 degree of freedom in a 2x2 contingency
table test), is then assessed. It is important to remember that the Chi-square test is a
measure of association and says nothing about causality.
Results of association are often expressed as an odds ratio (OR) or a relative risk
(RR), as in traditional epidemiological case-control studies. Strictly, RR is used in a
prospective study and OR in a retrospective study. A prospective study measures
whether two groups that differ in exposure to a risk factor do or do not develop the
primary outcome (e.g. does having a parent with BPAD increase the risk of
developing BPAD in the offspring?). A retrospective study used the primary outcome
as the basis of grouping and the level of the risk factor is measured in each (e.g. at
what level does a risk allele occur in BPAD and control individuals?). The RR
measures the risk rate of developing the primary outcome in exposed or non-exposed
individuals. The OR measures the odds of being exposed to the risk factor in cases or
controls. Thus, case-control association studies are retrospective. However, it is
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common for publications to refer to RR in retrospective studies because the values of
OR and RR are approximately equal when the primary outcome is relatively rare.
The OR (discussed in relation to the calculation ofLod scores in Section 1.5.1.1) is
obtained by calculating the ratio of the odds ofbeing exposed in cases (i.e. the
occurrence of the risk factor divided by non-occurrence of the risk factor) and the
odds of being exposed in controls. The RR is obtained by calculating the ratio of the
risk of developing the primary outcome when the risk factor is present (all
individuals with the risk factor and the primary outcome divided by all individuals
with the primary outcome) and the risk of developing the primary outcome when the
risk factor is not present.
A RR of 2.00 can also be expressed as an increased risk of 100%. However, this
obviously does not mean that individual with the risk factor has a 100% chance of
developing the primary outcome, but that their risk is 100% higher. Relative risk
refers to a population risk and not individual risk since the possession of a risk factor
does not predict whether that individual will develop the primary outcome.
A number of different association study designs can be applied. The case-control
design compares unrelated cases and unrelated controls from the same ethnic
population. For some diseases it may be necessary to select controls on some criteria
that may be associated with disease status, such as sex or age. Simplex family
designs, the affected child with its parents, or affected sibling pairs, have been
advocated to reduce the problem of population stratification that can be seen with the
case-control design and the spurious associations that result from this. However, the
family design can result in a loss of power. For example the transmission
disequilibrium test (TDT), that analyses the inheritance of parental alleles to an
affected offspring, is restricted to using only heterozygous parental genotypes. In
addition, the control population in a case-control design can be tested for
stratification using unlinked markers. Perhaps most importantly, a case-control
design is easier to perform due to the ease of sample collection (Risch, 2000; Cardon
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and Bell, 2001). A further advantage of the case control design is that individual
DNA can be pooled together to compare allele frequency, significantly reducing the
amount of genotyping (Breen et al, 1999; Le Hellard et al, 2002).
Association studies can be hypothesis driven, using candidate genes, or genome
wide, using random markers. The application of genome wide association studies
increased in popularity with the discovery of the commonality of the single
nucleotide polymorphism (SNP) (Altshuler et al, 2000, Syvanen, 2001).
Nevertheless, the limited availability of quick and cheap high throughput genotyping
techniques, the unknown patterns of genome wide linkage disequilibrium (LD) and
issues concerning which SNPs to choose and the question of whether common or rare
variants operate in complex disease still makes the utilisation of SNPs and genome
wide association studies problematic (Owen et al, 2000; Botstein and Risch, 2003).
1.5.2.2. The Power of Association Analysis
The power, i.e. the ability to detect what is being sought, of the association study
design lends itselfmore favourably than linkage to detecting the genetic effects of
common variants with low RRs (Risch and Merikangas, 1996; Risch, 2000). Most
initial studies aim for 80% power, but a higher power is desirable in replication
studies. In order to calculate power in a case-control association study, it is necessary
to determine firstly, the level of significance desired. This will reflect the level of
Type 1 errors to be tolerated. A p-value of at least <0.05 is standard (a 5% chance of
a Type 1 error). Secondly, it is necessary to estimate the size of the effect. This can
be parameterised in terms of the allele frequency in the controls and the increase in
RR expected in the cases: the RR of a particular allele for developing illness.
Unfortunately, RR is usually unknown and therefore it is prudent to design a study
based on a small RR. The RRs and ORs that have been reported in the literature for
psychiatric illness are variable but generally range from as low as 1.2 to -3.0
(O'Donovan and Owen, 1999; Li et al, 2004b).
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Allele frequency can also impact upon power calculations. For example, for a RR of
2 and a Type 1 error rate of 0.05, approximately 600 individuals would be required to
observe an association with a marker that has a susceptibility allele frequency 0.50,
but this increases to approximately 1500 if the allele frequency is 0.10 (Glatt and
Freimer, 2002). This is because a low susceptibility allele frequency means that the
same RR is harder to detect. For example, a RR of 2 and a susceptibility allele
frequency of 0.40 in controls would mean that the frequency of the allele in a case
population would be 0.57 (because RR = (0.57/0.43)/0.40/0.60) = 2). However, if the
susceptibility allele frequency is 0.10, the frequency in the case group would be 0.18.
Furthermore, the lower the RR, the larger the discrepancy (Glatt and Freimer, 2002).
For example, a RR of 1.2 and a susceptibility allele frequency of 0.10 in controls
would give a frequency in the case population of 0.12. Genotyping errors can also
significantly decrease the power of a test (Gordon et al, 2002) and it is possible
therefore to account for an error rate in the power calculation. Once these parameters
have been chosen, a formula (based on the sampling properties of the central Chi-
squared distribution under the null hypothesis and the non-central Chi-squared
distribution under the alternative hypothesis) determines the sample size required to
attain 80% power.
Inevitably, an association study will test many markers, increasing the occurrence of
Type 1 errors. A large number of simultaneous tests on the same data set is akin to
placing a single bet at a casino, but spinning the roulette wheel numerous times. The
chances ofwinning, or finding a positive result, increase. The Bonferroni correction
is used to correct for multiple testing by raising the standard of proof required to
identify a positive result, therefore reducing the Type 1 error rate. A Bonferroni
adjusted p-value is the desired Type 1 error rate divided by the number of outcomes
being tested. For example, testing 10 SNPs for association means that a p-value 10
times more stringent should be required to accept the hypothesis (0.05/10 = 0.005).
Corrections for multiple testing should also be considered if the study groups are split
for different factors (e.g. gender). Inappropriate correction results in either an
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increase in Type 1 errors due to weak correction or a decrease in statistical power due
to overly stringent correction (Cardon and Bell, 2001).
The application of correction for multiple testing in association analysis is
controversial. If tests are correlated, the problem ofmultiple testing is less critical
because each new test is not an independent opportunity for a Type I error. Markers
in LD are not independent tests and a bonferroni correction is likely to be too
conservative (Ott, 2000). However, Ott does not suggest what level of LD would be
sufficient, especially in light of the fact that LD calculations will vary depending on
the statistic used. Researchers also tend to carry on testing many markers in many
locations regardless of the results obtained. This raises the question ofwhether a
genome wide correction value is required and whether this should be based on how
many markers will be tested in the future (Nyholt, 2001). Furthermore, a reported
association study that has been corrected for a certain number of tests may have
originally tested a great deal more (Tomassi, 2004). Due to these problems, several
researchers stress the importance, not of correction per se, but ofproviding a detailed
appraisal of the strategies used and the importance of replication studies (Malhotra
and Goldman, 1999; Nyholt, 2001; Tomassi, 2004).
In a review, Cardon and Bell (2001) suggest a set of guidelines for performing
association analysis. More than one control population should be used in each study
and sample sizes should accommodate suboptimal scenarios, such as conservative
RR estimates. Multiple testing should be accounted for and different sample panels
(different ethnic backgrounds) should be considered to help refine regions of LD.
Independent confirmation of an association should be obtained and a lack of
association is meaningless. Very few studies conform to these guidelines and for
most it is simply not practical. In view of the associated problems with linkage and
association studies, the most effective strategy may be to combine them both, using
association studies to analyse regions of suggested linkage (Baron, 2001).
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1.5.2.3. Linkage Disequilibrium and its Role in Association
All measures of LD are based on the covariance measure D, where D is the difference
in the observed and expected frequencies ofAB gametes for two loci with alleles A,a
and B,b. Measures of LD differ in the way that D is scaled and studies that use
different measures cannot be compared (Nordborg and Tavare, 2002). The two most
common methods used to calculate LD are D' and r2 (Nordborg and Tavare, 2002).
Values lie between zero and one, where one indicates complete LD. The r measure
is the squared correlation coefficient of the alleles between two loci where r is D that
has been scaled by the standard deviations of the allele frequencies. The 2x2 Chi-
square contingency table test of gamete frequencies provides a significance test for
2 2 •the null hypothesis r =0. A disadvantage is that r is dependent on the difference in
allele frequencies at the two loci, so that r2 can only take on its full range of 0 to 1
when the allele frequencies at the two loci are the same. However, r2 is not biased by
small sample sizes and low allele frequency (Tishkoff and Verrelli, 2003). In
contrast, D' scales D by the maximum value it could take given the allele frequencies
at the two loci, so that D' can take on the full range of 0 to 1 whatever the allele
frequencies. However, low allele frequency and small sample size often result in D'
estimates of 1.
Most power calculations are based on the SNP in question being the susceptibility
SNP, but this is not generally the case. Although LD between SNPs ought to
maintain power, the relationship is complex and depends upon effect size, the disease
allele frequency (DAF), the marker allele frequency (MAF) and the LD between the
two. Using data from several susceptibility alleles reported in the literature,
Zondervan and Cardon (2004) show that if a susceptibility allele has a high RR (4.0),
a study will have high power to detect it with markers across a wide range of allele
frequencies even with only moderate LD between the two (D' <0.5). A moderate RR
(2.0) means that only common markers (>0.1) will have high power to detect
common disease variants, even if their allele frequencies are not the same, as long as
LD is high (D' >0.8). A low RR (1.2) means that common markers will only have
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power to detect association if the allele frequencies match and LD is high (Zondervan
and Cardon, 2004). It has also been found that haplotypes have greater power to
detect association than single marker tests and are more robust (i.e. less susceptible to
the effects of random drift, mutation and LD) (Akey et al, 2001).
The power to detect association is also affected by haplotype phase. For example, the
T allele of SNP T/t has a RR of 2 and a frequency of 0.3 (t = 0.7). A case-control
study genotypes two SNPs in this region: A/a and B/b. T occurs only on the AB
haplotype. This haplotype has a frequency of 0.3 in the population. A is present only
on the AB haplotype and therefore also has a frequency of 0.3. B occurs on
haplotypes AB and aB with a total frequency of 0.7. Thus, A is in complete LD with
T (according to both D' and r ), has the same frequency (0.3) and therefore also has a
RR of 2. B is also in complete LD with T in terms ofD' (since T only occurs with A
and B), but it has a different frequency (due to its presence on other haplotypes,
indicating an r2 of<1) and therefore has a reduced RR of 1.43. Detecting association
with either A or B would appear to be optimal since there is complete LD and the
allele frequencies are the same as T/t. However, because the haplotype phase is
different (i.e. the frequency of T and t is 0.3 and 0.7 respectively and the frequency of
B and b is 0.7 and 0.3 respectively, but it is allele B that shared a haplotype with T),
the RR is different. For equal statistical power, a sample size 5.5 times greater would
be required to detect an association with B than A. Therefore, matching allele
frequency and high LD is not enough to ensure power. However, haplotype phase
cannot be predicted (Zondervan and Cardon, 2004).
1.5.2.4. Findings of Association Analysis
Due to the problems discussed in the previous sections, association studies of
psychiatric illness have been subject to a similar excess of false positive and false
negative results as linkage analysis. In an analysis of 301 studies covering 25
different reported associations to a variety of complex disorders, under half (11) of
the reported associations had strong evidence for replication. The main reason for
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non-replication was underpowered studies due to small sample number (Lohmueller
et al, 2003). This highlights the fact that false negatives are just as prevalent as false
positive results (Owen et al, 2000). For example, the associations of schizophrenia to
both the DA D3 and the 5HT2A receptors are estimated to have small effect sizes
(1.2) and therefore sample sizes in the region of 1000 individuals would be required
for replication (O'Donovan and Owen, 1999).
Most association studies in psychiatric illness have been hypothesis driven studies of
candidate genes. However, even after a linkage study, there will be multiple potential
candidate genes and since the biological aetiology of psychiatric illness remains
obscure, almost any brain expressed gene can be posed as a candidate. The
neurotransmitter receptors and other components of their pathways have been the
focus ofmuch attention. The dopamine and serotonin family of receptors,
acetylcholine and GABA receptors and neurotransmitter related enzymes such as
MAO and COMT are among some of the examples (Mynett-Johnson and McKeon,
1996).
Significant association to schizophrenia was identified in a meta-analysis of all
published results of the 5HT2A receptor gene 102T/C polymorphism (Williams et al,
1997, cited in Owen et al, 2000). However, the association found fails to explain the
biological mechanism since the polymorphism is silent. No difference in receptor
density in the frontal cortex was observed in those with the susceptibility allele.
Another SNP in the 5' promoter region of the gene is in LD with 102T/C. However
102T/C does not show allele specific differences in promoter basal activity.
Furthermore, the presumptive ancestral allele of 102T/C is, paradoxically, also the
one that is associated with schizophrenia (Petronis, 2000). Epigenetic mechanisms,
such as genomic imprinting, could account for some of the inconclusive findings
from both linkage and association analysis. There is evidence to suggest that
expression of the paternal 5HT2A receptor gene is sometimes inhibited. Therefore, it
might be critical to determine how many individuals express both copies of the gene,
how many express one copy and which one it is (Petronis, 2000).
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The DA receptors have been the focus of numerous association studies. There has
been a consistent lack of replication of the original association between
schizophrenia and the DA D2 and D4 receptors (O'Donovan and Owen, 1999; Berry
et al, 2003). Again, mixed findings have been observed for the DA D5 receptor gene
(Muir et al, 2001; Berry et al, 2003). However, many studies seem to converge on a
consensus for an association between schizophrenia and the DA D3 receptor
(O'Donovan and Owen, 1999; Petronis, 2000).
The targets for association studies in mood disorders have been very similar to those
for schizophrenia, in particular the DA and 5HT receptors and transporters. Collier et
al (1996, cited in Tsuang et al, 2004) were the first to study the 5HT transporter in
BPAD and RMD patients, finding an association between a low expression variant
and illness. Replication studies have been variable (Tsuang et al, 2004). There
appears to be a general failure to find association between mood disorders and the
5HT2A receptor, despite this receptor consistently being unregulated in depression.
In addition, studies of the DA D2 receptor have been similarly inconsistent, although
results for the dopamine D4 receptor look more promising (Tsuang et al, 2004).
The Neuregulin (NRG1) gene on chromosome 8p is an interesting example where
linkage analysis and subsequent association analysis has provided compelling
evidence for the location of a susceptibility variant for schizophrenia. Stefansson et
al (2002) conducted a genome wide linkage study in 33 Icelandic families with
schizophrenia and reported a Lod score of 3.02 on chromosome 8p. Haplotype
analysis, with one marker every 75 kb, identified two risk haplotypes in a 600kb
region that contained the NRG1 gene. SNPs were identified by sequencing and an
association study was carried out on 394 controls and 478 schizophrenics. A few
SNPs showed mild but significant single-marker association. However, a 290 kb
seven marker risk haplotype (five SNPs and two microsatellites) was identified at the
5' end of the gene with a relative risk of 2.2. These findings were supported by a
TDT test in the linkage population, where the risk haplotype was transmitted at a
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ratio of 2:1. Since none of the individual markers showed the same association as the
haplotype, they concluded that the causative marker was not one of the haplotype
markers.
The same seven marker risk haplotype, conferring a risk of 1.8, was subsequently
identified in -600 Scottish schizophrenics (Stefansson et al, 2003), and the results
have also been replicated in a British population byWilliamson et al (Collier and Li,
2003). A further replication by Corvin et al (2004) in an Irish population identified a
two marker risk haplotype, overlapping with Stefansson's core haplotype.
In 246 Chinese Han schizophrenic family trios, Yang et al (2003) found positive
association for two randomly chosen SNPs in NRG1, but not for one of the SNPs
from the seven marker risk haplotype identified by Stefansson et al (2002). Again, Li
et al (2004b), in 138 Chinese Han schizophrenic trios and 298 case and 336 unrelated
controls, found that neither the seven marker risk haplotype, nor the individual
alleles, were in excess in the case and control group. However, three alternative risk
haplotypes were identified. One upstream of Stefansson's risk haplotype conferred a
relative risk of 3.1. A second, overlapping Stefansson's risk haplotype conferred a
relative risk of 2.1. A third risk haplotype, at the 3' end of the gene, was found to
confer a risk only in the TDT test in the trios. Iwata et al (2004) found no association
between Stefansson's risk haplotype and -600 Japanese schizophrenics. The different
haplotypes observed in Chinese and Northern Europeans is not surprising since a
different relationship between marker haplotypes and underlying pathogenic variants
could be expected to exist. It is possible that either the same variant operates, or that
there is locus heterogeneity (Li et al, 2004b). All of these results identify risk
haplotypes that confer greater risk than any of the alleles alone, and therefore none
claim to have identified the susceptibility variant itself (Collier and Li, 2003).
The NRG1 gene is a good candidate. The protein has multiple functions in a variety
of tissues, including directing the migration of cortical neurons along radial glial
cells, the regulation ofNMDA, ACh and GABA receptor expression and long term
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potentiation (Collier and Li, 2003). Stefansson et al (2002) showed that mice with
reduced NRG1 activity or expression display hyperactivity that was reversible with
antipsychotics, and impaired pre-pulse inhibition, a startle response that is impaired
in schizophrenic patients. Hashimoto et al (2003) identified a 16-23% increase in
expression ofNRG 1 type I isoform in the prefrontal cortex of schizophrenic post¬
mortem brains which was positively correlated with medication dose.
1.5.3. Heterogeneity in Psychiatric Illness
Locus heterogeneity in psychiatric illness can be inferred from the numerous genomic
regions implicated by linkage analysis (Berry et al, 2003; Tsuang et al, 2004). This in
turn implicates a number of candidate genes and replication studies from association
analysis are beginning to consistently implicate several genes, for example NRG1,
COMT and proline dehydrogenase (Collier and Li, 2003).
Locus heterogeneity does not preclude the possibility of allelic heterogeneity in
psychiatric illness, where multiple mutations in one gene can lead to the same
phenotype. This is common in monogenic disorders. For example, more than 963
mutations in the CFTR gene have been identified that cause cystic fibrosis (Wright
and Hastie, 2001). However, allelic heterogeneity in psychiatric illness is largely
hypothetical since the identification of susceptibility loci is in its early stages. Despite
this, some indications for allelic heterogeneity are emerging. For example, the seven
marker risk haplotype for schizophrenia in the NRG1 gene occurs in a number of
European populations (Collier and Li, 2003) but is not present in Chinese
populations (Li et al, 2004b). However, the Chinese population possesses three
alternative risk haplotypes, two ofwhich do not overlap with the European risk
haplotype (Li et al, 2004b). This strongly suggests that different susceptibility alleles,
from different regions of the NRG1 gene, operate in different ethnic populations.
Locus and allelic heterogeneity will mean that susceptibility variants will be harder to
detect by linkage and association analysis and has important implications for study
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design. Linkage studies might benefit from studying large families, where a more
limited number of interacting genes and environmental influences will be operating.
A number of genomic regions have been identified in such a manner. Linkage to
BPAD from multiple independent studies on large pedigrees has been observed on
chromosomes 4p and 12q (Blackwood et al, 1996; Blackwood et al, 2001). However,
in a single family, the disease may be the result of a rare highly penetrant variant and
therefore of limited application to the wider population (Blackwood et al, 2001).
Both association and linkage analysis will benefit from strategies to reduce the
proportion of a sample whose disease is caused by non-genetic factors, for example,
by studying severe forms of disease or extreme clinical phenotypes (Wright and
Hastie, 2001) and sample sizes should be large enough to detect small effects.
The complexity of the psychiatric phenotype is well known. DSM-IV-RT (American
Psychiatric Association, 2000) allows for substantial phenotypic variation between
individuals by diagnosing from a minimal number of core symptoms. Measuring
phenotypic heterogeneity might aid the detection of susceptibility variants. For
example, a psychotic form ofBPAD characterised by delusions and hallucinations
has been identified by several researchers (Leckman et al, 1984; Potash et al, 2001)
and Potash (2003) identified stronger evidence for linkage ofBPAD to chromosome
13q and 22q in pedigrees that were characterised by psychotic symptoms than
pedigrees that were not.
Consideration of ethnicity as a source of locus heterogeneity is also important. For
example, a meta-analysis of 24 studies of association of schizophrenia to an allele of
the DRD3 gene did not support association. However, when the samples were
divided into five different ethnic groups (African, Northern European Caucasian,
Mediterranean, Asian, and American), an association was identified in the Caucasian
group with an odds ratio of 1.23 for the homozygous genotype (Dubertret et al,
1998). These results suggest that the Northern Europeans possess a susceptibility
allele not present in the other four ethnic groups. The small OR could explain the
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lack of association identified in some of the individual studies but, without
consideration of ethnicity, even the meta-analysis did not identified an association.
1.5.4. Characterising Linkage Disequilibrium in the Human Genome
The characterisation of genome wide patterns of LD is an important consideration for
complex disease gene mapping. Consequently, recent attention has been on
characterising LD decay over genomic distance. Population simulations estimated
that LD would not extend much past 3 kb in a population and therefore -500,000
SNPs would be required for whole genome association and haplotype studies
(Kruglyak, 1999b). However, other simulations report that in the order of 30,000
SNPs or less would be sufficient (Collins et al, 1999, cited in Ott, 2000).
Population differences in LD decay have been observed. The theory is that younger
more genetically isolated populations, such as those founded recently in
geographically isolated regions, will be less genetically diverse and will show greater
LD around disease genes, making the disease gene easier to detect with fewer
markers. Increased LD has been observed around rare disease mutations in isolated
populations, but the situation for common disease is unclear (Jorde, 1995 cited in
Kruglyak, 1999a). Conversely, reduced LD was observed in the genetically
heterogeneous African (Nigerian) population, extending over just ~5kb compared to
~60kb in Europeans (Reich et al, 2001). However, the |D'| measure of LD used here
is biased inversely with sample size and the African sample was nearly twice the size
of the European sample. If only halfof the African samples are used, the LD patterns
of Africans and Europeans are more similar (Weiss and Clark, 2002). Lonjou et al,
(1999) performed a meta-analysis of three studies to compare LD in a number of sub-
populations from the eight major geographic regions (Europe, Near East, India and
Pakistan, Far East, sub-Saharan Africa, the Americas, Oceania and North Africa) for
two blood group loci on chromosome 4 and chromosome 1. Six of the populations
studied were genetic isolates. They found that while sub-Saharan Africa displayed
consistently lower LD, the other seven populations showed little variation, with only
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slightly higher LD in the genetic isolates (Kruglyak, 1999b). However, these two
genomic regions do not necessarily represent the entire genome and only four pairs of
loci were considered. Other research has also found that LD levels on chromosome
18 and X in the isolated populations of Finland and Sardinia did not differ markedly
from those in the more mixed populations of the UK and the US (Taillon-Miller et
al, 2000; Eaves et al, 2000).
In 2001, researchers began to find that LD, rather than decaying gradually over
genetic distance, occurred in blocks separated by recombination hotspots (Jeffreys et
al, 2001; Daly et al, 2001; Rioux et al, 2001). Empirical evidence for recombination
hotspots has come from studies of crossover in sperm (Jeffreys and May, 2004). The
implication of LD blocks was that there needed to be a shift from an assessment of
LD's dependence on genetic distance to the detection ofblock boundaries.
Consequently, a small number ofmarkers in each block could represent haplotype
diversity. For example, Daly et al (2001) showed that over an 84kb stretch of
sequence, two haplotypes accounted for more than 96% of the variation and that one
SNP would capture most of the variation over this stretch. In a genome wide study,
Patil et al (2001) identified haplotype blocks of limited diversity and found that
greater than 80% of twenty globally diverse human chromosomes could be
characterised by three common haplotypes (Patil et al, 2001). The implication of this
for association analysis is that a minimal number of SNPs could be chosen to
represent haplotype diversity.
There are many different methods, based essentially on two different types of
analysis, to statistically determine the presence ofblocks. The relative strengths and
weaknesses of each depend upon the study aims. The first type of analysis defines
blocks as regions of limited haplotype diversity. Low diversity is associated with
increased LD. However, thresholds for the number of haplotypes and proportion of
observations that define a block are often subjective and arbitrary and the algorithms
used to identify blocks need further validation (Tishkoff and Veralli, 2003). For
example, Patil et al (2001) analysed 24,047 SNPs from haploid copies of
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chromosome 21 isolated in rodent-human somatic cell hybrids. The algorithm used
identified 4,135 blocks using 4,563 SNPs. In contrast, Zhang et al (2002), using an
alternative algorithm on the same data set, identified 2,575 blocks using 3,582 SNPs.
If the goal for disease gene mapping is to minimise genotyping whilst maximising
information content then no reference to the underlying LD is necessary (Van den
Oord and Neale, 2004).
The second method of haplotype block detection uses pairwise disequilibrium to
identify transition zones in which there is evidence for recombination, i.e. a
contiguous set of SNPs in which the average LD is greater than some predetermined
threshold (Van den Oord and Neale, 2004). Reich et al (2001) used a D' half-life
value of <0.5 to detect blocks whilst Gabriel et al (2002) defined a block as a region
where less than 5% of SNP pairs show evidence for recombination (D' >0.9).
Genotyping errors mean that a D' of 1 is too stringent. For example, a genotyping
error of 2% and a D' threshold of 1 would mean that only 55% of the true blocks
would be identified, but a D' of 0.9 would identify 97% of blocks (Van den Oord and
Neale, 2004). However, if values are too low, blocks will be missed. In a simulation
study, a D' of 0.7 meant that 40% ofmarkers with a recombination between them
would be classified into a block, compared to 21% for a D' of 0.8 and 7% for a D' of
0.9 (Van den Oord and Neale, 2004). The measure of LD used will also affect the
block structure detected and evidence suggests that D' is better than r2. For example,
between two SNPs (with alleles A,a and B,b), the strict definition of a haplotype
block is where there has been no recombination and mutation is the only source of
variation. Therefore, three of the four possible haplotypes will be observed (A,B; a,b
and either A,b or a,B). D' in this case would be 1. However, r will only be 1 if two
of the four possible haplotypes variants are observed (A,B or a,b) (Van den Oord and
Neale, 2004). Simulation studies suggest that even for a region which is a block
according to the strictest definition, r2 will often be close to zero (Van den Oord and
Neale, 2004). However, D' is biased upward inversely with sample size. Therefore, if
a sample is to be used to design a global mapping panel, it should be large enough
that the observed LD structure is not an artefact of small sample size (Weiss and
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Clark, 2002). Simulations suggest that at least 100 chromosomes should be used to
adequately represent LD (Wang et al, 2002)
If blocks do exist and they are the result of recombination hotspots, they should be
shared across populations. However, if they are due to other factors such as
population bottlenecks, they will be population specific. Furthermore, they may not
apply to the whole genome (Tishkoff and Verrelli, 2003; Wall and Pritchard, 2003;
Van den Oord and Neale, 2004). A study using a selection of the SNPs from the
dbSNP database (www.ncbi.nlm.nih.gov/SNP/) for chromosome 19 showed that only
32% of the chromosome exhibited a block like structure, and recombination hotspots
were not required to fit the data (Phillips et al, 2003). Wall and Pritchard (2003)
estimated that haplotype blocks only account for 50% of the genome. If LD is to be
utilised for mapping, these issues need to be resolved.
Large scale projects are underway to utilise LD for disease gene mapping using
SNPs. The dbSNP database is a reference database of human SNP variation.
However, Johnson et al (2001) found that dbSNP did not hold sufficient SNPs to
capture the haplotype diversity for a 135kb region spanning nine genes (Johnson et
al, 2001). The HapMap project (The international HapMap consortium, 2003)
(www.hapmap.org/) builds on dbSNP and aims to characterise human diversity and
genomic LD patterns in populations from Africa, Asia and Europe, by detecting
common variants, their frequencies and the correlations between them. However, this
will only be useful if common SNPs underlie susceptibility to the diseases to be
mapped (Tishkoff and Verrelli, 2003).
1.5.5. The Common Disease/Common Variant Hypothesis
Common complex diseases are polygenic (multiple genes) or multifactorial (multiple
genes and environmental factors). Susceptibility variants have low penetrance
because they are not sufficient to cause the disease and, therefore, exist in the general
population. The Common Disease/Common Variant (CD/CV) hypothesis of common
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complex disorders states that, at each disease loci, one, or a small number of,
common (>0.10 frequency) susceptibility variants underlie disease. The implication
of this is that disease gene mapping by association analysis will be a powerful tool
for detecting loci of small effect and it underpins the applicability of the HapMap
project (Pritchard and Cox, 2002).
For the majority of common complex diseases, disease variants have not been
identified. However, a meta-analysis of 25 different reported associations to complex
disease found more positive replications than would be expected by chance,
suggesting that true positive associations make up a substantial portion of the
literature. Since the analysis was restricted to common variants, the results also
support the CD/CV hypothesis (Lohmueller et al, 2003). Common variants have been
identified for several common diseases. The APOE*E4 allele is a common allele
(frequency 0.04-0.49 in controls) that increases the risk ofAlzheimer's disease, the
PPARy allele (frequency 0.85 in controls) is implicated in the risk for type 2 diabetes
and the INS tandem repeat allele (frequency 0.75 in controls) is implicated in the risk
for type 1 diabetes (Pritchard and Cox, 2002).
The possibility exists that these alleles were identified because they are more
penetrant than most, or have a simpler allelic architecture than other disease alleles
(Pritchard and Cox, 2002). Furthermore, association analysis might not have enough
power to detect variants with a more complex allelic architecture. The NOD2 locus
involved in Crohn's disease is fairly complex, with several variants identified, each
with a frequency of ~1% in controls and a total frequency of susceptibility variants of
-10% in controls (Hugot et al, 2001; Ogura et al, 2001). However, these variants
were identified because the gene made good biological sense and the mutations were
obvious (non-synonomous and frameshift mutations). With lower penetrance, a gene
of unknown function, or synonomous SNPs, variants might not be so easily found
(Pritchard and Cox, 2002). A further implication is how applicable the CD/CV
hypothesis really is. Substantial allelic complexity might underlie many currently
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undiscovered common disease variants simply because association analysis does not
have the power to detect them.
Several historical factors favour the CD/CV hypothesis. Humans underwent a large
rapid population expansion between -18,000-150,000 years ago (700-6000
generations) increasing in size from 104 to the present 6xl09 (Smith and Lusis, 2002).
Alleles that negatively affected reproductive fitness in the founding population would
have been at a low equilibrium frequency, whilst alleles with little or no effect on
fitness, for example, diseases with late onset or a heterozygous advantage, would
have been at a high equilibrium frequency. Furthermore, alleles that were common in
the founder population will still be common today because there has not been enough
time to dilute them out (Wright and Hastie, 2001). Therefore, today's common
diseases are the ones that are caused by common alleles that were not under selection
pressure in the past. In contrast, alleles that were rare in the founder population will
today be a substantially rarer member of a diverse allelic set (Wright and Hastie,
2001). Today's monogenic diseases follow this. For example, Haemophilia B is a
monogenic disease with 167 distinct mutations, hypothesised to be the result of at
least 302 independent mutation events (Green et al, 1999).
Theoretical arguments are upheld by computer simulations. Modelling an ancestral
population of 10,000, with subsequent rapid expansion to 6xl09, Reich and Lander
(2001) analysed one disease locus with multiple disease alleles, where rare diseases
were subject to strong selection and common diseases were subject to mild or no
selection and/or a heterozygote advantage. The initial and final stages for a rare and a
common disease are the same, with low allelic diversity in the initial population and
high diversity in the expanded population, but the kinetics are different. Allelic
diversity occurs rapidly (over 1000s of years) for rare diseases and slowly (over
millions of years) for common diseases due to the effects ofmutation and selection.
The rate of new disease mutations per generation is the same for common and rare
disease but the pool of disease chromosomes they enter for the rare disease is much
smaller, resulting in a greater proportional effect on that class per generation and a
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more rapid turnover. Selection against the rare disease is more intense than for the
common disease, again leading to a more rapid turnover. However, genetic drift
(meaning that allele frequencies are not at equilibrium) and non-random mating (in
sub-populations and bottlenecks) were not accounted for. Genetic drift would lead to
a more complex allelic structure and non-random mating would lead to a simpler
allelic structure (Reich and Lander, 2001).
The CD/CV hypothesis is perhaps more of a guiding principle than a definitive rule.
Some common complex diseases, such as heart disease, are common because of
highly prevalent non-genetic influences, not because of common disease alleles and
show a reduction in heritability with increasing age (Wright and Hastie, 2001). Some
Mendelian disorders do not follow the predictions of allelic heterogeneity. Cystic
fibrosis, a recessive disorder, does show a high level of allele diversity, with >963
rare alleles identified, but, 70% of patients possess the deltaF508 allele, an allele that
is also found on 1.5% Caucasian chromosomes (Wright and Hastie, 2001). The skew
might be due to a selective heterozygous advantage. For example, it is believed that
deltaF508 allele confers resistance to cholera (Pritchard and Cox, 2002). Conversely,
the CD/CV hypothesis does not rule out the possibility of a large number of rare
alleles operating in complex disease (Smith and Lusis, 2002).
There are a number of implications of the CD/CV hypothesis for complex disease
gene mapping and the HapMap project. Association requires the enrichment of a
predisposing allele, but if substantial allelic heterogeneity exists, each new mutation
will arise on an independent haplotype background and association will not have the
power to detect a difference (Pritchard and Cox, 2002). It is also unknown what level
of locus heterogeneity exits for most complex disorders. Extreme heterogeneity
would make mapping difficult since the effect size of each locus would be reduced
(Pritchard and Cox, 2002). Again, strategies to reduce the proportion of a sample




1.6. The Human Genome Project.
Introduction
1.6.1. Why Sequence the Human Genome?
The draft sequence of the human genome was published in February 2001 and the
finished sequence was announced on the 14th April 2003. The coincident publication
of the 'rival' public (Lander et al, 2001) and private (Venter et al, 2001) draft
sequences represented a token gesture for the media and was fairly arbitrary. Even
with the announcement of the finished sequenced, sequencing is still ongoing and a
number of gaps remain. The current status (February 2004) reported at the Sanger
Institute (www.sanger.ac.uk/HGP/) is that 88.99% of the genome sequence is
finished and 4.23% of the sequence is of draft quality.
The benefits of the human genome sequence for biomedical research are
phenomenal. The Sanger Institute, responsible for approximately one third of the
finished sequence, is now beginning to focus on using the sequence to identify
disease genes. They claim that the finished sequence of chromosome 20 has
accelerated the search for susceptibility genes to diabetes, childhood eczema and
leukaemia. The benefits of the finished human genome sequence and follow on
projects such as the SNP databases and the HapMap project, promise to be most
pronounced for gene mapping in complex diseases and disorders. As has been
discussed, common multifactorial diseases, such as psychiatric illness, hypothesised
to be caused by common gene variants, are proving notoriously difficult to map. A
catalogue of human variation imposed upon the genes along a section of the genome
will help to guide future studies to define disease genes. However, the exact benefits
that these large scale projects will bring are unclear (Terwilliger et al, 2002).
1.6.2. Characteristics of the Human Genome
The most striking results of the human genome sequencing project (HGP) has been
the increasing confirmation of the relatively few genes that make up the human
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genome. The early estimates 100,000 have been curbed dramatically to the order of
30,000 or less (Pennisi, 2003). The fact that the nematode worm Caenorhabditis
elegans has approximately 20,000 genes means that there is not as much difference
between humans and simple life forms as previously thought. That the fruit fly
drosophila has less, at 14,000 than the distinctly less sophisticated C.elegans is a
further puzzle (Claverie, 2001). The belief is that increasing organismal complexity
must therefore come from alternative splicing or post-translational modifications. It
has been estimated that approximately 30-50% of genes might be alternatively
spliced (Lander et al, 2001; Venter et al, 2001). However, there is evidence that the
rates of alternative splicing and the number of alternative transcripts produced per
gene are comparable in seven organisms, including humans, using a bioinformatics
protocol to compare ESTs and mRNA sequences (Brett et al, 2002). Therefore, post-
translational modification, rather than alternative splicing, may account for the
increased complexity of humans. Post translational modification, ofwhich there are
over 200 different types known, for example phosphorylation and glycosylation, is an
important determinant of protein function (Banks et al, 2000).
Another puzzling finding identified as a result of the genome projects is that genome
size does not correlate with organism complexity. For example, the human genome is
200 times larger than that of the yeast S. cerevisiae, but is 200 times smaller than that
of amoeba dnbia (Lander et al, 2001). This can be explained by the fact that less than
5% of the human genome contains the coding and regulatory sequences of genes,
whereas approximately 50% of it is composed of five classes of repetitive sequence:
transposon-derived repeats (accounting for 45% of the genome), processed
pseudogenes, simple sequence repeats (for example microsatellite repeats), segmental
duplications and blocks of tandemly repeated sequences (Lander et al, 2001).
The transposon-derived repeats can be divided into four types: long interspersed
elements (LINEs), short interspersed elements (SINEs), long terminal repeat (LTR)
retrotransposons and DNA transposons. LINEs are 6-8kb in length and consist of a
polymerase II promoter and two ORFs. A translated LINE RNA, with its protein, will
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reverse transcribe itself from the 3' end into DNA; often not successfully completing
reverse transcription to the 5' end and creating a truncated insertion (Lander et al,
2001). SINEs are between 100 and 400 bp and do not encode proteins and are
thought to use the LINE machinery to retrotranspose themselves into DNA. The only
active SINE in the human is the Alu element (Batzer and Deininger, 2002). LTR
retrotransposons are DNA elements characterised by long terminal repeats and DNA
transposons are DNA elements that move about the genome by excision and
reintegration without an RNA intermediary (Smit and Riggs, 1996).
Pseudogenes are non-functional genes that result from a failure of transcription,
translation or result in an altered protein function. Processed pseudogenes arise by
reverse transcription of the mature mRNA into the genome sequence, utilising the
reverse transcription machinery of the transposon-derived repeats (Lander et al,
2001; Venter et al, 2001). Pseudogenes can also arise by genomic segmental
duplication. Evidence from chromosome 22 suggests that 19% of the genes are
pseudogenes and that 82% of these arose by retrotransposition (Mighell et al, 2000).
Pseudogenes and segmental duplication are considered to be one mechanism by
which genomes evolve, whereby mutation in the duplicated genes allows them to
take on new functional roles (Samonte and Eichler, 2002). The HOX gene cluster is
one example of a gene cluster that appears to have been duplicated four times in the
human genome, although it is unclear whether individual gene duplications or whole
genome duplication explain the findings (Spring, 2002).
In addition to the proteome, a significant proportion of human genes encode non-
coding RNAs (ncRNAs): RNAs that do not code for protein. These include transfer
RNAs that translate RNA into protein, ribosomal RNAs that are also involved in the
translational machinery, small nucleolar RNAs that are required for ribosomal RNA
processing, small nuclear RNAs that are a component of spliceosomes, and finally
ncRNAs that have known or unknown biochemical function (Lander et al, 2001).
46
Chapter One
1.6.3. Annotating the Human Genome
Introduction
It is increasingly important for the identification of disease genes to annotate the
finished human genome sequence. Genes can be identified in three different ways:
direct evidence by the alignment of sequenced ESTs and mRNA to the genomic
sequence, indirect evidence from the homology to known proteins and DNA in
humans and other species and programmes that calculate statistical infonnation about
gene structure such as splice sites and ORFs (Venter et al, 2001; Lander et al, 2001).
Gene and exon prediction programmes make predictions based on the characteristics
of known genes and their structure. This is made especially difficult in the human
genome due to the large amount of 'noise' from non-coding sequence, making ORFs
harder to distinguish (Lander et al, 2001). Computational gene identification is
composed of two non-trivial steps. First, they need to divide the sequence into
segments that are likely to correspond to an individual gene and secondly, they need
to construct a gene model that reflects the structure of the transcripts (Lander et al,
2001). Gene prediction programmes have been estimated to correctly predict
approximately 70-75% of individual exons (Burge and Karlin, 1997; Guigo et al,
2000). However, these figures may be overestimated since the training sets are
known genes which may have more standard gene structures.
Non-coding RNAs are often small and do not have a translated ORF or a
polyadenylation signal. They are therefore hard to identify by standard gene finding
programmes or experiments involving cDNA (since cDNA is generated by targeting
the poly-A tail ofmature mRNAs that is generated after recognition of the
polyadenylation signal) (Lander et al, 2001).
In addition to gene prediction programmes and homology based matches, CpG
islands represent another way of identifying genes. CpG islands are stretches of
unmethylated DNA with a high frequency (greater than 50%) ofCpG dinucleotides
that occur at the transcriptional start site of genes. It has been shown that most
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housekeeping genes possess a CpG island (Larsen et al, 1992) and that CpG island
methylation is correlated with gene inactivation (Venter et al, 2001). Venter et al
(2001) estimated a total of 26,826 CpG islands in the human genome by using a
computational method that used a ratio of the observed versus expected frequency of
CG dinucleotides that was equal to or greater than 0.8. Interestingly, this figure is
comparable to the estimated total number of genes in the genome (Pennisi, 2003).
However, it does not account for how many CpG islands are not associated with
genes. The finding of Antequera and Bird (1993), that 56% of human genes are
associated with CpG islands and the estimate ofVenter et al (2001), that there are
-27,000 CpG islands in the human genome, do not follow if there are only -30,000
genes in the human genome. They could be reconciled if some CpG islands are not
associated with genes.
1.7. The Chromosome 4 Linkage Families
1.7.1 The Families
Blackwood et al (1996) described a genome wide linkage study in a family of 120
individuals, F22, segregating BPAD and RMD (Figure 2-1). A three point linkage
analysis gave a maximum multipoint Lod score of 4.8 in the region D4S431-D4S403
on chromosome 4p. A 22Mb haplotype is inherited from one founder individual to all
11 cases of BPAD I and II and 14 out of 16 cases ofRMD. This haplotype defines
the disease associated chromosome in F22. Two individuals with early onset RMD
do not possess the haplotype, suggesting that they are phenocopies. Nine individuals
without a psychiatric diagnosis do possess the haplotype, suggesting that there is
incomplete penetrance of the susceptibility locus. As previously discussed,
psychiatric illnesses are complex disorders where multiple genes and environmental
factors contribute to the phenotype. Therefore, phenocopies and incomplete
penetrance are expected. In addition, there were six individuals with the haplotype,
including the founder, whose diagnostic status was unknown. A reanalysis of the
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family 22 data, using a method that does not require specification of the mode of
inheritance, confirmed the initial findings (Visscher et al, 1999).
A further 11 Scottish families were typed by this group for marker D4S394 in the
linked region. Linkage was tested on all 11 families together (a total of 40 cases of
BPAD I/II or schizoaffective disorder and 17 cases ofRMD) and a combined Lod
score of 3.3 with a broad phenotype was identified. It was subsequently shown that
only three families (including F59) contributed positive Lod scores. Analysed alone,
F59 had a Lod score of 1.2. From subsequent unpublished laboratory work by others
in the group, F59 has been shown to exhibit a chromosome 4p haplotype that is
transmitted from an unknown founder to all five cases ofBPAD I and II disorder and
one undiagnosed individual. The individual without a diagnosis who carries the
disease haplotype again suggests that there is incomplete penetrance of the
susceptibility locus. The Lod score contributed by this family is small (the odds for a
Lod of 1.2 are a little higher than 10:1 in favour of linkage), but the small size of the
family (n = 6) imposes limits on the maximum Lod score that can be achieved by this
family. Therefore, it is possible that the linkage result for F59 is spurious. Family 59
was included in the analysis of the chromosome 4p candidate region with these
limitations in mind.
Two remaining families, F50 and F48 (Figures 2-3 and 2-4), were reported in the
literature as showing linkage ofpsychiatric illness to chromosome 4p (Asherson et
al, 1998; Detera-Wadeligh et al, 1999) and access to these samples has been obtained
via collaboration. Family 50 segregates schizophrenia and schizoaffective disorder.
However, one individual has a form of psychosis that could not be further classified
due to incomplete data. The results of a genome wide linkage study in F50 found a
Lod score of 2.0 on chromosome 4p, and a haplotype is inherited with the disorder
(Asherson et al, 1998). This is below the level for genome wide significance, but the
maximum attainable Lod score is limited by the small size of the family. Family 48 is
a large family of 82 individuals who segregate BPAD, RMD and schizophrenia. A
genome wide linkage study identified a Lod score of 3.2 on chromosome 4p. There is
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also a haplotype that is inherited with the illness (Detera-Wadleigh et al, 1999). The
fact that families 48 and 50 segregate different psychiatric illnesses to families 22 and
59 was recognised. However, there is evidence for other overlapping genomic
susceptibility regions in schizophrenia and BPAD and clinical, epidemiological and
biological evidence suggests that RMD, BPAD, schizoaffective disorder and
schizophrenia should be seen along a continuum rather than separate diseases
(discussed in Section 1.5.1.4). These findings supported the consideration of these
linkage findings from families 50 and 48 together with those of families 22 and 59.
Other studies have replicated the linkage to chromosome 4p. Ewald et al, (1998)
studied 16 markers between 4pter-4pl2 in two Danish families. They identified a
Lod score of 2.0 for marker D4S394 under a recessive model, suggesting bilinear
inheritance. Although the linkage from Blackwood et al (1996) was found using a
dominant model, the results are not contradictory if allelic heterogeneity operates. In
a genome wide scan of 196 affected sibling pairs with schizophrenia, Williams et al
(1999), identified suggestive linkage on chromosome 4p, 18q and Xcen. The Lod
score on 4p was 1.7 for marker D4S2983 which lies inbetween D4S431 and D4S403,
the region implicated by Blackwood et al (1996). Lerer et al (2003) have also
identified suggestive nonparametric linkage to chromosome 4p 15-16 in a population
of Arab Israeli families. A recent study of schizophrenic and BPAD individuals from
the Faroe Islands found an association to several overlapping two and three marker
haplotypes on chromosome 4pl6.1 (Als et al, 2004). This is interesting in view of the
possible common ancestry between the Scottish and the Faroese populations.
However, this study was based on very small sample sizes. Interestingly, Ginns et al
(1998) identified a region on chromosome 4p linked to a 'mental health wellness'
phenotype in several large Old Order Amish families segregating BPAD.
1.7.2 Disease Associated Haplotypes
The haplotype inherited with illness in each of the four families studied defines the
region that contains the susceptibility polymorphism. Haplotypes are defined by
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tracing the inheritance ofmarker alleles from parent to offspring in a family. An
interruption in the inheritance of a contiguous haplotype from a parent to their
offspring with the commencement of the inheritance of the alternate haplotype from
the second chromosome of that parent constitutes a recombination breakpoint.
Haplotypes define the linkage regions, but they can also be studied for allele sharing
since this might be an indication of a founder effect. There are a number of reasons
why a common ancestor may be hypothesised. Firstly, three of the families are Celtic.
However, this is merely a cultural observation and does not have a genetic basis.
Secondly, the disease haplotypes of each of the four families overlap. This overlap
may point to a common susceptibility locus. Other studies have found a similar
founder effect, such as the seven marker haplotype in the NRG1 gene observed in
several Northern European populations (Stefansson et al, 2002; Stefansson et al,
2003) but not in Chinese or Japanese populations (Li et al, 2004b; Iwata et al, 2004).
The disease haplotypes of the four families do not fully overlap. There are two main
regions of interest: Minimal Region One (MR1), defined by the overlap ofF22, F59
and F50 and Minimal Region Two (MR2), defined by the overlap of F22, F50 and
F48 (Figure 1-4). MR1 is a good candidate region because the families are Celtic and
association has been found between MR1 markers and schizophrenia (Muir et al,
2001). However, MR2 comprises the two largest families, F22 and F48. As
mentioned previously, the Lod scores in F59 and F50 are small. However, a large
linkage region was identified from F22, containing many potential candidate genes.
Financial and time constraints meant that definition of the minimal regions helped
prioritise the research efforts into chromosomal regions ofmore manageable sizes.
However, it is recognised that the minimal region boundaries are dependent on the
validity of the linkage results of each family and on specific individuals within
families. Therefore, genes outside MR1 and MR2, but inside the F22 linkage region,
certainly cannot be discounted as potential candidates for future work.
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Figure 1-4: Overlapping haplotypes of families 22, 59, 50 and 48. The coloured bars
represent a marker haplotype on chromosome 4p inherited with psychiatric illness in each
family. The family number is marked along the top. The number above the bar shows the Lod
score for that family (F22 = a multipoint Lod score). The four haplotypes overlap, enabling the
delineation of smaller regions of interest. The solid horizontal lines mark two such regions:





At the start of this project (October 2000) the chromosome 4p disease associated
haplotypes of families 22, 59, 48 and 50 in the regions of linkage were in the process
of being defined and a BAC/PAC contig of part of this region had been constructed
(Evans et al, 2001a). The general aim of this PhD was to define the regions of interest
further and use this to guide association analysis of candidate genes. Four specific
aims were:
1. To define the genomic region that lies in the recombination breakpoint interval of
MR1.
2. To refine the two recombination breakpoint intervals that define MR1 by
microsatellite and SNP identification and genotyping.
3. To construct a transcript map ofMR1 and MR2. In order to direct and interpret
future association analysis of the two best candidate regions, it was important to
know the position of all the genes.
4. To carry out association analysis of two positional and functional candidate genes,
the orphan G-protein-coupled receptor 78 (GPR78) gene and the superoxide
dismutase 3 (SOD3) gene, within MR1 and MR2, respectively.
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DNA from Family 22 and 59 was collected as a blood sample by Professor D.
Blackwood and Professor W. Muir (Department of Psychiatry, Royal Edinburgh
Hospital, The University of Edinburgh, Edinburgh). Individuals were ascertained
through contact with general practitioners and local hospitals. Each individual was
interviewed using the Schedule for Affective Disorders and Schizophrenia (lifetime
version). Figure 2-1 and 2-2 detail the family pedigree and includes the diagnosis
and ID number of each individual. The sex of each individual was unavailable for
reasons of patient confidentiality. DNA from family 50 was obtained by
collaboration with Professor P. Asherson (Neuropsychiatric Genetics Unit, Divisions
of Psychological Medicine and Medical Genetics, University of Wales, College of
Medicine, Cardiff). Figure 2-3 details the family pedigree, and includes the sex,
diagnosis and ID number of each individual. DNA from family 48 was obtained by
collaboration with Professor S. D. Detera-Wadleigh (Clinical Neurogenetics Branch,
National Institute of Mental Health, National Cancer Institute, National Institutes of
Health, Bethesda, MD 20892). Figure 2-4 details the family pedigree and the
diagnosis and ID number of each individual. Again, the sex of each individual was
unavailable for reasons of patient confidentiality.
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Chapter Two
2.1.2. Case and Control Samples
Materials and Methods
Individuals suffering from schizophrenia (SCZ), bipolar affective disorder (BPAD)
and recurrent major depression (RMD) were recruited from the Royal Edinburgh
Hospital by Professor D. Blackwood and Professor W. Muir. Control patients were
recruited from the blood transfusion service, Edinburgh.
2.1.3. DNA Panels
2.1.3.1. Allele Sharing Panel
The Allele Sharing (AS) DNA Panel contains 46 DNAs, a control DNA pool
(Section 2.1.3.2.) and a negative control. The DNA was at a concentration of
lOng/pl. The plate contained thirty-one members of F22, five members of F59, seven
members of F50 and three members of F48. This represents multiple copies of the
four disease chromosomes, to enable unambiguous determination of the disease
haplotype, and 41 control chromosomes (defined as all non-disease chromosomes).
The control pool was included to give a measure of the range of alleles for
microsatellite markers and the allele frequency in a control population. See Figure 2-
5: A, for the plate layout and family IDs.
2.1.3.2. Pools Plate
DNA samples from the case and control groups (Section 2.1.2.) were pooled by S. Le
Hellard. Four DNA pools corresponding to diagnosis were constructed: 192
individuals with schizophrenia, 271 with BPAD I and II, 87 individuals with RMD
and 383 controls.
The pools plate was set up with either four or six replicates of each pool and 23
individual control DNAs. The 23 individual DNAs ensure that for SNPs with a minor
allele frequency of 0.20, there will be approximately five individuals with the minor
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allele. This provides enough individuals from which to calculate the K ratio (Section
































































































690 698 620 621 685 687 684 578 792 753 777 638
630 631 637 640 644 645 646 697 694 692 671 neg.
C C C C C C BP BP BP BP BP BP
S S S S S S RMD RMD RMD RMD RMD RMD
Figure 2-5: DNA panels used (96 well plate layout). A: Allele sharing panel. Top left = family
identification number (ID), bottom right = individual lab ID. pool = DNA pool of 383 control
individuals, neg = no template control. B: Pools plate. Number = control individual lab ID.
neg = no-template control. C = DNA pool of 383 control individuals, BP = DNA pool of 271
recurrent bipolar affective disorder I and II patients, S = DNA pool of 192 schizophrenia
patients, RMD = DNA pool of 87 patients with recurrent major depression.
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2.1.3.3. Monochromosome Hybrid Panel
Materials and Methods
A monochromosomal somatic cell hybrid DNA panel (MCHP) was obtained from
the MRC-RFGRC (Kelsall et al, 1995) (Table 2-1). This is a panel of rodent (mouse
or hamster) somatic cells that each retains a single human chromosome on a rodent
background. The panel is obtained in a 48 well microtitre plate containing 27
samples: lpg of each human chromosome in 25pl of sterile water, and lpg of
human, hamster and mouse control DNA. The MCHP was diluted to 30ng/pl, and
15ng was used in a lOjul PCR (Section 2.3).

























Table 2-1: Monochromosomal somatic cell hybrid DNA panel (MRC-RFGRC). Table shows






Primers were designed using a local copy of the Whitehead Institute for Biomedical
Research primer3 programme (http://www.broad.mit.edu/cgi-bin/primer/primer3/
www.cgi) (Rozen and Skaletsky, 2000), with inhouse defaults built in. Where the
primers amplified coding sequences, a BLASTn similarity search was performed to
check that there was no priming from related gene family members. Typically,
oligonucleotides were 18-30bp long with approximately 50% GC content and a
melting temperature (Tm) of between 50°C and 70°C. They were chosen to be stable,
and not predicted to form hairpin structures and primer dimerism where the primers
were used as a pair.
2.2.2. Oligonucleotide Synthesis
Oligonucleotides were commercially synthesised from MWG Biotech, Sigma
Genosys or Invitrogen, typically at the 0.03 pmol scale with standard purification.
One exception was the 224 vectorette primer which was synthesised at the 0.05 pmol
scale and purified by reverse phage cartridge. If a primer pair was used for
microsatellite genotyping, typically the forward primer was labelled at the 5' end
with one of hex, tet or fam fluorescent tags.
2.2.3. Oligonucleotide Primer Sequences
See Appendix I for details of the STSs used in each chapter. Primer sequences, the
resultant STS size, the optimal PCR cycling annealing temperature, the optimal PCR
buffer, additives included in the PCR and further comments about the PCR are
included.
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2.3. Amplification of DNA by the Polymerase Chain Reaction
(PCR)
The polymerase chain reaction allows the rapid and specific amplification of a DNA
template from a highly complex mixture ofDNA. The specificity is provided by
oligonucleotide primers complementary to the 5' ends of the sequence to be
amplified. The PCR reaction is a three step process. In the first step the DNA is
denatured at a high temperature. The next step reduces the temperature to allow the
oligonucleotides to anneal to the specific site on the DNA. In the final step the
temperature is adjusted to allow amplification of the desired sequence by a
thermostable DNA polymerase. Multiple cycles of these three steps results in
exponential amplification of the desired sequence. Numerous optimisations and
modifications to the basic technique have been used during this work.
2.3.1. PCR Reagents
Typically, a master mix was prepared on ice consisting of IX PCR buffer (supplied
by Roche, Applied Biosystems, Gibco BRL, NEB or Invitrogen), 1.5mM MgCl ,
between lOOpM and 167pM of each deoxy-nucleotide (dNTP) (Sigma), 0.5-1U Taq
DNA polymerase (Taq was either made inhouse or bought from Sigma) and between
0.33pM and 0.67 pM of each oligonucleotide primer. Optional additives to this basic
PCR were IX PCR Enhancer (Invitrogen) or 0.5pl PCR grade dimethyl sulfoxide
(DMSO) (Sigma, cat.no. D8418). DNA was prepared on a 96 well plate or in 0.5ml
eppendorfs. Typically, 20-40ng DNA was used, depending on the PCR final volume,
and then the master mix was alliquotted into the tubes or plate. PCRs were run on a
MJR-PTC 220 or MJR-PTC 200 thermal cycler (MJ Research). Heated lids were





PCR's consisted of an initial denaturing step of 93 °C for 1-2 minutes, followed by
25-35 cycles of the three steps: denaturation, annealing and extension. The
denaturation step typically lasted 5-20 seconds. The annealing step temperature is
determined by the predicted Tm of the oligonucleotide primers. Primers were
designed with a Tm of approximately 60°C and consequently the annealing
temperature step in the PCR was typically performed 5°C below this at 55°C. The
annealing step was 20-30 seconds. The extension step is carried out at 72°C, the
optimal temp for Taq DNA polymerase. The length of extension was estimated
depending on the size of the product; approximately 1 minute per lkb of sequence
was used. After the final cycle, a further elongation step of 5-10 minutes was used to
ensure fragments were complete. This was increased to 50 minutes for microsatellite
markers.
The 'Touch down' PCR was used to increase the specificity of the PCR reaction
(Don et al, 1991). An initial annealing temperature is used that is 10°C above that of
the final annealing temperature required. With every cycle, this is reduced by 1 °C,
until after 10 cycles the desired annealing temperature is reached. The normal 25-35
cycles at the desired annealing temperature can then proceed. This results in only
highly specific primer-template reactions occurring during the first few cycles, thus
selecting for the correct product during the remainder of the reaction. See Appendix I
for individual oligonucleotide sequences with the required PCR additives and
cycling conditions.
2.4. RT-PCR
2.4.1. RNA Extraction from Cells
RNA was extracted from a human lymphoblastoid cell line, using the RNeasy® Mini
kit (Quiagen) as per the manufacturers instructions, and stored at -70°C.
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2.4.2. cDNA synthesis and RT-PCR
Materials and Methods
cDNA was synthesised using the First Strand cDNA Synthesis kit (Boehringer
Mannheim) as per the manufacturers instructions, using the p(dN)6 primers. Control
tubes without reverse transcriptase and without RNA were also made at the same
time. RT-PCR was carried out as in Section 2.3, using 2pl RNA in a 15pl total
volume PCR.
Alternatively, Universal QUICK-Clone™ cDNA II (Clontech) was used to amplify
putative exons. This is a ready made human multiple tissue cDNA. The cDNA was
supplied as 2ng/pl, and was diluted to 0.4ng/pl for RT-PCR. RT-PCR was carried
out as in Section 2.3, using lpl of cDNA in a 25pl total volume RT-PCR.
STSs for RT-PCR were designed as in Section 2.2 (see Appendix I for details of each
primer). Where the genomic DNA product was larger than ~l-2kb, a number of
different buffering systems were used at a variety of different annealing temperatures
to produce product. Where the genomic DNA product size was smaller than ~l-2kb,
the RT-PCR was first optimised on genomic DNA for buffering system and
annealing temperature. In this case, the buffer, additive and annealing temperature of
the RT-PCR are noted in Appendix I.
2.5. cDNA Library Screening
cDNA library screening was carried out at the Sanger Institute, Cambridge.
2.5.1. cDNA Libraries
Twenty-two cDNA libraries (Table 2-2) were used. Each library consisted of
-100,000 clones that were divided into five superpools of-25,000 clones each. The
22 cDNA libraries were arranged on three 96 well plates: A primary plate of nine
libraries, a secondary plate of nine libraries and a tertiary plate of four libraries.
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Table 2-2 provides details of each cDNA library. Each plate contained the five
superpools of each library and a positive and a negative control. This was replicated
twice on each 96 well plate, enabling two STSs to be screened simultaneously.
The clones were prepared with a vectorette ligated onto the ends (Riley et al, 1990).
A vectorette is composed of two strands of non-basepairing sequence. The sequence
of each strand is the same and is in the same orientation (i.e. not reversed or
complimented). The vectorette primer (224) (see Appendix I) is a 30 base pair long
oligonucleotide that is identical in sequence (i.e. not reversed or complimentary) to
the vectorette sequence and therefore is not able to anneal to the vectorette. The
vectorette primer is used in conjunction with a specific oligonucleotide that anneals
to the cDNA insert sequence. The specific oligonucleotide is required to anneal to
the cDNA and amplify into the vectorette, thus creating the complementary sequence
for the vectorette primer to anneal and amplify back. Therefore, the vectorette is used
as a specificity regulator. However, non-specific product would be possible if the
cDNA library contains sequence complimentary to the vectorette primer sequence.
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2.5.2. cDNA Library Screening
Materials and Methods
2.5.2.1. Pre-screen
STSs were designed as in Section 2.2 (see Appendix I for details of each STS). PCR
with a pair of specific primers confirmed if the STS was represented as a cDNA. The
primary plate was screened first, and if no positive libraries were identified, the
secondary and tertiary plates were screened. The aim was to identify three positive
superpools, preferably from different libraries. PCR was carried out as in Section 2.3,
using IX NEB PCR buffer and including 0.2pl of 1/20 P mercapto ethanol (BDH)
and 0.25pl lOmg/ml bovine serum albumin (BSA) (NEB, cat.no. A7517) in a 15pl
total volume PCR. The PCR cycling conditions were as follows: 93°C for 1 minute,
followed by 10 cycles of 93°C for 15 seconds, 65°C for 30 seconds (- 1 second per
cycle) and 72°C for 45 seconds. This was followed by 30 cycles of 93°C for 15
seconds, 55°C for 30 seconds and 72°C for 45 seconds. Finally, an extension step of
72°C for 10 minutes. The product was run on a 2.5% 0.5X TBE agarose gel and
visualised under UV light.
2.5.2.2. Vectorette PCR
A vectorette PCR was performed with each STS primer and the vectorette primer
(224) from the pre-screen on three positive superpools. Vectorette PCR was
performed as in Section 2.3 except 0.12pl of each of Perfect Match, Taq extender
and Advantage-2 Taq (Clontech) was used instead of Taq DNA polymerase and
0.2pl of 1/20 P mercapto ethanol and 0.5pl 5mg/ml BSA were added in a 15pl total
volume PCR. The PCR cycling conditions were as follows: 95°C for 2 minutes,
followed by 17 cycles of 94°C for 5 seconds, 65°C for 30 seconds and 72°C for 3
minutes. This was followed by 18 cycles of 94°C for 5 seconds, 60°C for 30 seconds
and 72°C for 3 minutes. Finally, an extension step of 72°C for 10 minutes. The





The vectorette PCR was also amplified with nested primers, designed as described in
Section 2.2 (see Appendix I for details of each nested primer). This was to increase
specificity of the product. A 1:100 dilution of the vectorette PCR was used as a
template, and PCR was performed as in Section 2.3, with IX Perkin Elmer PCR
buffer and IX PCR enhancer (Invitrogen) in a 15-25pl total volume PCR.
2.6. Agarose Electrophoresis
2.6.1. Solutions
20X TBE 1,8M Tris.HCL, 40mM EDTA, 1,8M boric acid, pH 8.0
50X modified TAE 40mM Tris-acetate, 0.1 mM Na2EDTA, pH 8.0
10X DNA loading buffer 20% ficoll (Sigma), 100mM EDTA, orange G (Sigma)
2.6.2. Size Markers
The marker used depended on the expected band sizes to be resolved. Typically 250-
500ng ofDNA was loaded per marker lane and at least two marker lanes were run
per gel to check for even migration across the gel.
Size markers
1. lamda DNA digested with Hind III (Boehringer Mannheim).
2. Ready Load™ 1 kb DNA ladder (Invitrogen).
3. Ready Load™ 100 bp DNA ladder (Invitrogen).
4. Ready Load™ PhiX174 RF DNA /Haelll fragments (Invitrogen)
2.6.3. Agarose Gel Electrophoresis
Size fractionation ofDNA was achieved by migration through agarose gels. Agarose
was dissolved in 0.5X TBE or 0.5X modified (low salt) TAE buffer by heating. The
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final concentration of agarose depended on the size ofDNA fragments to be
resolved: lower concentrations for larger fragments. Most PCR products were run on
1-2% agarose gels, lpl per 100ml of buffer of lOng/pl Ethidium bromide (Sigma)
was added to all gels to stain the DNA. Ethidium bromide intercalates between bases
of nucleic acid and fluoresces upon stimulation by UV light. IX loading buffer was
added to the DNA prior to loading. Gels were placed in an electrophoresis tank of
appropriate size and covered with buffer to match the gel. An electrical current of
50-120 V was passed through the buffer, resulting in migration of the negatively
charged DNA and loading dye towards the anode. DNA fragments were visualised
on a UV transilluminator and photographed.
2.7. Purification and Concentration of DNA
2.7.1. PCR Purification
Prior to both SNaPshotI M genotyping and sequencing of PCR products it was
necessary to remove excess primers and dNTPs from the PCR. Therefore, the PCR
was treated with EXOSAP-IT (USB), a mixture of two exonucleases. The enzyme
exonuclease 1 (EXO) degrades the unincorporated oligonucleotides remaining in the
reaction and the enzyme shrimp alkaline phosphatase (SAP) removes any
unincorporated dNTPs. Typically, 1 -2jul of enzyme was used per 5pi PCR. If the
PCR was being sequenced, 10-40ng of the PCR was used in a final volume of 5pl.
The PCR concentration was estimated by running an aliquot of the PCR on an
agarose gel with 250ng and 500ng of PhiX174 RF DNA /Haelll fragments marker.
The enzyme and PCR mix was incubated on a hybaid thermocycler at 37°C for 1
hour, and the enzymes were inactivated by heating for 20 minutes at 80°C.
2.7.2. Purification of DNA from Agarose Gels
subsequent to RT-PCR, product that was to be sequenced was first excised from an
agarose gel and purified in one of the following ways.
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2.7.2.1. Spin Columns
RT-PCR product was excised from a 1.2% 0.5X Modified TAE (Millipore) agarose
gel. The gel slice was then placed in an Ultrafree®-DA gel extraction column
(Millipore) and centrifuged at 5000 g for 10 minutes on a Biofuge Fresco desk top
centrifuge. The resulting product was ready for direct sequencing.
2.7.2.2. Filter Tip Purification
RT-PCR product was excised from a 1.2-2% 0.5X TBE agarose gel. The gel slice
was then placed at the top end of a 200pl filter tip (Rainin), placed in a 1.5ml
eppendorf tube and spun at 10,000 g for 15 minutes on a Biofuge Fresco desktop
centrifuge. A 0.025pM drop dialysis filter (Millipore) was placed on the surface of a
pool of sterile water in a petri dish. The eluted PCR product was placed as a drop
onto the surface of the filter and left for 1 hour. The concentration of salts in the
sample equilibrates with the water, but the filter prevents the movement of
macromeolecules across the surface. The drop was then removed by pipetting.
2.7.2.3. Gel Purification Kit
RT-PCR products obtained from the vectorette PCR (Section 2.5.2.2.) were excised
from a 2.5% TBE agarose gel. The gel slice was added to 30pl sterile water and left
overnight so that product leached out into the water. This was used as a template for
a second round of PCR. Product from this second round was excised from a 2.5%
0.5X TBE agarose gel. The DNA was extracted from the gel slice using the
QIAquick Gel Extraction Kit (Qiagen) as per the manufacturer's instructions.
2.7.3. Ethanol Precipitation
Ethanol precipitation was used subsequent to sequencing products obtained from a
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PCR. A 1/5 volume of the PCR of 25mM EDTA and 2-3 volumes of 95-99.9%
ethanol (Fisher analysis grade) were added to the PCR to give a final ethanol
concentration of 67-71%. An optional 1/20 volume of pellet paint was also added.
This was incubated at room temperature for 15 min. If the precipitation was carried
out in 0.5ml eppendorf tubes, the mixture was centrifuged at 10,000 g on a Biofuge
Fresco desk top centrifuge for 40 minutes. If precipitation was carried out in a 96
well plate, the mixture was centrifuged at 10,000 g for 30-40 minutes on a Jouan CR
422 centrifuge. The supernatant was removed from eppendorfs by pipeting or from
96 well plates by inversion of the plate on a tissue and careful tapping. The pellet
was washed once or twice with 70% ethanol. In eppendorfs, 500pl of 70% ethanol
was added to the pellet, which was left at room temperature for five minutes and then
centrifuged at 10,000 g for five minutes. In a 96 well plate, 30pl of 70% ethanol was
added to the pellet and the plate was centrifuged for 15 minutes at 10,000 g. The
supernatant was then removed from eppendorfs by pipeting or from 96 well plates by
inversion of the plate on a tissue and careful tapping. If a second wash was
performed the process was repeated. If precipitation was being carried out in a 96
well plate, a final gentle spin of the inverted plate onto a tissue, by letting the
centrifuge reach 3000 g, removed the last of the ethanol not removed by inversion of
the plate alone. Pellets were left to air dry in the dark.
2.8. Sequencing
2.8.1. Sequencing PCR Products
Sequencing was carried out using dye terminator chemistry. Dideoxy-nucleotides
(ddNTPs) terminate the sequencing reaction at each base to generate a ladder of
fragments. Each of the four ddNTPs is labelled with a different dye, enabling a
computer to read the sequence. The sequencing reactions were performed using the
BigDye® Terminator v3.1. cycle sequencing kit (Applied Biosystems). Typically,
10-40ng DNA, 3.2pM of the appropriate primer and 0.5-1 pi of the BigDye
terminator cycle sequencing kit was used in a total volume of lOpl. The pGEM
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control vector supplied in the kit was sequenced with the Ml3 primer to control for
the quality of template.
The cycle sequencing reaction was performed on a hybaid DNA thermal cycler. The
cycling conditions were: 96°C for 1 minute and then 25 cycles of 96°C for 10
seconds, 50°C for 10 seconds and 60°C for 4 minutes.
Sequences were purified by ethanol precipitation (Section 2.7.3) and sequenced on
an AB1 PRISM® 377 or 3730 Genetic Analyser by Alison Condie. The output file is
directly amenable to computer analysis. Multiple sequence chromatograms were
aligned using the phredPhrap software and visualised with the Consed programme.
I individual sequence chromatograms were visualised with the Chromas programme.
2.9. Genotyping
All ABI PRISM® gel electrophoresis was performed by Alison Condie at the
Welcome Trust Clinical Researach Facility, Western General Flospital, Edinburgh.
For both SNP and microsatellite genotyping, the capillary system (ABI PRISM®
3730 or 3100 Genetic Analyser) was used in preference over the slab gel system
(ABI PRISM® 377 Genetic Analyser). The capillary system means that the
individual sample fluorescence cannot be distorted by neighbouring samples as it can
on a slab gel.
2.9.1. SNP Genotyping
2.9.1.1. SNaPshot™
SNP oligonucleotides were designed to the 16-24bp of sequence immediately
flanking the SNP. This consequently restricts the choice of oligonucleotide to either
the forward or reverse orientation. The decision of which orientation to choose was
based on the folding characteristics of the PCR template and the SNP
oligonucleotide. The mfold (http://www.bioinfo.rpi.edu/applications/mfold/old/dna/)
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programme (Zuker, 2003) at the Bioinformatics Centre at Rensselaer and Wadsworth
makes predictions about how a length ofDNA is likely to fold up at different
temperatures, and allows an assessment of the accessibility of the SNP
oligonucleotide to the PCR template. The decision to design the forward or reverse
orientation was made based on this.
The SNaPshot™ ddNTP primer extension lit (PE Biosystems) includes DNA
polymerase and fluorescently labelled ddNTPs, each labelled with a different dye.
The SNP oligonucleotide anneals to the DNA template and an extension reaction of
one base pair takes place, the ddNTP blocking the addition of further nucleotides.
Therefore, for example, an adenine nucleotide on the template DNA strand would
result in the addition of a tyrosine ddNTP to the SNP oligonucleotide, which
fluoresces red. A homozygote would be represented by a single dye peak, a
heterozygote by two dyes peaks.
SNP oligonucleotides were designed to be multiplexed together. A size difference of
four base pairs could be distinguished on a polyacrylamide gel and therefore,
oligonucleotides were designed to be 16, 20 or 24 bp in length. In addition, SNPs
that gave complementary genotypes could be distinguished by colour. Therefore, a
maximum of six SNP oligonucleotides could be multiplexed in one reaction.
Reactions were multiplexed after the SNaPshot1 M reaction to prevent differential
amplification of the SNP oligonucleotides during the SNaPshot™ reaction.
Typically, 2pM of oligonucleotide was used with 2pl of SNaPshot™ mix and 3pl of
the PCR template in a final volume of lOpl. Thermal cycling of SNaPshot1 M
reactions increases signal intensity and decreases sensitivity to reaction conditions.
Typically, 25-30 cycles were performed with a short 10 second denaturation step at
95°C, an annealing step of 50°C for 5 seconds, and an extension step at 60°C for 30
seconds. The SNapShot™ reaction was treated with lpl SAP enzyme (USB) to
remove unincorporated ddNTPs, incubated at 37°C for 1 hour and inactivated at
80°C for 15 minutes. A 1:15-1:40 dilution of the product underwent polyacrylamide
gel electrophoresis on an ABI PRISM 310 or 3730 Genetic Analyser, and was
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analysed using the GeneScan version 3.0, or the GeneMapper version 3.0, software.
Genotypes were scored blind to phenotype on two separate occasions.
DNA pooling was used as a means of dramatically reducing the number of
genotyping reactions required to perform association studies (Section 2.1.3.2.).
Genotyping was performed using the SNaPshot™ method. It was very important to
obtain the optimal dilution for the pools before running the sample on an ABI
PRISM platform. This is because an overloaded lane, where the signal exceeds the
maximum fluorescence readable, reduces the reliability of the results. Therefore, a
test run was performed, on a few control DNAs, to determine the dilution factor. The
same PCR template was used to perform a second SNaPshot™ reaction on the pools
plate.
2.9.1.2 TaqMan®
The probes and primers used in the TaqMan® genotyping assays were designed by
Applied Biosytems and the genotyping was carried out by A. Condie at the Welcome
Trust Clinical Research Facility, Western General Hospital on an ABI PRISM®
9700 sequence detection system.
The TaqMan® method requires a primer pair and an internal probe. The internal
probe consists of two types of fluorophores. The quencher fluorophore, on the 3' end
of the probe, reduces the fluorescence from the reporter fluorophore, on the 5' end of
the probe. The probe and the primers anneal to the DNA and Taq DNA polymerase
adds nucleotides to the primers and removes the probe from the template DNA. This
separates the quencher from the reporter, and allows the reporter to emit its energy.
The two alleles of a SNP are tagged with different coloured reporters. Therefore
detection of one colour in the assay represents a homozygous genotype and the
detection of an equal amount of both colours represents a heterozygous genotype.
The colour reported is plotted on a graph of the colour spectrum. Individuals with
either colour, or an equal mix of the two, cluster together. Samples that have been
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contaminated, or in which the DNA quality is poor are often seen as an outlier and
the data can be discarded.
2.9.1.3. Sequenom®
A number of SNPs were genotyped by the Sanger Institute using the Sequenom®
MassARRAY™ system. A PCR is performed of the region surrounding the SNP,
and this is used as a template for a primer extension reaction containing the primer,
DNA polymerase, a mix of dNTPs and one of the four possible ddNTPs. This
generates allele specific extension products that are generally l-4bp longer than the
original primer. For example, a SNP with variants cytosine/tyrosine would include a
guanine ddNTP in the reaction mix. This would stop the primer extension reaction at
either the cytosine variant of the SNP, or the next cytosine nucleotide in the
sequence. Genotypes are determined based on molecular weight using Mass
Spectrometry (MALDI-TOF). Homozygotes would generate one of two molecular
weights depending on the allele, and heterozygotes would generate both molecular
weights.
2.9.2. Microsatellite Genotyping
Di- and tri-nucleotide repeats were identified by the repeat finder programme
Sputnik (http://espressosoftware.com/pages/sputnik.jsp) developed by Chris Abajian
(The University ofWashington department of molecular biotechnology). The results
of this are displayed in the inhouse database ACeDB. Oligonucleotide primers were
designed as in Section 2.2 to flank the repeat and the 5' end of the forward primer
was labelled with a fluorescent tag. After PCR, a dilution of the PCR was run on the
ABI PRISM® 3730 or 3100 Genetic Analyser. The product was run with HiDi™
formamide (Applied Biosytems) with either the GeneScan®-500 [Rox]™ or
[tamra]™ size standard (Applied Biosystems) (Table 2-3). Microsatellite markers
were multiplexed based on STS size and fluorescent tag. Results were analysed using
the GeneScan version 3.0 or the GeneMapper version 3.0 analysis software.
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Genetic Analyser PCR Dilution Sample Preparation Size Standard
3730 1:100 10(_il HiDi formamide
1pl sample dilution
0.06f.il
3100 1:10-1:40 10|il HiDi formamide
1pl sample dilution
VI
Table 2-3: ABI PRISM® 3730 and 3100 Genetic Analyser sample dilutions.
A characteristic of microsatellite genotyping can be stutter peaks and the addition of
an adenine to the end of the product. Stutter peaks occur when the Taq DNA
polymerase slips as it moves along the repeat, missing out one or more of the repeat
blocks and therefore producing product that is one or more repeat blocks smaller
than the actual allele. The real allele is usually the largest and the strongest signal.
Therefore, microsatellite markers were genotyped on a minimum of 20 individuals to
aid the correct interpretation of the marker characteristics. The Taq DNA polymerase
also tends to add an adenine onto the end of the PCR product, making the product
one base pair larger where this occurs. To ensure the uniform addition to all PCR
products, all microsatellite PCR reactions included a final 72°C extension step of 50
minutes. See appendix I for primer sequences, PCR mix and PCR cycling conditions.
Genotypes were scored blind to phenotype on two separate occasions.
2.10. Bacterial Cell Culture
2.10.1. Solutions
Luria-Bertani (LB)-broth 1% (w/v) Bacto-Tryptone (Difco); 0.5% (w/v) Bacto-
yeast extract (Difco); 0.1% (w/v) NaCI; pH 7.
LB plates LB-broth with 15g of Bacto Agar/litre of liquid media.
Freeze Solution 15% glycerol in LB-broth with Mg.
2.10.2. Bacterial Cell Culture and Colony PCR
Five BACs were used for colony PCR. BACs RP11-264E23, RP11-751L19 and
RP11-626020 were stored at -70°C as a glycerol stock inhouse. CTD-2205P10 was
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obtained from the Research Genetics (Invitrogen) as a glycerol stock. RP11-180A12
was obtained from the Sanger Institute as an agar stab. These two clones were grown
on a plate containing L-agar and 12.5pg/ml chloramphenicol antibiotic and cultured
at 37°C overnight. Colonies were picked with a cocktail stick and twirled in 15ml
sterile water. This was used as a template for colony PCR. Colony PCR was
performed using 3pl of the template in a 15pl PCR, as described in Section 2.3. The
cocktail stick was then cultured in a 25ml falcon tube in 3ml LB-broth with
Magnesium, and incubated at 37°C overnight. Glycerol stocks were made by
spinning down 1ml of the culture at 10,000 g for 1 minute, to form a pellet. The
supernatant was removed and was re-suspended in 1ml freeze solution and stored at -
70°C.
2.11. Bioinformatic Tools
Websites that are referred to during the thesis are listed here.
ACeDB www.acedb.org/
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Contig Mapping in Minimal Region One
3.1 Introduction
In the early stages of the Human Genome Project (HGP), sequence information was
sparse. The group required a reliable physical map in order to proceed with
recombination breakpoint mapping, gene identification and to be able to direct and
interpret future association studies. A BAC/PAC contig ofMinimal Region One
(MR1), which comprises the overlap between the disease-associated haplotypes of
three families (Figure 3-1), was constructed by a combination of STS content
analysis and restriction fragment fingerprinting (Evans et al, 200 la). The contig was
displayed inhouse using the SAM (system for assembling markers) database
(Soderlund, 1995), a programme to aid marker ordering. The clone coverage of the
inhouse contig was more extensive than the publicly available map. In addition, the
results were regarded as more reliable because the degree of experimental input for
this small region outweighed that of a comparable region for the HGP.
Clones that are being sequenced as part of the HGP are displayed in an inhouse
ACeDB database (www.acedb.org/). ACeDB is a genome database, developed by J.
Thierry-Mieg (CNRS, Montpellier) and R. Durbin (Sanger Institute) in 1989, that
was originally used in the C.elegans genome project, from which its name was
derived (A C. elegans DataBase). The database is constructed and managed inhouse
by S. Morris and displays the sequence of the clones. It is then masked for simple
repeats and CpG islands, and annotated with the results ofBLASTn similarity
searches to human clones, vertebrate and invertebrate genomic DNA, vertebrate
mRNA and protein, and the results of the gene and exon prediction programmes
GenScan, FGenes and MZEF. In addition, it holds inhouse data. This gives the group
a central resource with which to enter and manage contig, microsatellite, SNP and
other data generated in the group, and also to study existing genes and other features
of the genomic landscape, including novel transcript evidence. The ordering of the
clones is not just a reproduction of the HGP, but the available data is inspected at a
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Figure 3-1: Overlapping haplotypes of families 22, 59, 50 and 48. The coloured bars
represent a marker haplotype on chromosome 4p inherited with psychiatric illness in each
family (the position of the centromeric recombination breakpoint in F50 has not been
determined). The family number is marked along the top. The four haplotypes overlap,
enabling the delineation of smaller regions of interest (horizontal lines). The solid horizontal
lines mark the delineation of Minimal Region One (MR1). The telomeric recombination
breakpoint region of MR1, defined by a member of family 50, is expanded. The red bars
represent the BAC clones (RP11-) containing the two markers defining the recombination
breakpoint (arrows). The region contains a contig gap (green arrow) and two genes: orphan
G-protein-coupled receptor 78 (GPR78) and Carboxypeptidase Z (CPZ).
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detailed level to iron out any inconsistencies and give a better quality of data than is
available publicly for our small region of interest. This was essential in the early
stages of the project, but has become less so as the HGP moves towards a finished
product. However, even today, there still remain small regions of incomplete
sequence.
The physical map and the sequence available at the start ofmy project, both from our
inhouse contig and the HGP, had numerous sequence and contig gaps. Over the three
years many of these have been closed. Both minimal regions currently have four gaps
(February 2004). One of the gaps in MR1 lies in between the existing recombinant
and non-recombinant markers defining the telomeric end of the disease haplotype in
F50. This is also the boundary which defines the telomeric end ofMR1. This gap was
also observed in the inhouse contig and estimated to be ~300kb by fluorescence in
situ hybridisation (FISH) analysis (Evans et al, 200 la). The HGP has not closed the
gap either, and in fact the clone map published around the gap changed significantly
with every release of the genome browser at the University of California, Santa Cruz
(UCSC) (genome.cse.ucsc.edu). The region on the telomeric side of the gap is not
represented in a number of different libraries (Evans et al, 200 la) and the sequence at
the centromeric side of the gap appears to be a highly repetitive region. For this
reason the in-house contig around this interval was not considered to be reliable.
However, closing this gap remains an important aim due to the presence of the
recombination breakpoint. At the start ofmy project the recombinant marker lay on
clone RP11-301J10 and the non-recombinant marker was positioned on clone RP11-
751L19 (Figure 3-1).
The December 2001 UCSC Golden Path release contained four clones between
RP11-751 LI9 and the gap (Figure 3-2; A). These overlapped with each other but not
with RP11-751LI 9. This included two clones not seen again in later releases: RP11-
423D16 was removed and is still unfinished, and RP11-30E22 is also still unfinished
and has now been localised to chromosome 11.
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The April 2002 UCSC Golden Path release inserted ~9.3 million base pairs in
between RP11-751 LI9 and the gap (data not shown). This was then removed from
the next release in June 2002 (Figure 3-2; B). The June 2002 release included two
fully sequenced clones, three partially sequenced clones and two unfinished clones
extending into the gap from RP11-751LI 9. All of these clones appear to overlap with
each other and RP11-751L19.
I started working with this region when the November 2002 UCSC Golden Path
release became available (Figure 3-2; C). The release contained five fully sequenced
clones extending into the gap from RP11-751L19, with two unfinished clones
spanning one gap and introducing two new sequence gaps. It contained all the same
clones as the June 2002 release, except in a different order and with two additional
gaps.
The April 2003 UCSC Golden Path release (see Figure 3-2; D), released after I had
started to work on this region, improved upon the previous release. It displayed three
of the same fully finished clones from the last release in essentially the same
position. However, these three clones now appeared to overlap and a fourth clone
replaced CTD-2205P10. This resembled the June 2002 release except that CTD-
2205P10 had been replaced and three clones have been removed. Two of the BACs
positioned in the gap by the April 2003 UCSC Golden Path release, RP11-264E23
and RP11-180A12, had been previously screened with markers and placed in this
region as part of our inhouse contig construction. However, the markers used in this
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I started working on this region after S. Morris had used the November 2002 release
to construct the ACeDB contig (Figure 3-3). The current resolution of the telomeric
recombination breakpoint ofMR1 had reached an impasse, as all putative
microsatellite repeats from the clones within the recombinant region had been
genotyped. The interval contained two known potential candidate genes and possibly
other genes. It was important to identify all the genes in our region of interest in order
to carry out further studies on them, such as association analysis. Therefore, not only
did these four clones provide a resource ofnovel polymorphic repeats to refine the
breakpoint, but they also provided a potential resource from which to identify novel
genes. However, the nature of this region and the variability of the publicly available
sequence assembly lead me to carry out experimental work to confirm their locations
before they were used to map transcripts and to refine the telomeric recombination
breakpoint interval ofMR1.
3.2 Bioinformatic Analysis
3.2.1. Searching for Bioinformatic Evidence of Clone Overlap
Clone RP11-751LI 9 contains single copy chromosome 4 sequence. If clone RP11-
180A12 overlaps clone RP11-751LI9, it may be that this overlap extends into this
chromosome 4 specific region. This overlap would not be displayed on the UCSC
Golden Path assembly. At the National Centre for Biotechnology Information (NCBI)
(www.ncbi.nlm.nih.gov/) it is possible to obtain the whole sequence of a clone.
These are in fragments if the sequence is incomplete. Each successive version of a
clone sequence at NCBI tends to be trimmed as clones are overlapped with their
neighbours. Therefore previous versions can be considerably longer than the full
length contiguous version. Neighbouring clones are trimmed to a standard lOOObp
overlap and a genuinely longer overlap is lost because it is redundant data. However,
for my purposes, a longer overlap could be extremely useful since it might show that
clones RP11-180A12 and RP11-751LI 9 overlap in the single copy sequence region.
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Previous sequence versions of clones are also available from NCBI. The latest
version ofRP11-180A12 is sequence AC105916.4. This constitutes one continuous
sequence of length 104,269bp. The previous version, sequence AC105916.3,
constitutes two unordered pieces of total length 143,787bp. The ~40kb that has been
lost between versions three and four may include sequence that overlaps with RP11-
751L19.1 took 60bp of sequence from the beginning and end of each fragment from
AC105916.3 and tested it for a match to RP11-751L19 in ACeDB. I did not find a
match. However, the end of one fragment did match part ofRP11-264E23. This
suggested that RP11-180A12 overlaps with RP11-264E23, but it does not anchor
these clones to this specific locality of chromosome 4 because they do not definitely
overlap with RP11-751LI9.
3.2.2. The Genomic Landscape
In order to localise the clones relative to each other and to chromosome 4p I carried
out bioinformatic analysis to identify single copy chromosome 4p sequences. This
information could then be used to direct the development of chromosome 4 specific
STSs, which could then be used to confirm overlaps between clones.
The clone RP11-751LI9 was known to be in the correct local position on
chromosome 4 since this clone contains a number of chromosome 4 specific genes. It
was the clones telomeric to RP11-751L19 into the contig gap (Figure 3-3) that I
wanted to determine the position of. Analysis of the region carried out by S. Morris,
revealed that the first 43kb of clone CTD-2205P10 contains a chromosome 4p
specific repeat identified by Kogi et al (1997). They identified cosmid clone,
CRS447, and located it to chromosome 4p 15.1-15.3 by FISH and human CHO-
hybrid cell panel mapping. This clone consists of 4.7kb units repeated in tandem, and
it was estimated that there are 50-70 repeats units per haploid genome. This was good
evidence for CTD-2205P10 being positioned in the correct chromosomal region, but
not definitive evidence for it being correctly positioned in the immediate local
environment. A 4.7kb repeat unit repeated 50-70 times gives an estimated size of
90
Chapter Three Contig Mapping in MR1
235-329kb. Therefore, approximately 192-286kb of CRS447 repeat containing DNA
does not appear in the public database. CTD-2205P10 is positioned adjacent to the
gap, and if this is correct then presumably the remaining repeat blocks are located in
the gap.
ACeDB displays the results ofBLASTn matches to clones in the HGP that have a
identity of greater than 99%. Historically, this was a useful tool to identify
overlapping clones that had not been overlapped in the HGP. However, it therefore
also displays fragments of clones from other chromosomes that are also greater than
99% identical to chromosome 4. Therefore, I used this feature ofACeDB to detect
regions of the chromosome 4 clones that display greater than 99% identity to clones
on other chromosomes. Clone CTD-2205P10 displayed regions of homology to
chromosome 8 clone RP11-354G4, and to two clones on chromosomes 11: CTD-
2313N18 and RP11-757C15. Clone RP11-264E23 also showed regions of homology
to the same two clones on chromosome 11 and in addition clone RP11-684B2 on
chromosome 11 and clone RP11-489M13 on chromosome 4pl6.3; a different region
of chromosome 4. Clone RP11-180A12 showed regions of homology with clones
RP11-540E4 and RP11-354G4 on chromosome 8 and clone RP11-167J8 on
chromosome 11. This sequence similarity supported the findings that this region is
highly repetitive.
Whilst ACeDB displays regions of 99-100% similarity, it does not display clones
from other genomic regions that are less that 99% similar, nor does it display regions
that are unique to chromosome 4. In order to design markers to confirm overlaps
between adjacent clones I used BLASTn sequence similarity searches against the
HGP draft sequence of clones CTD-2205P10, RP11-264E23, RP11-606020 and
RP11-180A12.1 used fragments from ACeDB of approximately 0.5-lkb, covering
the parts of the sequence that were not masked by the Sputnik or the Repeat Masker
simple repeat finder programmes or that already displayed 99-100% sequence
similarity with other clones. Unfortunately, I did not find any region that was
chromosome 4 specific. Every BLASTn result revealed multiple similar clones
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positioned on different chromosomes, and every match showed between 92 and 97%
identity. Therefore, I had identified that the four clones were highly similar to many
clones in other genomic regions, and that not one region was unique to chromosome
4. Therefore, I was not able to identify any regions suitable for marker design.
3.3. Contig Mapping
In the absence of any chromosome 4 specific regions to guide my experiments I
decided to design STSs to the sequence at the ends of each clone and screen
neighbouring clones with these markers using colony PCR.
3.3.1. Marker Design
I designed markers at the telomeric end ofRP11-751L19 and RP11-180A12 and at
the telomeric and centromeric end of RP11-264E23. The two markers on RP11-
264E23 involved redesigning existing inhouse markers that were non-specific to
chromosome 4 (Figure 3-4). Primers were designed by performing a BLASTn
similarity search, identifying those clones for which there was a high degree of








Figure 3-4: The position of STS markers (arrows) along the contig (from the inhouse
sequence database ACeDB) that spans the telomeric recombination breakpoint of Minimal
Region One (MR1). The ACeDB contig is based on the November 2002 human genome
working draft sequence at the University of California, Santa Cruz (genome.cse.ucsc.edu).
Coloured bars: sequence clones (see Table 3-1 for full clone details). Black dotted line:
contig gap (-150 kb). Red stars: markers defining the telomeric recombination breakpoint of
MR1. TEL = telomeric. CEN = centromeric.
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Sbjct: 145239 cagcaggtgggaaatgcaccctccacaggctcacacccttgtgggctatttcagttacct
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aggcctcacgaatgtgcctggcagttggtQuery: 303 ctdggagggccagctgggcggaacatccagg;
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Figure 3-5: Example of primer design around existing STS st26424.snp. Figure shows the
results of a BLASTn carried out at the national Centre for Biotechnology Information
(www.ncbi.nlm.nih.gov). Query sequence: sequence from clone RP11-264E23. The results
revealed matches to 20 sequence clones from other chromosomes. One of the 20 matches
is shown here (subject sequence: chromosome 16 clone, RP11-10K17). The black boxes
show an existing primer pair designed from RP11-264E23 sequence that are an exact match
at their 3' end to RP11-10K17. The red boxes delineate one pair of alternative primers
(st26424.m1), and the blue boxes delineate a second pair of alternative primers
(st26424.m2) that were designed from RP11-264E23. Both primer pairs have 3' mismatches
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I obtained the full sequence ofRP11-751L19 (AC098976) from the NCBI website
and performed similarity searches using BLASTn on Homosapiens. The first 900bp
matched five clones with between 93 and 95% identity: RP11-119D9 and RP11-
655M14 on chromosome 11, RP111-93K22 on chromosome 3, RP11-740N7 on
chromosome 7 and a section of chromosome 21q. Upon visual inspection, there was
no mismatch between RP11-751LI 9 and the other clones ofmore than one or two
base pairs in length. It was possible however, to design a pair of primers, named STS
stl75L19ml, with a mismatch of one or two base pairs at the 3' end to each of the
four similar clones.
3.3.1.2. RP11-180A12
I performed a BLASTn of 500-1000bp fragments along the telomeric end ofRP11-
180A12.1 identified a region that matched only one clone from chromosome 16
(RP11-10K17) with any significance. This region was at the end of clone RP11-
180A12, near the overlap with RP11 -626020, and therefore could be utilised in
mapping. When the chromosome 4 and chromosome 16 sequence fragments were
aligned it was possible to see that there was no region ofmismatch greater than two
or three base pairs long in which to design primers. Therefore I designed two STSs,
stl80A12ml and stl80A12m2, with l-2bp mismatches to the chromosome 16 clone
at the 3' end of each primer.
3.3.1.3. Centromeric end of RP11-264E23
Clone RP11-264E23 had previously been placed in this region in ACeDB, and
markers had been designed from its sequence. However, some of these markers had
been shown to amplify other chromosomes by others in the group and data from this
clone was considered to be unreliable. I chose a marker that had been designed to a
portion at the centromeric end of clone RP11-264E23 and performed a BLASTn of
the primers. The results revealed multiple matches at the 3' end of the primer to
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clones on other chromosomes. Therefore I performed a BLASTn of the entire STS
and lOObp either side (total 379bp). The results revealed 20 matches of greater than
93% similarity to clones on chromosomes 3 (RP11-803B1/379B18/77P16/CTB-
182H21), 4 (RP11-747H12/489M13), 7 (RP11-740N7), 8 (RP 11 -
419117/540E4/483N3/55605), 11 (RP 11 -167J9/138N3/119D9/RP13-726E6/RP5-
903G2), 12 (RP 11-90D4), 16 (RP11-10K17/382B13) and 17 (RP13-383M5). Clone
RP11-489M13 is located elsewhere on 4pl6.3 in the July 2003 UCSC Golden Path,
and clone RP11-747H12 has not been localised to a position on chromosome 4. In all
but one instance (chromosome 16 clone RP11-382N13) both existing primers
matched the clones in a position that would result in either the same size product or a
product one base pair larger from the other genomic region after PCR. However, by
manual inspection of these matches it was possible to design two primer pairs with 3'
mismatches to every non-chromosome 4 clone. These STSs were named st26424.ml
and st26424.m2.
3.3.1.4. Telomeric end of RP11-264E23
Marker stl75378snp had also been previously designed to clone RP11-264E23.1
performed a BLASTn of the primer pair, and considered only matches at the 3' end
of the primers. The forward primer matched exactly clone RP11-93K22 on
chromosome 3, and clones RP11-757C7 and RP11-655M14 on chromosome 11, and
matched clone RP5-1173A5 on chromosome 11 with one base pair mismatch in the
middle. The reverse primer did not have any 3' matches. However the first 15bp of
the primer did exactly match clones on chromosome 3 and 11 including RP11-93K22
and RP5-1173A5. This would produce product of the same size as product from
chromosome 4 after PCR. The primers also matched exactly clone RP11- 1396013
on chromosome 4. This clone has been localised to this region in some UCSC
sequence versions and it was also represented in the Ensembl human genome
working draft release (www.ensembl.org) and overlaps with the end ofRP11-
264E23.
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I performed a BLASTn of 600bp around the existing STS stl75378snp, and designed
two further sets of primers with 3' mismatches to the two clones RP11-93K22 and
RP5-1173A5. These STSs were named stl74378.ml and stl74378.m2.
3.3.2. Testing Marker Specificity
Markers were initially tested on three control DNAs. My aim was to find the highest
stringency PCR conditions that gave a clear single band with no evidence of
smearing or bands of the wrong size. Stringency was achieved by performing a test
PCR at three annealing temperatures: 55°C, 60°C and 65°C. If a clean band was
obtained in one of the conditions, no further modifications were made. If bands of the
incorrect size or smearing were obtained, the annealing temperature was increased to
a maximum of 70°C and/or the Mg+ concentration was reduced to l-1.25mM. If no
band was obtained, the annealing temperature was decreased and/or additives were
tried in the PCR (e.g.DMSO). For example, if a PCR at 55°C amplified multiple
sized products, but a PCR at 60°C did not amplify any product, the PCR was tried at
57°C. Once these conditions (i.e. PCR conditions that gave a single clear band) were
satisfied, primer pairs were tested for specificity to chromosome 4 by PCR of a
somatic cell monochromosomal hybrid panel (MCHP). This is a panel of rodent
somatic cells that each retain a single human chromosome on a rodent background.
The exception is the chromosome 20 hybrid, which as well as chromosome 20 also
retains chromosome 4p. Therefore all markers would be expected to be positive both
in the chromosome 20 and the chromosome 4 hybrids. Ifmarkers were found to
amplify from additional hybrids, PCR conditions were further optimised by changing
the annealing temperature of the PCR or by altering the reaction mix, for example,
using a different PCR buffer, altering the magnesium concentration or varying an
additive such as dimethyl sulfoxide (DMSO).
STS markers stl80A12.ml and stl80A12.m2 amplified from chromosomes 4 and 20
only using the PCR conditions determined from the genomic DNA test. Therefore no
further modifications were necessary (Figure 3-6).
96
Chapter Three Contig Mapping in MR1




M 10 9 Y X 22 21 20 19 18 17 + - H m h M
765bp
Figure 3-6: Agarose gels showing the results of a PCR on a monochromosome hybrid panel
(MCHP). Human chromosomes in the MCHP are on a background of hamster and mouse
DNA. Each lane on the gel is labelled with the corresponding human chromosome. The
human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. A: Marker st180A12.m1 amplifies
product of the correct size (550 bp) from chromosomes 4 and 20 and the two human
genomic DNA controls (H and +). B: Marker st180A12.m2 amplifies product of the correct
size (765 bp) from chromosomes 4 and 20 and the two human genomic DNA controls.
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STS marker st751L19ml was not specific to chromosome 4 using the conditions
determined from the control DNA test (Figure 3-7; A). However, as can be seen, the
greatest intensity of signal was seen in the correct lanes at the correct size and
therefore more stringent PCR conditions were tried. Increasing the annealing
temperature by five degrees from 55°C to 60°C, whilst also decreasing the MgCl
from 1.5mM to 1.25mM was too stringent and the STS did not work (data not
shown). Increasing the annealing temperature by five degrees from 55°C to 60°C was
enough to make the STS specific (see Figure 3-7; B).
Figure 3-7: Agarose gels showing the results of a PCR on a monochromosome hybrid panel
(MCHP). Human chromosomes in the MCHP are on a background of hamster and mouse
DNA. Each lane on the gel is labelled with the corresponding human chromosome. The
human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. A: Marker st751L19.m1, after a PCR at a
55°C annealing temperature, amplifies product of the correct size (244 bp) and bands of
incorrect sizes, from multiple chromosomes, but amplifies the correct sized product only form
the two genomic DNA controls. B: Marker st751 L19.m 1, after a PCR at a 60°C annealing
temperature, amplifies product of the correct size from chromosomes 4 and 20 only and the
genomic DNA controls.
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STS marker st26424.m2 displayed some low level amplification on the MCHP for
chromosomes 3, 4, 5, 11, 18 and 19, although the background bands were a different
size to the specific product (Figure 3-8; A). However, st26424.ml was specific
(Figure 3-8; B). It was noted from the primer design stage (Section 3.3.1.3) that there
was a high degree of similarity to chromosome 4 clones RP11-747H12 and RP11-
489M13 from other regions of the chromosome. Whilst the primers were designed to
have 3' mismatches to these clones, it is not possible to determine regional
specificity from the MCHP. However, since the marker did not amplify the highly
similar clones from other chromosomes, there was no reason to suspect that it would
also amplify these two clones from chromosome 4. Furthermore, the marker used to
localise the other end clone RP11-264E23 to CTD-2205P10 acts as an independent
test for correct localisation. Therefore, it was not necessary to screen RP11-747H12
and RP11-489M13 with this marker.
A B
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Figure 3-8: Agarose gels showing the results of a PCR on a monochromosome hybrid panel
(MCHP). Human chromosomes in the MCHP are on a background of hamster and mouse
DNA. Each lane on the gel is labelled with the corresponding human chromosome. The
human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. A: Marker st26324.m2 amplifies product
of the correct size from chromosomes 4 and 20 and the genomic DNA controls, but also
shows faint amplification of a larger product from chromosomes 3, 4, 5, 11, 18 and 19. B:
Marker st26424.m1 amplifies product from chromosomes 4 and 20 only and the genomic
DNA controls.
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Using PCR conditions optimised from control DNA tests, stl75378snp was not
specific on the MCHP, amplifying chromosomes 2, 3, 4, 6, 8, 11, 12, 13, 15 and 20
(Figure 3-9; A). A 5°C increase in annealing temperature still resulted in
amplification from chromosomes 3, 4, 11, 15 and 20 (Figure 3-9; B). The BLASTn
of the primers had previously revealed similarities to clones on chromosomes 3 and
11 but not on chromosome 15 (Section 3.3.1.4). This could be because this region of
chromosome 15 had not been sequenced in the human genome sequencing project at
that time. Further attempts to increase the specificity of the PCR by reducing the
magnesium concentration and increasing the annealing temperature were not
successful (data not shown). Therefore, the primers were redesigned, and two novel
STSs were tested: stl75378.ml and stl75378.m2.
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 2021 22 X Y H m h - + M
Figure 3-9: Agarose gels showing the results of a PCR on a monochromosome hybrid panel
(MCHP). Human chromosomes in the MCHP are on a background of hamster and mouse
DNA. Each lane on the gel is labelled with the corresponding human chromosome. The
human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. A: Marker st175378snp amplifies the
correct sized product (244 bp) from chromosomes 2, 3, 4, 6, 11, 12, 13, 15, 20 and the
genomic DNA controls. B: After a PCR with a 5°C increase in annealing temperature,
st175378snp amplifies the correct sized product from chromosomes 3, 4, 11, 15, 20 and the
genomic DNA controls.
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Tests on control DNA for STS stl75378.ml were variable (data not shown). For
some samples there was a high degree of smearing. Flowever, when it did work it
appeared to be specific, although at quite a low annealing temperature. Under these
conditions the STS did not work at all on the MCHP except in the human DNA
control, and gave some very low level amplification of a smaller product from
chromosomes 1, 4 and Y, a larger product from chromosome 7 and the correct sized
product from chromosome 6 (Figure 3-10).
M12345678 9 10111213141516 M M17 18192021 22XYHhM-+M
Figure 3-10: Agarose gels showing the results of a PCR on a monochromosome hybrid
panel (MCHP). Human chromosomes in the MCHP are on a background of hamster and
mouse DNA. Each lane on the gel is labelled with the corresponding human chromosome.
The human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. Marker st175378.m1 amplifies incorrect
sized product from chromosomes 1, 4, 6, 7 and Y. It does not amplify the correct sized
product (288 bp) from chromosome 4, or the in house genomic DNA control (+), but does
amplify the correct sized product from the genomic DNA control provided with the MCHP (H).
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STS marker stl75378.m2 did not work consistently on all control DNA either, but
produced a clean band for some samples (data not shown). Under these conditions it
did not amplify from the chromosome 4 or the chromosome 20 hybrid, but did
amplify from the positive human controls, producing a clean band (Figure 3-11; A).
Amplification was observed from other chromosomes. The chromosome 1-5, 18 and
19 hybrids all show a similar pattern of amplification and all have hamster DNA
background. This suggested that at least some of the amplification was from hamster
DNA. Increasing the annealing temperature from 55°C to 60°C, altering the buffer
and using DMSO additive did not get rid of all of the spurious amplification (Figure
3-11; B). Using the original buffer at an annealing temperature of 60°C eliminated
the background but also reduced the efficiency of the STS. It worked poorly on the
positive controls (Figure 3-11; C). There is also a non-specific band in lane 18, but
this is a different size compared to the specific product.
These experiments lasted over some time. After the above experiments had been
carried out, I again performed a BLASTn of the first lOOObp ofRP11-264E23 and
the results revealed a 100% match to chromosome 4 clones CTD-2205P10 and
RP11-1396013. This would be due to the increased amount and/or quality of the
sequence in the public database, and provided very strong evidence that the clones
overlap. Therefore, further optimisation was not carried out and marker stl75378.m2
was tested using the original buffer and an annealing temperature of 60°C (Figure 3-
11: C).
102
Chapter Three Contig Mapping in MR1
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 1819 20 21 22 X Y H m h - + M
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 21 22 X Y H m h - + M
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 21 22 X Y H m h - + M
Figure3-11: Agarose gels showing the results of a PCR on a monochromosome hybrid panel
(MCHP). Human chromosomes in the MCHP are on a background of hamster and mouse
DNA. Each lane on the gel is labelled with the corresponding human chromosome. The
human chromosome 20 hybrid also contains a fragment of human chromosome 4p. The
marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). The MCHP provides human (H),
mouse (m) and hamster (h) genomic DNA controls. An inhouse human genomic DNA control
(+) and a no-template control (-) was also included. A: After a PCR at an annealing
temperature of 55°C, marker st175378.m2 amplifies the correct sized product (184 bp) from
the human genomic DNA controls (H and +) only. Product of the incorrect size is amplified
from chromosomes 1, 2, 3, 4, 5, 6, 10, 17, 18, 19. 20, 21, X ,Y and the mouse and hamster
genomic DNA controls. B: After a PCR with an annealing temperature of 60°C and different
PCR reagents, marker st175378.m2 amplifies the correct sized product from chromosome 8
and the human genomic DNA controls (H and +) and product of the incorrect size from
chromosomes 2, 3, 4, 5 and 8. C: After a PCR at an annealing temperature of 60°C and the
original PCR reagents, marker st175378.m2 amplifies the correct size product from only the
human genomic DNA controls (H and +) and a larger product from chromosome 18.
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The four STSs were screened on the BACs by colony PCR and each STS was found
to amplify the BAC screened. Positive genomic DNA and no template controls were
included in each PCR.
Marker st751L19.ml amplified from both RP11-751L19 and RP11-180A12 (fig 3-
12; A), confirming that these two clones overlap. Both stl80A12ml and
stl80A12m2 amplified from RP11-180A12 and RP11-626020 (Figure 3-12; B, C &
D) highlighting the error in the November 2002 Golden path release which leaves a
gap between them. This has been rectified in the April 2003 release. Marker
st26424.ml was positive for both RP11-626020 and RP11-264E23 (Figure 3-12; E)
confirming the Golden Path April 2003 release. Marker stl75378.m2 amplified from
both RP11-264E23 and CTD-2205P10 but did not amplify from the genomic DNA
control (Figure 3-12; F & G). As observed in the previous section, the STS did not
work very efficiently. Flowever, the STS could be expected to work better in a colony
PCR, where the amount of template far exceeds that of the 20ng used in the genomic
DNA control. The April 2003 sequence assembly was released subsequent to this
work being carried out. After the above experimentation, a BLASTn sequence
similarity search of stl75378.m2 revealed a sequence identity of 99-100% to RP11-
264E23, CTD-2205P10 and RP11-1396013. Therefore it was not deemed necessary
to test the STSs on RP11-1396013 as well.
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Figure 3-12: Agarose gels showing the results of colony PCR for five markers. Each marker,
except st751L19.m1, was tested on two BAC clones. Colony PCR was performed on either
colonies grown overnight from a glycerol stock, or from a crystal taken directly from a frozen
glycerol stock of the clone. The size of each marker (in base pairs) is shown by the arrow.
The DNA marker (M) = Ready Load™ 1 kb DNA ladder (Invitrogen). Human genomic DNA
(+) and no-template controls (-) are included for each PCR. A. Marker st751L19.m1 is
positive for four BAC colonies (1-4) grown from a glycerol stock of RP11-180A12, and a
glycerol stock crystal of RP11-751L19 (G). B. Markers st180A12.m1 (M1) and st180A12.m2
(M2) are positive for a glycerol stock crystal of RP11-626020 (G). C.& D. Markers
st180A12.m1 (M1) and st180A12.m2 (M2) are positive for six out of 10 (1-10) colonies of
RP11-180A12 grown from a glycerol stock. E. Marker st26424.m1 is positive for a glycerol
stock crystal of RP11-264E23 (G1) and RP11-626020 (G2). F. Marker st175378.m2 is
positive for seven out of eight (1-8) colonies of CTD-2205P10 grown from a glycerol stock.
The genomic DNA control (+) failed to amplify. G. Marker st175378.m2 is positive for glycerol
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The publicly available contigs from UCSC in the region between RP11-301J10 and
RP11-751L19 on chromosome 4 have varied, sometimes significantly, with each
subsequent release. The inhouse contig did not reliably extend past RP11-751L19,
therefore novel clones in this region would be a potential source of novel genes to
include in future association studies, and also a source of novel microsatellite and
SNP markers to use in refining the F50 recombination breakpoint. Therefore it was
important to determine unequivocally which clones were positioned here and their
relative order.
The inhouse contig built prior to the start of this project, and every release of the
human sequence to date, has a gap that lies between RP11-301J10 and RP11-
751LI9. This interval also defines the telomeric recombination breakpoint interval of
MR1. The continuing presence of this gap could be due to the repetitive nature of the
DNA, as has been observed on the centromeric side and/or, due to the low
representation of this region in genomic libraries, as has been observed on the
telomeric side. This was confirmed by others by the fact that some of the markers in
the region, when attempting to construct the inhouse contig past RP11-751L19, were
non-specific to chromosome 4.1 have also confirmed this by noting that ~43kb of the
chromosome 4p specific tandem repeat CRS447 positioned at the end ofCTD-
2205P10 suggests that the remainder of this repeat lies within the gap, and also by the
results of the series ofBLASTn similarity searches I performed across four clones
telomeric to RP11-751L19.
Evidence from FISH mapping (Evans et al, 200 la), and from the six releases studied
of the UCSC Golden Path suggest that the gap is in the order of 50-300kb in size. An
average BAC size of ~150kb means that only one or two clones are required to span
the gap. As mentioned above, a significant proportion of the sequence in the gap may
be composed of the CRS447 repeat. It has been estimated that this is 235-329kb in
length (Kogi et al, 1997), and approximately 192-286kb of this is therefore missing
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from the sequence of the clone flanking the gap, CTD-2205P10. However, this is
dependent on how many copies of the repeat occur in the individuals forming the
HGP, as the number of repeats has been shown to be highly polymorphic between
individuals (Gondo et al, 1998). This repeat possesses a 1590bp ORF encoding a
deubiquinating enzyme (designated USP17), shown to have a functional promoter
and mRNA expression in a number of tissues (Saitoh et al, 2000). Despite this,
USP17 could not be located in either the July 2003 UCSC Golden Path or the 34b
Ensembl genome browsers and was not an entry at NCBI.
The repetitive nature of the clones telomeric to RP11-751L19 made it difficult to
design chromosome 4 specific markers. This had hindered those working on the
inhouse contig in the past as mentioned above, and meant that despite the fact that
the inhouse contig extended past RP11-751LI9, it was considered to be very
unreliable. In order to design markers I used the results ofBLASTn similarity
searches to identify which clones had a high level of similarity with the end of the
clone of interest and then used these to design primer pairs specific to chromosome 4
at their 3' end. I then used increasing levels ofPCR stringency to attain specificity to
chromosome 4 on a monochromosomal cell hybrid panel. It is the 3' end of the
primer that is the most important for the specificity of PCRs and this was bourne out
by my results. A difference of only one or two base pairs was enough to confer
specificity to chromosome 4.
My results also highlight the fact that the human genome sequence is not yet
complete. Marker stl75378snp amplified a portion of chromosome 15, but a
BLASTn similarity search did not reveal any similarity to chromosome 15 clones.
In addition, my results also showed that STSs do not necessarily behave the same in a
MCHP situation compared to whole genomic DNA. In the absence of the correct
position to anneal to it appears that other non-specific locations can be amplified.
However in the presence of the correct position these alternative sites are not
amplified at all. This was seen for example in marker stl75378.ml (see Figure 3-11).
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Therefore some caution is needed when interpreting the results of a PCR on one type
of template if generalising it to another type of template. In addition, when designing
the markers I did not perform the BLASTn against mouse or hamster sequence, but
human only. Therefore some background could be due to homology between the
species. A BLASTn of the primer sequences against hamster genomic sequence is not
possible since the hamster genome has not been sequenced. However, subsequent
BLASTn against the mouse genome for STSs stl75378.ml, stl75378.m2,
st26424.ml and st26424.m2 (the STSs that amplified bands of various sizes from
multiple chromosomes) revealed several matches to mouse genomic DNA at the 3'
end of each primer. The forward and reverse primer for each STS did not match the
same clone and product of the expected size from human genomic DNA would not
have been amplified. It does suggest, however, that some of the amplification of
product of a different size to that expected from human genomic DNA could be due
to amplification from mouse and/or hamster DNA. It seems reasonable to suggest
that a low level of non-specificity, when the bands are of a different size to the
specific band, can be tolerated on the MCHP when the specific chromosome
amplifies from the appropriate hybrid only.
Since this work was carried out a subsequent sequence release from the HGP (July
2003) is available at UCSC. In this release, clone RP11-626020 has been removed
from the latest sequence assembly (Figure 3-2: E), despite there still being a gap
between the flanking clones. However, I have shown in my results that it is correctly
positioned between clones RP11-180A12 and RP11-264E23.
There were some clones that were not included in this work. Clone RP11-1286E23,
overlapping RP11-1396013 (Figure 3-2), has been removed from the April and July
2003 releases. It also appears to have been completely removed from the UCSC
Golden Path; searching with either the clone or the sequence name produces no
results. Therefore, I did not include this clone in my work. There is also an additional
clone, RP11-637J21, that in the July 2003 release was positioned into the gap from
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the telomeric side. This clone could also be another source of novel microsatellite
and SNP markers to refine the recombination breakpoint.
In conclusion, I have succeeded in accurately mapping four clones into the contig gap
within the recombination breakpoint interval of the telomeric boundary ofMR1.
These clones can now be used as a source ofmarkers to refine the breakpoint, and as
a potential source of novel genes.
109
Chapter Four Recombination Breakpoint Mapping of MR1
Chapter Four
Recombination Breakpoint Mapping
Of Minimal Region One
no
Chapter Four Recombination Breakpoint Mapping ofMR1
Recombination Breakpoint Mapping of Minimal
Region One
4.1. Introduction
Blackwood et al (1996) described a genome wide linkage study in a large family of
120 individuals, F22, segregating bipolar affective disorder (BPAD) and recurrent
major depression (RMD) (Figure 2-1). A three point linkage analysis gave a
maximum multipoint LOD score of 4.8 to a 14cM region on chromosome 4p. A
22Mb haplotype is inherited from one founder individual to all 11 cases ofBPAD I
and II and 14 out of 16 cases ofRMD. This haplotype defines the disease associated
chromosome in F22 (Figure 4-1). Two individuals with early onset RMD did not
possess the haplotype, which suggests that they are phenocopies. Nine individuals
without a psychiatric diagnosis did possess the haplotype, which suggests that there
has been incomplete penetrance of the susceptibility locus. Since psychiatric illness is
a complex disorder where multiple genes and environmental factors contribute to the
phenotype, phenocopies and incomplete penetrance are expected when a single
genetic locus is analysed.
A further family, F59, also showed evidence for linkage to the region (Figure 2-2).
From subsequent unpublished laboratory work by others in the group, F59 has been
shown to exhibit a -8Mb disease associated haplotype (Figure 4-1). This is
transmitted from an unknown founder to all five cases ofBPAD I and BPAD II
disorder, and one undiagnosed individual. The individual without a diagnosis who
carries the disease associated haplotype again suggests that there is incomplete
penetrance of the susceptibility locus.
Two remaining families, F50 and F48 (Figures 2-3 and 2-4), were reported in the
literature as showing linkage ofpsychiatric illness to chromosomes 4p (Detera-
Wadeligh et al, 1999; Asherson et al, 1998) and were obtained via collaboration. The
results of the genome wide linkage study in F50 found a LOD score of 2.0 on
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chromosome 4p. This is small, but is limited by the small size of the family. The
genome wide linkage study in F48 identified a LOD score of 3.2 on chromosome 4p.
These two families also show marker haplotypes that are inherited with the disorder.
Family 50 segregates schizoaffective disorder, and was shown to have a disease
associated haplotype greater than 20Mb (Figure 4-1). The six individuals who carry
the disease haplotype are diagnosed with schizophrenia (SCZ) or schizoaffective
disorder. In addition, one individual has a form of psychosis that could not be further
classified due to incomplete data (Asherson et al, 1998). Family 48 is a large family
of 82 individuals who segregate BPAD, RMD and SCZ. Subsequent unpublished
work by others in the group has identified a ~14Mb disease associated haplotype
(Figure 4-1).
The disease associated haplotype in each family defines the region that contains the
susceptibility polymorphism. Haplotypes are defined by tracing the inheritance of
marker alleles from parent to offspring in a family. An interruption in the inheritance
of a contiguous haplotype from a parent to their offspring with the commencement of
the inheritance of the alternate haplotype from the second chromosome of that parent
constitutes a recombination breakpoint.
All of the above work was carried out before the start of this PhD project, when it
was also observed that the disease associated haplotypes from the four families
overlap (Figure 4-1). If the families have a common causative ancestral allele, or a
different causative ancestral allele affecting the same gene, this overlap provides an
informative way to significantly reduce the size of the susceptibility locus detected in
F22. The overlapping haplotypes of the four families divide the linked region in F22
into four main candidate regions. Those ofmost interest are minimal region one
(MR1) and minimal region two (MR2), where three of the four family haplotypes
overlap. MR1 is defined by F22, F59 and F50. This is a good candidate region
because all three families are ofCeltic origin, making a founding variant more likely.
In addition, an association has been found between MR1 markers and SCZ (Muir et
al, 2001). However, families 59 and 50 are small and can contribute only small LOD
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scores. MR2 is a good candidate region because it is defined by the two largest
families, F22 and F48, who have the largest LOD scores. However, F48 originates
from a different ethnic background; they are an Ashkanazi Jewish family from the
USA. This makes a common ancestral variant less likely, but it does not preclude it.
Here I describe the analysis ofMR1. The recombination breakpoints defining the
other minimal regions have been studied and refined by other members of the group,
and the current resolution of these are detailed in Figure 4-1. At the start of this
project, the recombination breakpoints defining MR1 were defined by widely spaced
markers (those detailed in Figure 4-1). When I started, the recombination breakpoint
interval of the centromeric end ofMR1 was ~1.8Mb and the telomeric end ofMR1
was ~800kb. This meant that MR1 was ~4.8Mb. Previous marker genotypes had
shown that the centromeric end ofMR1 is defined by a recombination breakpoint in
individual 2081 from F59 and that the telomeric end is defined by a recombination
breakpoint in individual 12 from F50. It is important to refine the disease associated
haplotypes to delineate the locus to a high resolution, thus eliminating unlinked genes
from further study. Therefore more markers needed to be typed within the breakpoint
intervals. I refined the recombination breakpoints by identifying novel microsatellite
and SNP markers within the recombination breakpoint intervals and genotyping these
in the families.
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Figure 4-1: Overlapping marker haplotypes of families 22, 59, 50 and 48. The coloured bars
represent a marker haplotype on chromosome 4p inherited with psychiatric illness in each
family. The family number is marked along the top. The number above the bar shows the
LOD score for that family (F22 = a multipoint LOD score). The four haplotypes overlap,
enabling the delineation of smaller regions of interest. The horizontal lines mark the
delineation of each minimal region (MR), with the corresponding region number (1-4) and the
markers flanking the recombination breakpoints alongside. The size of each MR is noted.
The markers delineating the breakpoint and corresponding size of MR's 2, 3 and 4
represents the current resolution (February 2004). The markers and corresponding size of
MR1 represents the resolution at the start of my project (October 2000).
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4.2. F59 Recombination Breakpoint
A recombination breakpoint in individual 2081 from F59 constitutes the centromeric
boundary ofMR1. It was important to refine this interval as far as possible to include
or exclude genes from this high priority region. At the start of the project, inhouse
markers stba473M13.2 (non-recombinant) and st362C2-72Jl (recombinant) defined
the breakpoint. These markers were derived from BACs RP11-473M13 and RP11-
11C13 respectively. The exact distance between these markers was not known
because the intervening sequence was incomplete. However, the human genome
sequencing project reported an average BAC insert size of 150kb, suggesting that the
two markers were approximately 1.4Mb apart. Now that the sequence is complete, it
has been possible to determine that they are 1.8Mb apart. At the start of the project,
there were no known genes within this recombination interval. However, a formal
transcript map of the region had not been constructed. Subsequently, I have identified
a novel gene, 74M11, of unknown function within this interval on RP11-74M11
(Chapter 6).
4.2.1. Family Members
In order to map the recombination breakpoint, all eight members ofF59 were
genotyped. Data was obtained for seven members, not including sample 2082 where
PCR amplification failed, probably due to poor DNA quality. I genotyped the entire
family for all new markers in order to ensure that unambiguous determination of the
phase of all chromosomes was possible. In addition, nine members of F22 (93, 94,
137, 139, 16, 17, 50, 51, 53) and five members of F50 (3, 4, 11, 12, 15) were
genotyped. This was to determine the disease associated haplotype in these families,
allowing the assessment of allele sharing between the three families, and to ensure
that individual marker characteristics are accurately interpreted and the correct
genotypes are scored. It is important to genotype enough individuals to deal with
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At the start ofmy PhD the recombination breakpoint was defined as falling between
telomeric marker stba473ml3.2 and centromeric marker st362C2-72Jl (Figure 4-1).
Neither the contig produced by the human genome mapping project, nor the sequence
of the BACs mapped to this interval, were complete at this time. However, previous
work in the lab had resulted in the construction of a contig spanning MR1 (Evans et
al, 2001a). The contig data is displayed in the System for Assembling Markers
(SAM) database (Soderlund, 1995). This programme aids the ordering of BACs on
the basis of marker hybridisation and/or BLAST matches of STSs to partially
sequenced BACs. A minimal tiling path of nine BACs that spanned the
recombination interval between markers stba473ml3.2 and st362C2-72Jl was
chosen from this contig (Figure 4-2). The nine BACs were being sequenced as part of
the human genome sequencing project, allowing new marker design. Where possible,
BACs were chosen that contained one or more markers that hybridised to both BACs.
Where BACs did not directly overlap it was possible to determine their relative
position based on their overlap with surrounding BACs and PACs.
stba473M13.2
st362C2-72J1
Figure 4-2: Tiling path of nine BAC clones (RP11-) between recombinant and non-
recombinant markers stba473m13.2 and st362C2-72J1 that mark the centromeric
recombination breakpoint of the chromosome 4p disease associated haplotype in family 59
and the centromeric boundary of Minimal Region One. BACs 4E12 to 3M2 overlap. The
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There were four phases of genotyping. The aim of the first phase was to identify and
genotype an average of one marker per BAC. Primers were designed to flank putative
polymorphic dinucleotide, pentanucleotide or tetranucleotide repeats identified by the
software programme Sputnik (cbi.labri.ff/outils/Pise/sputnik.html). Although a repeat
length of greater than 12 was used to judge whether a marker was likely to be
polymorphic, each marker had to be tested on a set of control individuals to check
that the repeat was polymorphic. In phases one and two of genotyping, ten putative
polymorphic repeats were tested in this way (Table 4-1, page 115, details all the
markers used). The PCR assay did not work for markers 19 and 20, and therefore I
redesigned the primers. Markers 2, 4, 5, 6, 16 and 20 were polymorphic and marker
14 was monomorphic. An eleventh publicly available microsatellite marker (3) was
also tried but the PCR repeatedly failed and therefore it was dropped. Therefore, nine
microsatellite markers were typed in Phase one and two. In phase three of
genotyping, four putative single nucleotide polymorphisms (SNP) identified in
dbSNP (www.ncbi.nlm.nih.gov/SNP/) were tested for polymorphism in the family
members. Primers were designed to flank the SNP's and genotypes were determined
by sequencing. Two STSs were designed with two SNPs in each STS. Two of the
SNP's (markers 8 and 11) were polymorphic and used for recombination breakpoint
mapping. Phase four is discussed in greater detail in Section 4.4.
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Clone Marker Marker Name Marker Note Distance Phase
(RP11-) Code Type (bp)
473M13 1 stba473M13.2 Microsat -
74M11 2 stba74M11.p1 Microsat 181 768 1
74M11 3 stD4S3352 Microsat PCR failed 54 838 1
1J7 4 StbalJ7.p1 Microsat 236 640 1
4E12 5 stba4E12.p1 Microsat 185 458 1
352E6 6 stba352E6.p1 Microsat 363 429 1
352E6 7 stb352E6.p2 Microsat 14 345 4
352E6 8 rs1402045 SNP 18 289 3
352E6 9 rs545029 SNP monomorphic 68 3
352E6 10 rs 1402034 SNP monomorphic 8571 3
352E6 11 rs1520285 SNP 132 3
426F15 12 stb426F15.p4 Microsat 20 908 4
426F15 13 D4S2906 Microsat 34 087 4
426F15 14 stb426F15.p2 Microsat monomorphic 14 516 2
426F15 15 stb426F15.p5 Microsat 2957 4
426F15 16 stb426F15.p3 Microsat 19 436 1
426F15 17 stb426F15.p1 Microsat 21 336 2
22A3 18 stba22A3.p1 Microsat 194 494 1
3M2 19 stba3M2.p1b Microsat 86 266 2
11C13 20 stbal 1C13.p1b Microsat 193 861 2
11C13 21 st362C2-72J1 Microsat 132 536 -
Table 4-1: Details of the markers used to refine the family 59 recombination breakpoint. The
breakpoint marks the centromeric end of the haplotype inherited with psychiatric illness in
family 59 and delineates the centromeric boundary of Minimal Region 1. The table shows a
tiling path of nine clones identified between the current recombinant and non-recombinant
markers and the markers designed from them. The marker number refers to Figure 4-6. The
distance alongside a marker refers to the distance between it and the preceding marker.
Distance is measured from the first nucleotide of the forward primer for each marker. Four
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The nine microsatellite markers were tested using a variety of different conditions on
three control DNAs to establish optimal PCR amplification. Each marker was then
tested for polymorphism on the family members. A PCR was carried out using the
optimal conditions and a dilution of the product was run on the ABI 3100 Genetic
Analyser. Genotypes were analysed using the GeneScan version 3.0 software (Figure
4-3). Markers were multiplexed where possible. Genotypes were scored blind to
phenotype and family relationship and then checked for Mendelian segregation.
SNPs were genotyped by manual inspection. Sequence chromatograms were aligned
using the phredPhrap software and visualised with the Consed programme (Figure 4-
4)
4.3. Definition of the F59 Recombination Breakpoint Interval
Figure 4-5 details the four phases of genotyping and the relative position of the
markers in each phase, and Figure 4-6 shows the genotyping results in the family. Six
markers were used in phase one: 2, 4, 5, 6, 16 & 18 (Table 4-2 and Figures 4-5 and 4-
6). Markers 2 and 4 are uninformative because the transmitting parent, F59-2078, is
homozygous. This makes it impossible to distinguish between the disease associated
and the non-disease associated chromosome. Both offspring, 2080 and 2081, share
the same parental chromosome for markers 5 and 6, and therefore these are non-
recombinant. Markers 16 & 18 are uninformative because again the parental
genotype is homozygous. From these results it is possible to say therefore that the
recombination breakpoint is centromeric to marker 6. Four markers were genotyped
in phase two: 14, 17, 19 and 20. Marker 14 was not polymorphic. Markers 17, 19 and
20 show that offspring 2080 and 2081 inherit different chromosomes from parent
2078. Therefore, there has been a recombination event between marker 6 and marker
17, meaning that markers 17-20 are on the centromeric side of the recombination
breakpoint.
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140 150 166 168 172
Figure 4-3: Fluorograms of microsatellite marker stD4S2906 (green) (visualised using
GeneScan version 3.0 software). Size standard peaks are seen in red. Allele size (in base
pairs) is marked along the top. The marker shows two major stutter peaks two base pairs
apart, with minor background peaks in between. The genotypes of three individuals are
shown A: Individual with homozygous 166 genotype. B: Individual with heterozygous 166/168
genotype. C: Individual with heterozygous 166/172 genotype.
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File FdH Options Help
File: s361_stef21_h09_h9_076.abl Sequence Name H9 Run ended Apr 2, 2001
110 120 130 140 ISO 160 170 180 19C
File: s36 l_stef2 l_h03_h3_028.ab 1 Sequence Name: H3 Run ended: Apr 2, 2001
100 110 120 130 140 150 160 170 180
Figure 4-4: Part of the sequence trace for STS st585128.snp. The sequence trace is
displayed using the Chromas software (www.technelysium.com.au/chromas. html). A single
nucleotide polymorphism (rs1520285) is observed (arrow). The sequence traces of three
individuals are shown with genotypes A: homozygous t/t, B: heterozygous t/a, C:
homozygous a/a.
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There are two ways of interpreting who the recombinant individual is. I have
assumed that the recombination event occurred in individual 2081. However, it could
have occurred in both 2080 and 3688 in the same region and not 2081. However, the
simplest explanation is that only one recombination event has occurred.
Recombination is a relatively rare genetic event, and it is very unlikely to happen
independently in two individuals in the same place.
Markers 6 and 17 that flank the recombination breakpoint are positioned on
overlapping BACs. However, the sequence for both BAC's was unfinished at this
time (February 2001), and therefore the extent to which I had resolved the
recombination interval was impossible to determine accurately. Both BACs were
known to contain a T7 end clone marker called stb272L7.t7, from BAC RP11-272L7.
Therefore, the sequence fragment ofRP11-3523E6 and RP11-426F15 that contained
this marker could be unambiguously placed between markers 6 and 17.
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Figure 4-5: Four phases of genotyping were employed to refine the recombination
breakpoint marking the centromeric end of the haplotype inherited with psychiatric illness in
family 59 (delineating the centromeric boundary of Minimal Region 1). A minimal tiling path of
nine BACs (RP11) between RP11-473M13 and RP11-11C13 was chosen between the
current recombinant and non-recombinant markers (arrows). The relative position of each
marker (number) in each phase is shown. Phase 1 resulted in the extension of the disease
associated haplotype (red). Phase 2 resulted in the extension of the recombinant haplotype
(blue). Phases 3 and 4 did not result in further refinement of the breakpoint.
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Unfortunately, this sequence fragment did not contain any putative microsatellite
repeats. It did, however, contain a number of putative SNPs identified in dbSNP.
In phase three of genotyping, two STSs were designed to flank four of these SNPs.
STS st585142.snp contained markers 8 and 9, and STS st585128.snp contained
markers 10 and 11. After PCR and sequencing, marker 8 and marker 11 were found
to be polymorphic in the sample. However, neither SNP is informative for the
recombination breakpoint because the genotype of parent 2078 is homozygous. At
this point the recombination breakpoint could not therefore be resolved any further.
The best option was to wait for the BAC sequences to be completed by the human
genome sequencing project, and then to identify and test further putative
polymorphic repeats in the interval.
4.4. Phase 4: Further Refinement of the Recombination
Breakpoint
The sequence of both BACs was complete at February 2003. Markers 6 and 17 that
flank the recombination breakpoint were found to be ~155kb apart.
4.4.1. Family Members
The markers were tested directly on the Allele Sharing (AS) panel (Figure 2-5) and
F59-2081 which is not on the AS panel. This is a panel of 46 individuals from each
of the four families. It enables the recombination breakpoint to be analysed but also
enables allele sharing between the families to be assessed as well as providing a large
population to interpret individual marker characteristics from (Section 4.2.1).
4.4.2. Markers
Four markers were genotyped in phase four. I designed markers 7, 12 and 15 to
putative polymorphic repeats identified by Sputnik. In addition, I typed a publicly
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available polymorphic marker (13) that was in the interval. I also inspected the region
for SNPs identified by dbSNP that were located within existing STSs in ACeDB.
Unfortunately there were none.
4.4.3. Genotyping
Microsatellite markers 7, 12, 13 and 15 were tested on three control DNAs to
establish PCR conditions. They were diluted appropriately and genotyped on the ABI
3730 DNA sequencer and analysed using GeneScan version 3.0 software. Markers
were multiplexed where possible. Genotypes were scored blind and segregation was
checked before using the results.
4.4.4. Results
Figure 4-5 details the position of these phase 4 markers, and Figure 4-6 shows the
genotyping results in the family. Marker 7 was uninformative in F59. From the AS
panel, only two alleles were observed for this marker, and the minor allele was only
observed four times in F22 and once in F59. Markers 12, 13 and 15 were
polymorphic in the family but unfortunately the genotype of the transmitting parent
2078 was homozygous and therefore uninformative. Therefore the recombination
interval could not be refined further as a result of genotyping these four markers.
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Figure 4-6: The marker haplotypes for 13 microsatellites and two single nucleotide
polymorphisms in family 59. A recombination breakpoint in 2081 is revealed. Black infill =
BPAD. Unfilled = no diagnosis. The crossed through individual is deceased, and the
haplotype inferred. Markers with a star are fully informative for the breakpoint (marker
number refers to Table 4-2). Coloured bars represent each of the different haplotypes and
show the inheritance pattern. Red = disease associated haplotype because it is inherited in
all cases of psychiatric illness. Offspring 2081 inherits part of the disease and part of the non-
disease associated haplotype. It is not possible to determine which haplotype 2081 inherits
between markers 6 and 17 (~155kb) with these marker genotypes. / = missing data.
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4.5. F50 Recombination Breakpoint
The recombination breakpoint in F50 constitutes the telomeric boundary ofMR1. At
the start ofmy PhD the recombination interval lay between markers stb301 J10.p3
and stbl49bl5_3p24 (Figure 4-1) that map to clones RP11-301J10 and RP11-
751LI9 respectively. The exact distance between these markers is not known because
there is a gap both in our inhouse contig and in the publicly available sequence.
However, FISH mapping estimated the gap to be ~300kb (Evans et al, 2001) and
therefore the distance between the two markers was approximately 800kb.
The November 2002 release of the UCSC Golden Path positioned four clones (RP11-
180A12, RP11-626020, RP11-264E23 and CTD-2205P10) into the gap on the
centromeric side (Figure 4-7). In chapter 3 I describe how I confirmed that they had
been positioned correctly by bioinformatic analysis and a series of colony PCR
experiments. These four clones provided a new resource from which to design
microsatellite markers to refine the recombination breakpoint.
The F50 recombination breakpoint interval is important because it contains two
known genes. The carboxypeptidase Z (CPZ) and orphan g-protein-coupled receptor
78 (GPR78) genes could either be included or excluded from MR1 depending on
where recombination has occurred. CPZ, GPR78 and the recombinant marker
st301 J10.p3 are all positioned on BAC RP11-301J10. At the start of this project the
sequence of this BAC was incomplete. However, by analysing the contig in SAM it
was possible to determine the location ofGPR78 and CPZ relative to the
recombinant marker st301 J10.p3. In the contig, marker SHGC18179 was telomeric to
every other marker that had been tested for hybridisation to clone RP11-301J10. This
marker lay within the same sequence fragment as the non-recombinant marker
stb301J10.p3. Therefore, both genes were likely to be centromeric to this non-
recombinant marker. This positioning was upheld with the release of the completed
sequence ofRP11-301J10.
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Figure 4-7: The telomeric recombination breakpoint region of Minimal Region One defined
by family 50. A. At the start of the project only the two clones containing the non-recombinant
(stb149b15_3p24) and recombinant (stb301 J10.p3) marker flanking the recombination
breakpoint were correctly positioned. B. Subsequently, the position of four clones was
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The AS DNA panel was developed during these experiments, and therefore each
marker was either typed on a selection of family members or the AS panel. Details
for each marker can be found in Table 4-2. Eight of the 10 markers were typed on the
AS panel, and two were typed on a selection of family 50, 59 and 22 members.
4.5.2. Markers
4.5.2.1. Microsatellite markers
As mentioned, the recombination breakpoint had previously been defined by others
to between telomeric non-recombinant marker stb301 J10.p3 and centromeric
recombinant marker stbl49bl5-3p24 (Figure 4-1). The publicly available BAC
contig spanning this interval was incomplete at the start of this project. Today
(February 2004), the BACs within the interval have been fully sequenced but one
contig gap remains.
The details of the markers can be seen in Table 4-2. In summary, ten microsatellite
repeats were typed. Markers were designed to flank putative polymorphic repeats
identified by Sputnik and Repeat Masker, except marker 34. This marker was
identified by bioinformatic analysis carried out by Dr. Colin Semple from a fragment
of Celera sequence Ce:GA_x54KRCDMTNS.l-l 12114. This lies beyond the limits
of the public ally available and inhouse contig on the telomeric side. Two of the
markers (3 and 38) had been previously identified, designed and tested for
polymorphism by others in the group.
I described in Chapter 3 how the sequence on the centromeric side of the gap is
highly repetitive, and it may be that this is prohibiting the identification of BACs that
span the gap. As discussed previously, the human genome sequencing project
sequence releases at UCSC have varied with respect to one another in this region.
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The April 2003 release positioned four clones on the centromeric side of the gap and
I confirmed their position by colony PCR (Chapter 3). This provided me with an
additional resource for identification ofmicrosatellite markers. However, the
repetitive nature of these four clones makes it difficult to design any markers around
putative polymorphic sequences, as many potential primers are likely to amplify from
more than one chromosome.
Six of the ten markers (35, 36, 37, 38, 43 and 44) are in this highly repetitive region.
Primers were designed by performing a BLASTn similarity search of the region
surrounding the putative microsatellite repeat. The BLASTn alignment was used to
identify highly similar clones from other genomic regions and then to design primers
with mismatches to these highly similar regions at their 3' ends. The markers were
then tested for specificity to chromosome 4 on a somatic cell monochromosomal
hybrid (MCHP) panel. For example, for marker 38,1 performed a BLASTn of a
769bp region around the microsatellite repeat. The results showed that it was greater
than 94% similar to 11 clones from other chromosomes. I designed two pairs of
primers with mismatches at their 3' end to every similar clone. Primers to five other
markers in the repetitive region were designed in a similar way.
These six markers were then tested to obtain optimal PCR conditions on three control
DNAs and then tested on the MCHP for specificity to chromosome 4. Marker 35
amplified from only chromosome 4 using the optimal PCR conditions determined.
Marker 36 was not specific to chromosome 4. However, it is very close to marker 37
and therefore I did not pursue this marker. Marker 37 was not specific to
chromosome 4 using the optimal PCR conditions. I redesigned the primers and these
were specific to chromosome 4 under PCR conditions established from a control
DNA test. However, under these conditions, the marker did not amplify efficiently
from the AS panel. I performed a second PCR, lowering the annealing temperature
by 2°C, and ran both the high and the low stringency PCR products on the ABI3730
Genetic Analyser. The samples that had worked in both PCRs had the same
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genotypes. Therefore I decided that the samples that had only worked in the lower
stringency PCR were also reliable.
Marker 38 amplified only from chromosome 4 using the PCR conditions determined
from the control DNA test. However, after PCR on the AS panel, the signal intensity
of the product on an agarose gel was very low. Therefore I performed another PCR
on the AS panel with 40ng ofDNA in the PCR instead of 20ng. The signal intensity
of the product on an agarose gel was much stronger. However, it was possible that
providing excess DNA in the PCR could have enabled the primers to anneal to other
chromosomes. Therefore I ran both high and low stringency PCRs on the ABI 3730
Genetic Analyser and compared the results of the samples that had worked in both
conditions. There was complete agreement of the results from both PCRs and
therefore the extra genotypes obtained from the PCR with double the amount of
DNA in the reaction were deemed reliable.
Using the PCR conditions determined from the control DNA test, marker 43
amplified from only chromosome 4 using the MCHP. After PCR on the AS panel,
these conditions resulted in non-specific bands when the product was run on an
agarose gel. Therefore this marker was discarded. Exactly the same was observed for
marker 44. However, on an agarose gel, only one extra band of approximately double
the expected size was observed. Therefore I ran this on the ABI 3730 Genetic
Analyser and was careful to check segregation before accepting the results as reliable.
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4.5.2.2. Single Nucleotide Polymorphism Markers
Details of the SNP markers can be found in Table 4-2. The GPR78 gene lay within
the recombination interval as defined prior to the start ofmy project. I identified 23
SNP's in the GPR78 gene (markers 4-26) by sequence analysis of family members
using the AS panel. SNPs were genotyped by direct inspection of the sequence traces.
The CPZ gene is the second known gene in the recombination interval. Stephanie Le
Hellard had previously identified six SNP's from the CPZ gene (markers 27-32) by
sequence analysis of members of F22, F50 and F59.
Seventeen primer pairs developed in house by others for other experiments contained
putative SNPs in dbSNP. The SNPs in five STSs had been previously tested by
others for polymorphism in F50 and they were either uninformative or not
polymorphic. Therefore PCR conditions were tested for twelve STSs on three control
DNAs. These conditions were then used to test for specificity to chromosome 4 on
the MCHP since they were in the repetitive region. Seven STSs were specific to
chromosome 4 using the PCR conditions optimised on control DNA.
These seven STSs contained a total of 17 SNPs identified in dbSNP. A PCR of each
STS was performed on seven individuals from F50: -1, -2, -3, -4, -11, -12 and -15.
The PCR products were sequenced and the sequences examined for the presence of
SNPs. I identified six SNPs in F50. SNPs 39-42 were identified in STS
stl80A12.ml, and SNPs 45 and 46 were identified in STS stc202024.2. A BLASTn
of these two STSs revealed that they were highly similar to other genomic regions.
The BLASTn of the 736bp STS st202024.2 revealed that there were multiple clones
showing 90% similarity or greater but that none of these aligned to more than a
652bp stretch of continuous sequence. A BLASTn of the 550bp STS stl80A12.ml
revealed that clone RP11-10K17 from chromosome 16 was 93% similar; a difference
of 39bp. Therefore, this result in addition to the specificity of the STSs to
chromosome 4 on the MCHP led me to conclude that the six SNPs identified were
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Markers were tested on three control DNAs to establish PCR conditions. They were
diluted appropriately and run on an ABI 310, 377 or 3730 Genetic Analyser and
analysed using the GeneScan version 3.0, or GeneMapper version 3.0, software.
Markers were multiplexed where possible. SNPs were genotyped by direct
sequencing. After PCR, sequence chromatograms were aligned using the phredPhrap
software, visualised with the Consed programme and manually inspected for
polymorphism. Genotypes were scored blind to phenotype and family relationship
and then Mendelian segregation was checked.
4.6. Definition of the F50 Recombination Breakpoint interval
Six microsatellite markers and 35 SNPs were used to analyse the telomeric
recombination breakpoint ofMR1 as defined by F50-12 (Figure 4-8). The results
showed that individual 12 inherits the disease associated chromosome from marker
37 to marker 47. This extends the disease associated haplotype as defined at the start
ofmy project by a further 336kb.
The results were interpreted as follows. The transmitting parent F50-3 is
heterozygous for marker 37. F50-4 is also heterozygous for marker 37. The
genotypes of the two offspring 12 and 15 allow for the correct interpretation ofwhich
chromosome the recombinant individual F50-12 has inherited. F50-15 inherits the
green and the grey chromosomes, and has a homozygous genotype for marker 37.
Therefore, the grey and the green chromosome must each contain allele 1. F50-12 has
a heterozygous genotype for marker 37, and inherits the grey chromosome from
parent F50-4, which as has been seen from F50-15 must contain allele 1. Therefore,
allele 2 must have been inherited from parent F50-3. It can also be seen that F50-15
inherits the green chromosome from parent F50-3 and that this also contains allele 1.
Therefore, allele 2 in F50-12 must be on the red disease associated chromosome. The
argument also follows for markers 38, 39, 41, 42 and 45.
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The results mean that the GPR78 and CPZ genes in the recombination interval cannot
be ruled in or out ofMR1. In addition, there are a number of putative genes in the
region centromeric to marker 37 which are now included in MR1 as they lie within
the newly defined region of disease associated chromosome.
By sequencing seven members of F50, seven STSs, that contained 17 putative SNPs,
actually contained only six that were polymorphic in the family. This was probably
due to two reasons. Firstly, my sample number is too small to represent all variation.
Secondly, five of the STSs are in the repetitive region centromeric to the gap.
Therefore the SNPs in the public database that have been localised to this region of
chromosome 4 could in fact be due to the amplification of other chromosomal
regions.
The homozygosity of F50-3 for markers 2-35 makes the determination of a
recombination breakpoint in F50-12 impossible. This region of homozygosity
extends over 203kb of known sequence between heterozygous markers 1 and 37,
including an undetermined distance in the contig gap. This is investigated further in
the following section.
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Figure 4-8: The marker haplotypes for six microsatellites and 35 single nucleotide
polymorphisms in family 50. Black infill: schizoaffective disorder. Unfilled: well. Colours
represent each of the different haplotypes to show inheritance pattern. Red: disease
associated haplotype as it is inherited with a psychiatric illness. F50-12 inherits part of the
disease and non-disease haplotypes, but it is not possible to determine inheritance between
markers 2 and 35. / = missing data. Marker number as Table 4-3. Arrow: sequence gap.
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4.7. Investigating the Homozygosity of F50-3
It seems unlikely that the genotypes ofmarkers 2 to 35 of the transmitting parent
F50-3 should all be homozygous. It is possible that there has been a loss of
heterozygosity in this region. Any such region would have to extend over 203kb of
known sequence and possibly includes the sequence in the contig gap.
The current data shows that a loss of heterozygosity would have to have occurred
spontaneously in F50-3 rather than having been inherited from the parents F50-1 or -
2. This is because over the length of homozygosity in F50-3, both F50-1 and -2 have
heterozygote genotypes at a number ofmarkers (Figure 4-9).
By inspecting the genotypes ofF50-3, -4, -12 and -15 in Figure 4-8, it is possible to
see that F50-15 inherits the green chromosome from F50-3, and is heterozygous for
markers 2, 4, 5, 6, 9, 10, 11, 12, 13, 27, 31 and 32. This would not be possible if the
green chromosome had been lost from F50-3. Therefore, if a loss of heterozygosity
has occurred it must be on the disease associated chromosome. F50-12 also has
heterozygous genotypes for markers 2, 4, 5, 6, 9, 10, 11, 12, 13, 27, 31 and 32, but,
because we don't know if this individual inherits the red or the green chromosome,
we cannot say for certain that the red disease associated chromosome is not missing
in the F50-3. Furthermore, even ifF50-12 has inherited a red disease associated
chromosome from F50-3 for markers 2, 4 -3, and 28-46 it still leaves a section of
homozygosity, from marker 14-27, which could still, theoretically, be lost in F50-3.
However, this is unlikely because 13 of these 14 markers only span ~lkb (Table 4-2).
Markers 14-26 were typed on the AS panel and the minor alleles of these 13 SNPs
form a single haplotype, occurring on only five chromosomes in family 22 and not
once in family 50, 59 or 48, giving a haplotype frequency of 11.4%. Therefore, a
homozygous genotype is not unusual for these SNPs.
The region of homozygosity in F50-3 from marker 2-34 flanks the telomeric side of
the contig gap and therefore could extend into this gap. One side of the contig gap
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Figure 4-9: The marker haplotypes for six microsatellites and 35 single nucleotide
polymorphisms in family 50 members, F50-1 and F50-2, the parents of F50-3 (Figure 4-6).
Black infill: schizoaffective disorder. Unfilled: no diagnosis. Colours represent each of the
different haplotypes. Red: disease associated haplotype since it is inherited in all cases of
psychiatric illness. Marker number refers to Table 4-3. / = missing data.
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is a region that appears to be poorly represented in genomic libraries (Evans et al,
200 la). The other side of the contig gap is highly repetitive. It might be in just such
regions that during DNA replication errors could lead to the elimination of stretches
ofDNA.
4.7.1. Assay to Detect Chromosome Loss in F50-3
Two somatic cell hybrids, one derived from F50-1 and another derived from F50-3,
had previously been made in the lab by Ian Anderson. Four hybrids which retained
one copy of chromosome 4 for individual F50-1 had already been identified. The
hybrids retaining one copy of chromosome 4 for F50-3 had not been identified.
Therefore I genotyped 24 hybrids derived from F50-3 with five chromosome 4
microsatellite markers for which F50-3 is heterozygous. Three markers showed
clearly which hybrids were haploid and which were diploid (Figure 4-10). The PCR
failed for one marker and the other marker appeared to be completely homozygous
suggesting a mistyping. Out of 24 hybrids, three hybrids had segregated one
chromosome 4 (A) and one hybrid had segregated the other chromosome 4 (B)
(Table 4-3). I amplified six STSs from GPR78 and CPZ, in the region of
homozygosity in F50-3, from the four haploid hybrids in F50-3 and the four haploid
hybrids in F50-1 (Figure 4-11). Each of the STSs amplified both chromosomes and
therefore did not support the hypothesis of a loss of heterozygosity.




Table 4-3: Genotyping three chromosome 4p microsatellite markers on 24 somatic cell
hybrids of individual F50-3. F50-3 is heterozygote for the three markers after genomic DNA
PCR. Therefore, the hybrids retaining one chromosome 4 are determined from a
homozygous genotype. Of the 24 somatic cell hybrids, four hybrids retained one copy of each
chromosome 4 (Chromosome A and B).
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Figure 4-10 (continued overleaf): Fluorograms (displayed on the GeneMapper 3.0
software, Applied Biosystems) for three chromosome 4p microsatellite markers genotyped on
somatic cell hybrids of individual F50-3. F50-3 is heterozygote for the three markers after
genomic DNA PCR. Therefore, the hybrids retaining only one chromosome 4 are determined
from a homozygous genotype. Of the 24 somatic cell hybrids, four hybrids retained one copy
of each chromosome 4. The size standard marker is shown by the red peak in each case.
The size of each allele (base pairs) is marked above. The figure shows the results for two of
the hybrids, each retaining one chromosome 4. A. Marker stD4S2633. A1. hybrid displaying
chromosome A genotype. A2. Hybrid displaying chromosome B genotype. B. Marker
st473mca.5b. B1. Hybrid displaying chromosome A genotype. B2. Hybrid displaying
chromosome B genotype. C. Marker st481L13. C1. Hybrid displaying chromosome A
genotype. C2. Hybrid displaying chromosome B genotype. Despite the single predominant
genotype in each fluorogram, it is still possible to see the other allele at a low level (except
C1 where the stutter peaks of the major allele masks the region).
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Figure 4-11: Agarose gels showing amplification of three STSs from the orphan G-protein-
coupled receptor 78 gene and three STSs from the carboxypeptidase Z gene from four F50-1
and four F50-3 somatic cell hybrids that each retain only one chromosome 4. Since F50-1 is
the parent of F50-3, this is a total of three chromosomes (A. B or C). Chromosome A is
inherited from parent F50-1 to offspring F50-3. Three F50-1 hybrids retain chromosome A
(B5, C4 and D2) and one retains chromosome C (D5). One F50-3 hybrid retains
chromosome B (A4), and three retain chromosome A (A5, B5 and B6). Amplification was
performed to test for the presence of both copies of chromosome 4p in the region containing
these two genes in both individuals. A lack of amplification would suggest the deletion of this
part of the chromosome. As can be seen, all hybrids amplify for each individual, although not
equally. M = ReadyLoad™ 1 kb DNA ladder (Invitrogen).
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Although the majority of cells in a hybrid cell line will be monovalent for a given
chromosome, a small number of cells will be bivalent. Therefore, the use ofPCR is
not ideal because sometimes only a very small amount of template DNA will result in
successful amplification. I noticed that for four of the six STSs, the PCRs did not
amplify equally for each hybrid, and that the same amplification pattern was
observed for each STS. In Figure 4-11 it is possible to see that the two F50-3 hybrids
A4 and B5 (chromosome A) amplify less efficiently than samples A5 or B6 for four
of the six STSs. Therefore a re-examination of the genotyping gel for F50-3 (Figure
4-10) was undertaken to see if there was a correlation between how well the hybrid
PCR worked on the STS compared to how large the peak of the 'contaminating'
chromosome was in the genotyping gel. As can be seen from Figure 4-10, this was
only possible for markers A and B, since the 'contaminating' peak ofmarker C was
masked by the stutter peak of the major allele. Table 4-4 notes the peak height of the
'contaminating' peak. I found that the 'contaminating' peaks for hybrid A4 and B5
were smaller than A5 and B6 for marker B but not marker A. In the absence ofmore
data, it was not possible to determine from this whether the presence of the other
chromosome in the hybrid in Figure 4-10 could account for the efficiency of the PCR
assay in Figure 4-11.




A (A4) 61 1667
B (A5) 586 12 224
B (B5) 308 10 601
B(B6) 1666 2528
Table 4-4: Three chromosome 4p microsatellite markers were genotyped on somatic cell
hybrids of individual F50-3. F50-3 is heterozygote for the markers on genomic DNA. Hybrids
retaining only one chromosome 4 will have a homozygous genotype. Of 24 somatic cell
hybrids, four retained one copy of each chromosome 4 (A4, A5, B5 and B6). However, on a
fluorogram (Figure 4-10), a peak the size of the second allele is present, suggesting the
presence of the second chromosome. The table shows the peaks heights of the second
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The underlying biology of psychiatric disorders is largely unknown and the
mechanism by which current treatments operate is also unclear. Therefore, virtually
any gene can be proposed as a candidate, making candidate gene selection from large
genetic susceptibility regions problematic. The disease associated haplotypes of the
four families studied overlap. This has provided a suitable way of reducing the
candidate intervals, assuming that the same susceptibility gene operates in the
families. This has revealed four priority regions. It is very important to define the
recombination breakpoints and these overlapping regions as precisely as possible for
inclusion and exclusion purposes. It is also important to define each family disease
associated haplotype as precisely as possible because they may have different
ancestry.
Here I describe the genetic analysis ofMR1, a candidate region for susceptibility to
psychiatric illness. MR1 is defined by the overlapping haplotypes from families F22,
F59 and F50. This is an important region because all three families are ofCeltic
ethnicity, which makes a common ancestor hypothesis more likely. In addition,
association has previously been found between MR1 markers in the region of the
dopamine D5 receptor (DRD5) candidate gene and SCZ (Muir et al, 2001).
As a result of typing markers in family members I have refined the centromeric
recombination breakpoint ofMR1 to within 155kb. At present there are no known
genes within this interval and therefore further refinement is unnecessary. I have also
extended the disease associated haplotype in the telomeric recombination breakpoint
ofMR1 by a further 336kb. The exact size of the new recombination interval is
unknown because there is a contig gap between the recombinant and non-
recombinant marker. However, it can be estimated at approximately 500kb. At
present there are two known genes, CPZ and GPR78, within this interval, and
therefore further refinement is desirable. However, this will be made difficult by the
repetitive nature of the sequence in the region.
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A disadvantage of recombination breakpoint mapping is that recombination is a
relatively rare event. The breakpoints the create MR1 are defined by only one
individual in each family. Consequently, the size of this region is still large.
Furthermore, in a smaller family the recombinant individual could be a phenocopy,
sharing a haplotype by chance. With these limitations in mind it is still worthwhile
refining an already large disease associated haplotype in a family to include or
exclude potential candidate genes.
The possibility that part of one of the chromosomes in individual F50-3, the parent
that transmits the recombination breakpoint, has been lost has been shown to be
extremely unlikely. Furthermore, the possibility of loss of heterozygosity does not
impinge on the disease process because the chromosome loss could not have arisen in
individual F50-1. Therefore it is not the cause of illness in the family.
There is evidence that whole genome amplification (WGA) increases homozygosity
(S. LeHellard, personal communication) which, whilst not desirable normally, would
in this case perhaps reduce the problem associated with using a PCR based assay on a
hybrid cell line. An interesting future experiment could be to subject the somatic cell
hybrid ofF50-3 to WGA, as this may produce a more reliable sample for PCR
analysis of partial chromosome loss.
In conclusion, I have refined the recombination breakpoints ofMR1, one of the two
best candidate regions for the susceptibility to psychiatric illness in four families.
Future work should aim to refine the telomeric boundary further because it contains
two known genes.
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Transcript Map of Two Candidate Regions for
Psychiatric illness on Human Chromosome 4p
5.1. Introduction
The production of sequence from the human genome sequencing project (HGP)
facilitates the identification of genes and their regulatory regions. This will not only
help to identify disease genes but also the biological processes underlying normal
cellular function.
It has been possible to begin genome annotation with draft sequence. However,
because draft sequence is inherently fragmentary, high quality finished sequence is
preferable. The finished sequence was announced on the 14th April 2003. However,
sequencing is still ongoing and a number of gaps remain. The Sanger Institute
(February 2004) (www.sanger.ac.uk/HGP/) reports that 88.99% of the genome
sequence is finished and that 4.23% is of draft quality, totalling 93.22% of the human
genome. The latest University ofCalifornia Santa Cruz (UCSC)
(www.genome.ucsc.edu) sequence release (July 2003) claims to cover 99% of gene
containing regions. The aim of the sequencing project is to achieve an accuracy of
greater than 99.99%. In addition to aiding the discovery of all the genes in the human
genome, this level of coverage and accuracywill permit the identification of variation
between human genomes to identify disease genes and allow comparison with other
species to identify regulatory elements and elucidate evolutionary processes.
Known and predicted genes are annotated by a mixture of expression evidence and
bioinformatic prediction methods. Bioinformatic tools are informative for gene
discovery, providing support to expression evidence and suggesting the presence of
genes where no expression evidence is available. Three common gene and exon
prediction programmes are Fgenes, GenScan and MZEF. The results of these are
displayed in our inhouse database ACeDB. The gene prediction programme Fgenes
(www.softberry.com), developed at the Sanger Institute uses pattern recognition to
148
Chapter Five Transcript Map ofMR 1 and MR2
detect promoters, exons and poly-adenylation signals based on the linear discriminant
function (LDF) method. This calculates a score of any open reading frame (ORF),
between a start and a stop codon and predicts an exon if the LDF is above a
threshold. Each exon is considered in the context of possible 5' and 3' exons with
respect to splicing donor and acceptor sites, the ORE, start and stop codons and poly-
adenylation and promoter sequences. The objective is to find the arrangement with
the maximal value from all possibilities. Fgenes does not perform well if there are
several genes within the sequence being analysed, when the GC content is low, and if
there are short (<25bp) exons. Furthermore, the prediction of terminal exons is poor
resulting in genes being split or joined together. Therefore, Fgenes is most likely to
correctly identify genes that have a standard intron and exon length and standard
TATA boxes and poly-adenylation signals.
GenScan, developed at Stanford University (Burge and Karlin, 1997) is another
commonly used gene prediction programme. It uses a similar method of gene
prediction as Fgenes and suffers from a similar set of problems. MZEF, developed by
Michael Zhang, is an internal coding exon prediction program. It identifies a
potential exon by the presence of splice sites and an ORF, measures a set of
discriminant variables and then calculates the exon probability. If the probability
exceeds a threshold an exon will be predicted. As with GenScan and Fgenes, false
positives are a problem. Comparison of the overlap between multiple programmes,
particularly those that use different methodologies, is useful. However, evidence
from gene and exon prediction programmes should not generally be taken alone.
With the HGP nearing completion, large scale cDNA sequencing projects are
increasingly common and provide a similar large scale genomic approach to gene
identification. Comparative genomics is also proving to be a valuable tool for gene
identification since cross species sequence homology is often likely to reflect the
evolutionary conservation of genes and regulatory regions. Gene prediction
programmes can be validated where these lines of evidence co-occur.
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It is very important in this project to identify all the genes in our linkage regions,
especially our best candidate regions, minimal regions one (MR1) and two (MR2).
These candidate regions are large and because a definitive theory of the pathological
processes in psychiatric illness is lacking, candidate genes are hard to define. The aim
is to perform association studies in MR1 and MR2 in order to focus future protein
based studies. Therefore, in turn, a map of the genes in these regions would help to
focus these association studies.
This chapter describes efforts to build a transcript map ofMR1 and MR2. To achieve
this I used a combination ofbioinformatics methods, cDNA library screening and
RT-PCR.
5.2. Defining the Region
5.2.1. ACeDB
ACeDB, described in chapter three, is the inhouse database that displays the genomic
sequence ofMR1 and MR2. The database is constructed and managed inhouse by S.
Morris and displays the sequence of the clones that span MR1 and MR2. Sequenced
clone are obtained from the HGP and are re-analysed for sequence overlap. Where
necessary the clone order is adjusted to satisfy this more rigourus inhouse analysis.
Therefore, ACeDB represents a further layer of analysis to that of the HGP. This was
of greater importance in the past when the HGP sequence was fragmentary.
The sequence in ACeDB is masked for simple repeats, annotated with CpG islands,
and the results of BLASTn similarity searches to human clones, vertebrate and
invertebrate genomic DNA, vertebrate mRNA and protein, and the results of the gene
and exon prediction programmes GenScan, Fgenes and MZEF (Table 5-1). Figure 5-
1 shows an example of an ACeDB map view of a known gene. As can be seen, it
provides a fully integrated view of a gene, displaying the BLASTn alignments of
ESTs and mRNA, the results of gene prediction programmes and in inhouse data.
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Annotation Website
Simple repeat finder RepeatMasker repeatmasker.genome.washington.edu/




Human EST database Unigene www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene
Human EST database Tigr www.tigr.org/
Human EST database Stack www.sanbi.ac.za/Dbases.html








Gene predictor programme Fgenes www.softberry.com
Table 5-1: List of the programmes and databases used to annotate ACeDB, the inhouse
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5.2.2. Minimal Tiling Path
Transcript Map of MR1 and MR2
In order to position known genes and identify novel genes in the two minimal
regions, I first needed to identify a clone contig. The group had previously described
a BAC/PAC contig ofMR1 (Evans et al, 200 la). However, the clones that form the
MR1 contig were not necessarily being sequenced in the HGP. Therefore, I used the
inhouse contig, displayed in the SAM database (system for assembling markers)
(Soderlund, 1995) in conjunction with the HGP sequence displayed in ACeDB. First,
a minimal tiling path ofBACs across MR1 was constructed using SAM. I determined
which clones were part ofboth the SAM and the ACeDB contigs, referring back to
SAM to bridge sequence gaps in ACeDB. At this time, many of the BACs displayed
in ACeDB from the HGP were not fully sequenced and in many fragments, and
contiguous sequence contigs were short. Therefore, the inhouse contig formed a
useful resource to order clones with respect to one another. An insilico contig of
MR2 consisting of clones being sequenced as part of the HGP, had been constructed
previously in SAM by S. LeHellard. I chose a minimal tiling path from this contig to
work from in ACeDB. Tables 5-2 and 5-3 detail the minimal tiling paths I
constructed ofMR1 and MR2.
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Table 5-2: The minimal tiling path (December 2001) of Minimal Region One, the region of
chromosome 4p identified by the overlapping disease associated haplotypes of families 22,
50 and 59. A contig built inhouse was used to select a tiling path of clones that were also
being sequenced as part of the human genome project (HGP) and available on the University
of California, Santa Cruz genome browser (genome.csi.ucsc.edu). Boxes identify overlapping
clones. Clone names, sequence accession numbers and sequencing status were obtained
from the National Centre for Biotechnology Information (www.ncbi.nlm.nih.gov). The gap
between clones RP11-301J10 and RP11-751L19 represents a contig gap in the inhouse
contig and the HGP contig. The gap between clones RP11-494H11 and RP11-26P5
represents a contig gap in the HGP contig only.
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Table 5-3: The minimal tiling path (December 2001) of Minimal Region Two (MR2) the
region of chromosome 4p identified by the overlapping disease associated haplotypes of
families 22, 48 and 50. An in silico contig, built inhouse by S. Le Hellard using the clone
contig created by the human genome project (HGP) available on the University of California,
Santa Cruz genome browser (genome.csi.ucsc.edu), was used to select a minimal tiling path
of clones being sequenced as part of the HGP. Boxes identify overlapping clones. Clone
names, sequence accession numbers and sequencing status were obtained from the
National Centre for Biotechnology Information (www.ncbi.nlm.nih.gov). A clone name for
sequence AC006393 was not available.
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5.3. Sequence Composition of the Region
Giemsa staining (G-banding) of chromosomes is a technique that enables individual
chromosomes to be identified. The giemsa dye stains regions of the chromosome that
are rich in adenine and thymine nucleotides, producing a dark band under a
microscope. Due to these properties of the Giemsa stain, the banding patterns reflect
the GC content (Bickmore and Sumner, 1989).
To determine the GC content ofMR1 and MR2,1 first had to localise our inhouse
markers defining the minimal regions to the public map at UCSC. MR1 is defined by
inhouse telomeric marker st301J10.p3 and inhouse centromeric marker st426F15.pl.
I positioned the centromeric marker very near to public marker SHGC-50831 at
position 8,613,965 in the UCSC July 2003 release, and the telomeric marker ~50kb
from public marker D4S504 at position 12,450,000. MR2 is defined by inhouse
telomeric marker stl7E2.pl and inhouse centromeric marker stl31K9.pl. I
positioned the telomeric marker ~70kb from the 3' end of gene GPR125 at position
22,090,000, and the centromeric marker ~70kb before public marker MFD281 at
position 26,300,000. In this way I could locate the recombination breakpoint
boundaries ofMR1 and 2 and calculate the GC content of the regions.
The first ~2.1Mb ofMR1 corresponds to a light band, and the last ~1.4Mb
corresponds to a dark band. The first ~720kb ofMR2 corresponds to a dark band and
the last ~3.7Mb corresponds to a light band (Figure 5-2). The GC content ofMR1
reduces as you move from the telomeric to the centromeric end (Figure 5-3: A). This
corresponds to the move from a light to a dark band. The GC content ofMR2 does
not change as clearly, but does show an increasing trend from the telomeric to the
centromeric end (Figure 5-3: B). Thus, the GC content corresponds to the banding
pattern.
The GC rich light bands are thought to represent gene rich regions whilst the GC
poor dark bands are thought to represent gene poor regions. This is bourne out by the
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gene density and location of the genes in MR1 and MR2 (Section 5-4). MR1 is
relatively gene poor compared to MR2, consistent with a larger proportion of it being
in a dark band.
157















Figure 5-2: Schematic of the Giesma bands (Black and white) on chromosome 4p with
respect to the position of both Minimal Region One (MR1), identified by the overlapping
disease associated haplotypes of families 22, 50 and 59 and Minimal Region Two (MR2),
identified by the overlapping disease associated haplotypes of families 22, 48 and 50 The
size (Megabases) and name of each band is shown. Giesma stains regions rich in the
nucleotides AT, and thus bands are dark (black) or light (white), representing GC poor and
GC rich regions respectively. TEL = telomeric, CEN = centromeric.
158
Chapter Five Transcript Map ofMR1 and MR2
A
B GC Content of MR2
Distance (Mb)
Figure 5-3: Graphical representation of the percentage of GC nucleotides in A: Minimal
Region One (MR1), the region identified by the overlapping disease associated haplotypes of
families 22, 50 and 59 and B: Minimal Region Two (MR2), the region identified by the
overlapping disease associated haplotypes of families 22, 48 and 50, on chromosome 4p.
Data is taken from the July 2003 release of the University of California, Santa Cruz genome
browser (genome.csi.ucsc.edu). Each data point represents the percentage of GC
nucleotides in a 20 kilobase window of genome sequence. Distance is measured in
Megabases (Mb). The telomeric end of each minimal region corresponds to 0Mb.
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5.4. Known Genes in MR1 and MR2
5.4.1. The Known Genes
Today (February 2004) there are seven known genes in MR1 (Table 5-4) and 13
known genes in MR2 (Table 5-5), known genes being defined as 100% alignment of
the mRNA to the DNA sequence. The tables show the gene symbol and the full name
with accession numbers of the mRNA and protein sequence, and the National Centre
for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov/) reference sequence
(RefSeq) validation status. Predicted and provisional sequences constitute mRNA
that has been through a round ofBLASTn and for which there is a full-length coding
sequence. All provisional sequences undergo a manual review step which makes
corrections to the sequence, adds additional publications, adds a summary of gene
function, provides additional records for splice variants, adds feature annotations to
the nucleotide or protein sequence, and provides an indication of completeness.
The position of each known gene, in each minimal region, can be seen in Figures 5-4
and 5-5. Every gene except HS3ST1 in MR1 is located in the light band 4pl6.1, and
every gene in MR2, except GPR125 and GBA3, are located in the light band 4pl5.2.
This follows with the observations in the previous section that G-banding
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5.4.2. Evaluating the Known Genes
Transcript Map ofMR1 and MR2
CpG islands can be a means of locating the start of a transcript. Antequera and Bird
(1993) reported that 56% of genes are associated with CpG islands. Furthermore, it
has been shown that all housekeeping genes are associated with CpG islands,
compared with 40% of tissue restricted genes (Larsen et al, 1992). The completeness
of a transcript can be assessed at the 3' end of a gene by the identification of a poly-
adenylation signal. The two most common signals are AATAAA or ATTAAA,
occurring within 10-30 nucleotides of the end of transcription. It has been estimated
that 90% of genes possess the AATAAA poly-adenylation signal, and that the
remaining 10% is accounted for by the ATTAAA poly-adenylation signal (Wahle and
Keller, 1996). However, there are a small number of alternative poly-adenylation
signals that account for some of the variation. Beaudoing et al (2000) identified ten
such putative variant poly-adenylation signals by identifying sequences significantly
overrepresented in the 3' end ofmRNA.
Characterisation of the known genes for the presence of a CpG island and a poly-
adenylation signal can be seen in Table 5-6. In accordance with what has been shown
for other genomic regions, the majority of the genes have a CpG island on or near
exon one. Although, in the SOD3 and SLC2A9 genes, they occur in exons 3 and 2
respectively. In SOD3 this may be because the protein coding sequence begins in
exon 3. The most common poly-adenylation signal is AATAAA, observed in eleven
genes (55%), and the second most common, ATTAAA, is observed in four genes
(20%). This also follows the findings from other genomic regions. Five of the genes
did not have either of these common poly-adenylation signals.
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Gene MR CpG island AATAAA ATTAAA
GPR78 1 Y N N
CpZ 1 N N Y
DRD5 1 Y Y N
SLC2A9 1 Y(ex2) N N
WDR1 1 Y N Y
MIST 1 N N N
HS3ST1 1 Y Y N
GPR125 2 Y Y N
GBA3 2 N Y N
PPARGC1 2 N Y N
DDX15 2 Y Y N
SOD3 2 Y(ex3) N Y
LG12 2 Y Y N
SLA/LP 2 Y N N
PI4K2B 2 Y Y N
ZCCHC4 2 N N Y
ANAPC4 2 Y Y N
SLC34A2 2 N Y N
RBPSUH 2 Y Y N
CCKAR 2 N N N
Table 5-6: Characterisation of the known genes in Minimal Region One (MR1) and Minimal
Region Two (MR2). Genes are characterised by the presence or absence of CpG islands




5.5. Identifying Novel Genes
Transcript Map ofMR1 and MR2
5.5.1. cDNA Library Screening
5.5.1.1. Primer Design
I designed primers to putative exonic sequence in order to identify novel genes by
cDNA library screening. Using the contigs of the two minimal regions (Tables 5-2
and 5-3), I used ACeDB to identify regions with a build up of transcript evidence.
The best evidence for a novel transcript is from multiple splicing ESTs from different
libraries, and/or homology to proteins (identified from the protein database
SwissProt). However, this was fairly rare in the two regions. As mentioned
previously, gene prediction programmes have a certain degree of inaccuracy and
therefore I did not consider exon prediction programmes unless they were supported
by expression evidence (ESTs, mRNA or protein homology), and never where they
were located in a repeat. SwissProt protein matches are good evidence of a gene
protein motif, however, to avoid pseudogenes it is imperative to check for a
continuous ORF. ESTs are also good evidence for a transcript, however in some
instances an EST can be the result of genomic contamination in the cDNA library
from which it was generated. Since ESTs are generated from cDNA libraries using
dT primers that target the poly-A tail on a mature mRNA, they can also be primed
from a contaminating genomic poly-A tract. Therefore, I did not consider single
ESTs or ESTs that aligned to a genomic poly-A. I designed 21 STSs in MR1 and 13
STSs in MR2.
Primer pairs were tested to establish optimal PCR conditions on three CEPH control
DNAs before cDNA library screening. It is worth noting that at this time (January-
March 2002), STS design was made difficult by the unfinished nature of the BACs
which made it impossible to see a whole putative gene structure since the order of




Transcript Map ofMR1 and MR2
My strategy was to screen the STSs on 22 cDNA libraries from various adult and
foetal tissues (Table 2-2). Previous evidence from the Sanger Institute (Dr G Howell,
pers comni) suggested that 80-90% of STSs are expressed in nine of these libraries.
Therefore, STSs were first screened on a primary plate of these nine libraries. A
secondary plate of nine libraries and a tertiary plate of four libraries were
subsequently screened if no positives were identified from the primary plate. Each
cDNA library was represented on the plate as five superpools of approximately
100,000 clones each.
5.5.1.3. STS Screening
An example of an agarose gel showing the results of an STS screened on the cDNA
library primary plate can be seen in Figure 5-6. Twenty-nine of the 34 STSs were
positive for multiple cDNA library superpools. Twenty-five of the 29 STSs were
positive on a suitable number of library superpools from the primary plate and the
remaining four STSs required screening on the secondary plate. Of the five STSs not
positive on the primary plate, two STSs were also screened on the tertiary plate.
Neither was positive in any library and therefore are either not part of genes or are
not represented in these cDNA libraries. Three STSs were positive for every single
superpool and the 'no template' control on the primary plate, although at a lower
intensity. Therefore either the reactions were contaminated or, in addition to
contamination, the STSs were not specific to chromosome 4. They were not pursued
further because the sequence fragment to which they were designed in ACeDB had
subsequently been removed from this region of the genome. Table 5-7 details the
results for each STS.
5.5.1.4. Vectorette Screening
Three positive superpools, preferably from different libraries in order to maximise
access to independent clones, were chosen for each of the 29 STSs. For each STS, six
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Figure 5-6: Example of an STS screened on the cDNA library primary plate. The primary
plate contains five superpools of each of nine cDNA libraries (F.lung: fetal lung; n.blastoma:
neuroblastoma), two genomic DNA controls (+), and one 'no template' control (-). Each cDNA
library (-500,000 clones) has been divided into five superpools of -100,000 clones each. M =
Ready Load™ 100 bp DNA ladder (Invitrogen). In this example, the STS is positive for seven
libraries, but not every superpool in each library.
Figure 5-7: Vectorette schematic. Each cDNA library has a vectorette (hexagon) ligated onto
the end of the cDNA insert which acts as a specificity regulator. A vectorette is two strands of
identical, non-complimentary sequence which cannot anneal to one another. In addition, the
vectorette primer (224) sequence is identical to and cannot anneal to the vectorette
sequence. When the specific primer (blue arrow) anneals to the cDNA (red line) and
amplifies into the vectorette (hexagon) it creates the necessary reverse complimented
sequence for the 224 primer (black arrow) to anneal and amplify back.
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reactions were performed: each primer was paired with the vectorette primer (224)
for each of the three superpools. Only one vectorette primer is required for both ends
as the vectorette ligated onto the end of each insert is a bubble of non-basepairing
sequence. The 224 primer cannot anneal to the vectorette sequence until the specific
primer has annealed to the cDNA insert and extended into the vectorette (Figure 5-7).
This acts as a specificity enhancer.
PCRs were run out on agarose gels. Large, well separated bands were cut out for
sequencing. In addition, a 1:100 dilution was made of the vectorette PCRs for all 29
STSs. Twenty-five out of 29 STSs had bands cut out in this way from the vectorette
PCR. There was not necessarily a suitable band to cut out for every superpool, but
this was not due to a lack of amplification, rather that the bands were not well
separated from one another. A further round ofPCR was performed on the bands
before cleaning and sequencing. A successful second round PCR was performed for
20 out of 25 STSs. Therefore, a total of 40 clean bands from 20 STSs were
sequenced. Table 5-7 details the results.
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5.5.1.5. Vectorette PCR Problems
Transcript Map ofMR1 and MR2
The product produced after the vectorette PCR had many more bands than was
expected (Figure 5-8: A). It was possible that this was due to a proportion of the
bands being amplified from genomic regions other than the targeted region. These
could be produced by either the 224 primer, or the specific primer, annealing
randomly to the cDNA. Previous experiments by others at the Sanger Institute have
found that product is produced if a superpool is amplified with 224 only. Figure 5-8
B, shows an example where the forward primer produces clean bands but the reverse
primer produces many bands. This discrepancy could be due to the non-specificity of
the reverse primer.
However, it is possible that the results could be due to experimenter error. I
performed a number of experiments to address this. Firstly, the vectorette PCR was
performed on four STSs (st473M13pt26, st751L19pt32, st401G6pt42 and
st301J10pt31) by Jackie Bye, by whom this work was routine. The results showed
that, whilst there was some variation between reactions, in general the level of
specificity was similar between the two experiments (Figure 5-9: A). Secondly, I
performed the vectorette PCR using an STS (SGI58641) known from previous
experiments by others at the Sanger Institute to give clean results with two particular
superpools. The results showed that the STS gave clean results as expected (Figure 5-
9: B).
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Figure 5-8: Two examples of non-specific amplification from the cDNA libraries. The
vectorette PCRs, PCRs on a cDNA library with one specific primer and the vector primer in
order to obtain the full length cDNA, produced more bands than was expected. Each primer
is amplified on three cDNA superpools and a 'no template' control (-). M = Ready Load™ 100
bp DNA ladder (Invitrogen). A. The forward (F) and reverse (R) primers, amplified from adult
kidney (AK), cervical carcinoma (HeLa) and leukaemia (U) cDNA libraries, show multiple
banding. B. The forward (F) primer amplified from testis (T), leukaemia (U) and T cell (HPB)
cDNA libraries shows less banding than the reverse (R) primer.
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Figure 5-9: Results of the experiments to test the effect of experimenter error. The
vectorette PCR is performed with the vector primer (224) and each of the forward (F) and
reverse primer (R) of the specific STS in order to obtain a full length cDNA. A 'no template'
control (-) is included. M = Ready Load™ 100 bp DNA ladder (Invitrogen). A: The vectorette
PCR was performed by myself and a second independent person (J. Bye) A1: STS
st473M13pt26 A2: STS st751L19pt32 A3: STS st401G6pt42 A4: STS st301 J10pt31. B: The
vectorette PCR was performed by me on two superpool cDNA libraries using STS
SG158641.
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In order to address the lack of specificity, nested primers were designed to four STSs:
st352E6pt30, st301J10pt31, st74Ml lpt34 and stl06M4pt41b. A PCR was performed
using the nested primer and 224 on a 1:100 dilution of the bands cut out from the
vectorette PCR and a 1:100 dilution of the vectorette PCR itself.
Of the ten bands cut out for these four STSs, only one amplified after PCR with the
nested primer. However, this failure may have been because the template was too
dilute rather than because the band was not from the specific locus. Using the
vectorette PCR as a template for the nested PCR revealed that the nested PCR was
significantly cleaner than the vectorette PCR. This suggested that some of the
product in the original vectorette PCR was non-specific. Figure 5-10 shows an
example of the vectorette PCR and the corresponding nested PCR. It can be seen that
the nested PCR is cleaner than the vectorette PCR. In addition, the band cut out from
the vectorette PCR did not amplify with a nested primer, suggesting it was not
specific to chromosome 4. Two bands amplified from the nested PCR were
sequenced and found to be from the correct locus on chromosome 4.
Figure 5-10: Examples of the results obtained from a nested experiment. A: PCRs were
performed with the forward (F) and reverse (R) primer of st74M11pt34, each with the vector
primer (224) on three cDNA libraries (1-3) and a no-template control (-). B: A nested primer
was designed to the reverse primer. PCR was performed using this nested primer (R) and
224 using a 1:100 dilution of the vectorette PCR as a template. In addition, one band (b) cut
out from cDNA library 1 (boxed in A) was used as a template for the nested primer and 224.
M = Ready LoadTM 100 bp DNA ladder (Invitrogen).
175
Chapter Five Transcript Map ofMR 1 and MR2
To further address the problem of specificity, I sequenced eight bands cut out from
the vectorette PCR. The sequencing reaction failed for the four STSs. Two of the
sequenced products were multiple templates and two successfully sequenced. A
BLASTn similarity search of the two successfully sequenced bands revealed that they
did not originate from the appropriate locus. The failure of the other sequencing
reactions could also have been the result of non-specificity.
Finally, I performed a PCR with only the 224 primer (data not shown) of the bands
cut out from the vectorette PCR. The results showed amplification from most bands.
However, eleven bands were different from the expected size. I sequenced six of
these (the remaining five were too small to be more than vector sequence). Three of
the bands gave product non-specific to chromosome 4, two failed to sequence and
one was specific to chromosome 4. In conclusion, it was clear that there were non¬
specific bands in the vectorette PCRs and that the specific bands might be targeted by
nested PCR.
5.5.1.6. Nested PCR Results
1 designed nested primers to each of the STSs for which I had already performed a
vectorette PCR (from Table 5-7). I then used a 1:100 dilution of the vectorette PCR
as a template to perform a nested PCR, in which primers were designed to nest the
chromosome 4 specific primer. Nested PCR conditions were identical to the original
vectorette PCR (see Section 2.5.2.3). I then compared this to a PCR with the 224
primer only and a PCR with the specific primer only, in order to distinguish the
bands that were specific to the nested PCR (Figure 5-11). It is possible to see in
Figure 5-11, that a band in cDNA libraries 1 and 3 from the nested PCR (N) is not
observed in either the specific (S) or the 224 (V) PCR. These bands are likely to be
specific to the chromosome 4 locus. In contrast, the bands observed in cDNA library
2 are identical in each PCR and are therefore likely to be non-specific product.
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1kb ladder
Figure 5-11: A vectorette PCR was performed on three cDNA libraries (1-3) using the vector
(224) and the specific primer in order to obtain a full length cDNA. A 1:100 dilution of this
vectorette PCR was then used to perform three PCRs with different combinations of primers:
the nested primer and the vectorette primer (N), the specific primer only (S) and the
vectorette primer only (V). A no-template control (-) was included in each PCR. M = Ready
Load™ 1 kb DNA ladder (Invitrogen).
STS Specific bands
St448G15pt2n F (1) R (2)
St301J10pt31n R(2)
St751 L19pt32n F (1)
St74M11pt33n F (2)
St74M11pt34n F (2) R (1)
St17E2pt38n R (1)
St362l16pt39n F (1) R (1)




Table 5-8: Nested vectorette PCR results. A vectorette PCR was performed on cDNA
libraries using the vector primer and a chromosome 4 specific primer in order to obtain full
length cDNA product. The vectorette PCR was then used as a template for a PCR using the
vector primer and a primer designed to nest the specific chromosome 4 primer. The results
of this were compared to PCRs using the same template and only the vector primer or only
the specific primer. Bands obtained that were present only in the PCR with both the nested
and vector primer were sequenced. The table shows the specific primer, either the forward
(F) or the reverse (R), that had a band sequenced that was specific to chromosome 4
(number of bands successfully sequenced in brackets).
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I obtained and sequenced 91 bands in this way (see Table 5-8 for a summary of the
results). The sequencing reaction failed repeatedly for 34 of these. Of the remaining
57, a BLASTn similarity search of the sequences revealed that 30 were not from the
intended locus. Twenty-four bands were amplified from the correct locus and gave
genie product. Three products were the same size or smaller than the vector sequence
and therefore would not contain cDNA sequence. Therefore, despite trying to target
specific bands in the vectorette PCR by the above methods, only 26% ofbands were
actually specific. In addition, only 63% of these bands sequenced successfully.
However, sequencing failure could also be due to non-specificity of the bands to
chromosome 4 since every sequencing reaction was performed with a pGEM
template control. These results are discussed on a gene by gene basis in Section 5.6.
5.5.2. RT-PCR
5.5.2.1. Primer Design
In addition to the cDNA library screening described in the previous section, I also
performed RT-PCR in order to identify novel transcripts. Furthermore, an additional
source of bioinformatic evidence was available subsequent to cDNA library
screening. The NCBI LocusLink database (www.ncbi.nlm.nih.gov/
LocusLink/) provides an integrated site for gene descriptions. Every annotated known
gene and hypothetical protein is provided with a unique locus ID (LOC) number. In
addition, as part of the NCBI's genome annotation project, locus link also generates
its own hypothetical gene predictions based on the results of gene prediction
programmes and EST and/or mRNA alignment. Since these hypothetical genes are
unique to the NCBI database, their only identifier is the LOC number. S. Morris
linked this resource into ACeDB so that all LOCs were overlaid onto the sequence.
However, the LOC genes do require individual inspection because many are
apparently only based on evidence from gene prediction programmes. For example,
there are a number that are contained entirely within repeat sequence (Figure 5-12).
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Figure 5-12: A screen shot from ACeDB, the inhouse database of annotated chromosome
4p sequence, showing several hypothetical (LOC) genes from the National Centre for
Biotechnology Information (NCBI) LocusLink sequence database. It can be seen that these
LOC genes are located entirely within repeat sequence (blue bar).
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I classified LOC genes into four groups:
Transcript Map of MR1 and MR2
1. No evidence: exon prediction programmes either alone and/or in a simple
repeat.
2. Pseudogene: Swissprot match across intron and/or the match to Swissprot
protein is disrupted for at least one exon. No other convincing evidence to
other exons.
3. Putative gene:
3a. EST match to only one exon or a few ESTs with no splicing, plus
evidence a, b or c from category four, to one exon.
3b. Evidence d, e or f from category 4 to one or more exons.
3c. Multiple gene predictions to multiple exons plus one of a-f from category
4 to one exon.
4. Gene:
a, b or c of the following plus at least one other:
a. Splicing human/mouse ESTs
b. Multiple ESTs non-splicing
c. Swissprot match with ORE
d. CpG island
e. Mouse/rat homology
f. Multiple exon predictions to more than one exon.
There were 63 LOCs in MR1 and MR2. Fifty-nine novel STSs were designed
(Appendix I) to 20 LOC genes for RT-PCR (Table 5-9). Some of the LOCs were part
of a known gene already identified from cDNA library screening. All category 4
LOCs were studied, but only a selection of LOCs were chosen from category 2 and 3
in order to test whether LOCs in these categories were genes or not. None of the
LOCs in category 1 were studied since it was almost certain that these were not
genes. STSs that were located in the repetitive region ofMR1 (described in Chapter
3) were designed to lie completely within an exon and then these were tested for
specificity to chromosome 4 by a PCR on a MCHP.
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RT-PCR was performed on human lymphoblastoid cDNA. Lymphoblastoid cell lines
are known to undergo altered gene expression where some gene expression is
switched off. Therefore, if an RT-PCR was negative on an agarose gel, a second RT-
PCR was then performed using human universal cDNA (Clontech). This comprises
cDNA from a selection of human tissues and is more likely to represent a wider
number of genes. If this RT-PCR was negative, a small amount of this was used as a
template for a further round ofPCR since the universal cDNA was used at a
relatively dilute concentration.
5.5.2.2. RT-PCR Results
In summary, no evidence from RT-PCR was obtained for eight of the putative genes
studied in Table 5-10. RT-PCR produced bands that were not specific to
chromosome 4 for two gene structures, and bands that were not supported by
sequence data for five gene structures. Specific bands with supporting sequence
evidence were obtained for seven structures. These results, and the results from the
cDNA library screening, are discussed in more detail in Section 5.6.







Table 5-9: The classification of LOC genes in Minimal Region One (MR1) and Minimal
Region Two (MR2). LOC genes were classified from 1 to 4, according to the amount and
type of supporting evidence from other sources to indicate that the LOC was or was not likely
to be a real gene (e.g. ESTs, homology to known protein domains, cross species homology,
gene prediction programmes), I being a very poor level of supporting evidence and 4 being
good level of supporting evidence. I studied a proportion of these for expression evidence in
cDNA.
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285479 264E23 1 4 P NB
202024 180A12 1 4 P B
255668 180A12 1 3a P NB
285544 180A12 1 4 P B
202025 448G15 1 4 K* S
133258 494H11 1 2 P B
133259 494H11 1 2 P NB
133260 494H11 1 2 P S
202015 136113 1 4 P B
257414 136113 1 2 P B
166522 26P5 1 3b K S
166450 473M13 1 3b P NS
74M11 74M11 1 - K* S
166647 362116 2 4 K* S
152715 362116 2 4 K* NB
132895 380P13 2 3a P S
133214 324H7 2 2 P NB
133218 750A13 2 4 P NS
S27 10G12 2 - P NB
206041 617A17 2 3c P NB
91050 106M4 2 4 K* S
133225 106M4 2 2 P NB
Table 5-10: The results of RT-PCR performed on a selection of LOC genes in Minimal
Regions One (MR1) and Two (MR2). Table notes the LOC name, the clone it is located on
and the minimal region it is in. LOC were classified from 1-4 based on the supporting
evidence for it (e.g. ESTs, protein homology, cross species homology), 1 being a very poor
level of supporting evidence and 4 being a good level of supporting evidence. The
classification of each LOC studied is noted, and whether it forms a completely novel gene
(P), part of an existing gene structure identified from cDNA library screening (K*) carried out
in the previous sections, or part of a previously known gene (K) annotated in the genome
browser at the University of California, Santa Cruz (genome.csi.ucsc.edu). RT-PCR was also
performed on two structures that were not LOCs (74M11 and S27). The RT-PCRs were run
out on agarose gel and bands were cut out for sequencing. RT_PCR results: NB = no band
obtained. B = band obtained but not successfully sequenced. NS = band obtained,
successfully sequenced, but sequence comes from a genomic region other than
chromosome 4p. S = band obtained, successfully sequenced and sequence is specific to
chromosome 4p locus.
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5.6. Results from cDNA Library Screening and RT-PCR
5.6.1. Putative Genes Without Evidence
As mentioned above, there were four LOCs for which I obtained bands by RT-PCR
on universal cDNA, but for which the sequencing failed (Table 5-11). I concluded
that the bands were not specific to the correct locus on chromosome four, but rather
the result of spurious amplification of non-specific product after one or two rounds of
RT-PCR. Performing a second round ofRT-PCR using the first as a template, as was
the case for three of the four LOCs, would encourage such non-specific
amplification.
LOC RT-PCR Round RT-PCR Sequencing Conclusion
133258 1 Smear - Non-specific









Table 5-11: Troubleshooting four RT-PCR results. If a first round of RT-PCR did not produce
a band, a second round was performed using an aliquot of the first round as a template. The
results of either one or two rounds of RT-PCRs were suggestive of non-specificity to the
intended chromosome 4p locus based either on the band pattern of the RT-PCR on an
agarose gel, or the results of sequencing the band.
5.6.2. Novel genes identified
5.6.2.1. 74M11 Gene
Two STS, st74Ml lpt33 and st74Ml lpt34, were designed to EST evidence in
ACeDB and screened on the cDNA libraries. Both amplified from the testes cDNA
library, but st74Ml lpt34 also amplified from the foetal lung and st74Ml lpt33 also
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amplified weakly from the neuroblastoma and T-cell cDNA libraries. The vectorette
PCR revealed two bands for st74Ml lpt34 from the foetal lung cDNA library and two
bands for st74Ml lpt33 from the testis cDNA library that were successfully
sequenced. This revealed a gene structure of five exons, and revealed the 5'-3'
orientation of the gene due to the presence of standard splice site consensus
sequences. RT-PCR between st74Ml lpt33 and st74Ml lpt34 revealed that the gene
was not expressed in lymphoblastoid cDNA. This, coupled with the restricted
expression of the two STSs in the cDNA libraries, suggests that it is a relatively rare
transcript. Two additional STSs, st74Ml lpt50 and st74Ml lpt51, were designed from
EST evidence for RT-PCR on universal cDNA. RT-PCR was performed on universal
cDNA in all combinations for the four STSs. The RT-PCR was positive between
st74Ml lpt33 and st74Ml lpt51, but not for the other combinations. This was
sequenced successfully. The resulting gene structure can be seen in Figure 5-13. The
failure of some of the RT-PCRs may have been due to the low level of expression of
the gene and the dilute nature of the cDNA.
The gene, positioned at the centromeric end ofMR1, has conventional splice sites
which orient it 5' to 3', but it does not have continuous ORF. The longest protein
within the seven exons obtained runs from exon iv to v and is 88 amino acids long.
This is quite short for a protein, but not unprecedented, and untranslated exons have
been identified for a number of genes in the human genome (Zhang, 1998).
A BLASTn of the exon sequence, a BLASTp of the protein sequence, and tBLASTx
of every possible ORF of the sequence to every possible ORF in the genome, reveal
no similarities in any species. The intriguing possibility is that either this gene gives
rise to a protein that is a member of a previously unidentified protein family, or that it
is a non-coding RNA gene. RNA genes do not code for protein, but have been shown
to act by multiple mechanisms and are involved in multiple cellular processes
(Szymanski et al, 2003). The absence of a CpG island, splicing ESTs or homology to
other proteins or genes meant that it was not possible to determine how much of the



































Figure 5-13: A novel gene was identified (74M11) on clone RP11-74M11. Four STSs (1:
st74M11pt34, 2: st74M11pt33, 3: st74M11pt50, 4: st74M11pt51) were designed to EST
evidence in ACeDB and screened on cDNA libraries (red) and cDNA (blue). Sequencing the
bands obtained revealed the seven exon gene structure (purple).
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5.6.2.2. G-protein-coupled receptor 125 (GPR125)
Two STSs, st362I16pt39 and stl7E2pt38, were designed for eDNA library screening
from EST evidence. Both STSs were expressed in seven out of the nine cDNA
libraries on the primary plate, evidence for widespread expression of the gene. Three
bands were successfully sequenced from the vectorette nested PCR; one for
ptl7E2pt38 and two for st362I16pt39. Subsequent to this, two LOC genes and an
image clone were annotated on to the genomic sequence. The two bands sequenced
for st362I16pt39 revealed that two LOC structures were in fact one gene (Figure 5-
14). The fragment of genie sequence obtained for stl7E2pt38 was located some way
downstream of this gene. I postulated that the two structures may be connected, but
RT-PCR did not support this. The RT-PCRs for st362I16pt39 did however show that
the gene is expressed in lymphoblastoid cDNA, which together with the cDNA
library expression evidence again suggested that it is an abundant and widely
expressed gene. The ample EST evidence in ACeDB also supported this.
I performed seven RT-PCR reactions in order to extend the sequence I had obtained
from the cDNA library screen. Two of the STSs gave a positive result from RT-PCR
of the expected size, but failed to sequence and five failed to give a positive result.
However, this may be because the assays did not work as the genomic DNA product
was too large to test (except 166647.3 which did work on genomic DNA).
Subsequent to these findings, a gene corresponding to the two LOC structures was
published as an orphan g-protein-coupled receptor GPR125 (Fredriksson et al, 2003).
They identified three splice variants from over 50 ESTs and mRNA sequences. At
this time, exactly how much of the gene they had identified was unclear. The paper
suggested that GPR125 (AY181243) has 17 exons. However, mRNA AY181243
referred to a partial coding sequence at NCBI of 13 exons, and mRNA XM291 111,
with 14 exons, was suggested to represent the full length coding sequence. It
appeared therefore that neither Fredriksson et al, nor UCSC had identified the full
gene structure. I predicted five exons 5' to the existing mRNA, based on homology
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(97-98% identity) to a LOC gene on chromosome 18p. I had evidence from RT-PCR
for the first five exons, but this was not supported by sequence data and I had not
linked this to the remaining GPR125 exons. Therefore, I performed RT-PCR to link
the putative 5' start of the gene to the existing exons, but was unable to confirm the
link. This could have been due to the primers not working together in the RT-PCR
assay. Subsequent to these experiments, the full gene structure, from the CpG island
and including the five exons 5' to the existing mRNA, was published (still accession
XM291111).
The GPR125 gene, located right at the telomeric end ofMR2, encodes an orphan G-
protein-coupled receptor ofunknown function. Structurally, it belongs to a group of
LN-TM7 G-protein-coupled receptors that have long serine/threonine rich N-terminal
domains that are suggested to be involved in cell-cell communication, functioning as
ligands for other proteins (Fredriksson et al, 2003).
187

















stc206037.1 Stc166647.2 stcl66647.1 stcl66647.4 stcl66647.3 stcl52751.1b Stc152751.2
Figure5-14:OrphanG-p otein-coupledr ceptor125(GPR125).TwSTSs )ered sign dfoDNAlib arycr ning.Atim ,CpGisl (yellow),aregionofhomologytchrom s me18(li htpurple),RNAh m ogy(darku ple)andESTevidencn tsh wn)weran ota edt sequenceinACeDB.cDNAlibraryscr eningofthwoSTSsproducedsequ cext ingv rightx saseq nce3'thi(r d).TwoLOC genes(li htblua dreen)imageclon(d rkbluw ran otatedo othsequ nceAC DBs bs quenttcDNAlib ryc n. Subsequenttohisannotation,GPR125mRNAwaspublished(Fredrik sl,2003)andnnota edithp blicsequen edatab s( l v orange).ThhomologytLOCgenechromosome18pdtCpGislasuggest dfiv5' xonsw ra tfGPR125.S v nRT-PCRs wereperformed(r danblacks)txtenhseque ceob ai edfortcDNAlib arysc n.S qu cew sobtain df rt oRT-PCRre ctions (redbars).Thecurr ntGPR125mRNADec2003),stillaccessionXM_291111,inclu est eextrafivo .
Chapter Five
5.6.2.3. LOC91050
Transcript Map ofMR1 and MR2
Four STSs, stl06M4pt40, stl06M4pt41b, st401G6pt42 and st401G6pt47, were
designed to screen the cDNA libraries based on EST evidence adjacent to the SOD3
gene in MR2 (Figure 5-15). The nested vectorette PCR produced bands that were
successfully sequenced for STSs stl06M4pt40 and stl06M4pt41b. This produced
sequence which provided no evidence for splicing. Subsequent to this, the sequence
was annotated with LOC91050 and the hypothetical protein DKFZp761B107.
LOC91050 followed the structure of hypothetical protein DKFZp76B107, except
without exon one. RT-PCR between st401G6pt42 and st401G6pt47 on
lymphoblastoid cDNA gave a band that was successfully sequenced and followed the
LOC structure. I designed four further STSs for RT-PCR and obtained a positive
result and sequence for stc91050.1, stc91050.2b and stc91050.5. Therefore, I had
extended the hypothetical protein DKFZp761B107 at its 3' end to include more EST
evidence. It could be that there are two alternative splice variants, one extending the
length ofDKFZp761B107 and the other extending to include further 3' exons.
Construction and a BLASTp similarity search of the ORF revealed that the gene has
a chromosome segregation ATPase protein domain, contained within both the long
and the short version of the protein, and could therefore be involved in cell division
and chromosome partitioning. This is a fundamental cellular process without which a
cell cannot survive and this gene is therefore not a good candidate for psychiatric
illness. Therefore I did not investigate the gene structure further.
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Figure 5-15: Novel gene LOC91050. Figure shows a screen shot from the genome browser
at the University of California, Santa Cruz (genome.csi.ucsc.edu). The NCBI
(www.ncbi.nlm.nih.gov) predicted gene LOC91050 is not shown on the genome browser but
has an identical structure to the annotated mRNA AL834257 and hypothetical protein
DKFZp761B107. Four STSs were designed, based on the mRNA and EST evidence, to
screen on the cDNA libraries (arrows). Sequence was obtained for STSs 1 and 2 (red), but
not for STSs 3 or 4 (black). Three of the four subsequent RT-PCRs (red and black lines)
identified the remaining exons (red). RT-PCR was not carried out to confirm the presence of
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Two STSs, st448G15pt4 and st448G15pt2, were designed to screen the cDNA
libraries (Figure 5-16). LOC202025 was annotated subsequent to the cDNA library
screen, and follows the structure of the AL713660 mRNA and the hypothetical
protein DKFZp667E0512. One STS gave a band from the nested experiment that was
successfully sequenced and exactly matches one LOC exon then splices to near the
3'UTR of the WDR1 gene in MR1. This was interesting because it suggests that the
LOC is an alternative 3' UTR ofWDR1 (splice sites suggest that the direction of the
two genes are the same). It also suggests that the LOC, even if it is separate to
WDR1, is itself alternatively spliced since or has been incorrectly annotated, as its
second exon was absent from my results.
RT-PCR performed on lymphoblastoid and universal cDNA failed to extend the
transcript further. Bands a and b were obtained (Figure 5-16). However, the signal
was weak and a second round ofRT-PCR, to increase the amount of template for
sequencing, did not work. An attempt to sequence the low level of product also
failed.
A BLASTp protein similarity search of the hypothetical protein DKFZp667E0512
does not reveal any conserved protein domains. The most significant match reveals
31% amino acid identity to a hypothetical protein in the mycobacterium bovis
bacteria, a hypothetical protein in the mycobacterium tuberculosis bacteria and a
transcriptional regulator in the pseudomonas putida bacteria.
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Figure 5-16: Novel gene LOC202025. Figure shows a screen shot from the July 2003
genome browser at the University of California, Santa Cruz (genome.csi.ucsc.edu). The
NCBI (www.ncbi.nlm.nih.gov) predicted gene LOC91050 is not shown on the genome
browser but the mRNA AL713660 (red arrow), at the 3' end of the gene WD repeat domain 1
(WDR1), follows the structure of LOC202025. Two STSs (black arrows) were used in cDNA
library screening and sequence was obtained (red). The five RT-PCR reactions performed to
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RT-PCR between two exons ofLOCI 32895 (Figure 5-17) in MR2 revealed sequence
specific to chromosome 4, although RT-PCR between the ESTs annotated on Figure
5-17 did not. The sequence did not splice between the exons and did not contain a
continuous ORF. Therefore, I suspected that the band obtained was the result of
genomic DNA contamination in the cDNA, especially since the expression and
prediction evidence supporting the LOC gene structure was not very convincing.
Therefore I concluded that the LOC was not a gene.
Figure 5-17: A LOC gene, LOC132895 (boxed), from the National Centre for Biotechnology
Information (www.ncbi.nlm.nih.gov) annotated in ACeDB. The exons were partially supported
by mouse homology but the EST evidence did not overlap with any of the LOC exons. Due to
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It is important to characterise the pseudogenes in the minimal regions in order to
eliminate them from further study. Pseudogenes are the result of gene duplication
that can occur by retrotransposition, where a processed mRNA is inserted into the
genomic sequence, or by genome duplication. Pseudogenes are non-functional genes
either due to a failure of transcription or translation or by the production of a protein
that does not have the same functional repertoire as the protein encoded by the
original gene. Evidence of retrotransposition can be found by the presence of a poly-
A tail incorporated into the genomic sequence and the absence of intronic and
untranslated sequence. The genes in a duplicated genomic region can either remain
functionally equivalent, take on new adaptive functions or become neutralised as a
pseudogene by the accumulation ofmutations. Most pseudogenes are no longer
expressed, although it is possible that the insertion of a processed mRNA into a
promoter, or genome duplication, may result in continued expression of the gene.
However, a novel promoter may alter the pattern of transcription (see Mighell et al,
2000 for a review).
There were ten LOCs in MR1 and MR2 that had exons with pseudogene
characteristics, although the LOC exon structure and the pseudogene structure did not
correspond in five of the LOCs. I studied five LOCs for expression in cDNA. I
obtained no product from lymphoblastoid or universal cDNA for any except
LOC 133260. This was subsequently identified as a chromosome 4 pseudogene in the
NCBI public database.
I predict that there are seven pseudogenes in MR1 and four in MR2 (Table 5-12).
Nine of the pseudogenes are very similar in structure. They have no poly-A tail and
multiple matches to protein domains in the Swissprot database, but none of the
matches are exact as evidenced by a disrupted ORF. Some have more than one
'exon' if the protein homology splices. No corresponding expressed gene can be
identified in the genome and the multiple protein domain homologies are the only
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expression evidence (Figure 5-18). This suggests that they are very old pseudogenes














2205P10a 1 Yes Yes No No
2205P10b 1 Yes Yes No No
2205P10 c 1 No Yes No No
264E23 1 No Yes No No
494H11 a 1 Yes Yes No No
494H11 b 1 Yes Yes No No
287J14 1 Yes No Yes RNPS1 (16p) - 8 exons
10G12 a 2 No No Yes S27 (1q) - 4 exons
302F12 a 2 Yes Yes No No
302F12 2 Yes Yes No No
401G6 2 Yes Yes No No
Table 5-12: Pseudogenes in Minimal Region One (MR1) and Minimal Region Two (MR2).
Likely pseudogenes were characterised by the number of exons, the presence of a disrupted
open reading frame (ORF), the presence of a poly-A tract in the genomic DNA sequence
immediately after the terminal exon and whether a corresponding transcribed gene could be
located elsewhere in the genome.
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Figure 5-18: A putative pseudogene on chromosome 4p annotated in ACeDB. The region
shows homology to an oxidoreductase protein domain (blue bar: the wider the bar, the
greater the homology) identified in the protein database Swissprot. There is no genomic poly-
A tract and no open reading frame. Three of the possible six translation frames are
annotated on the figure. The horizontal lines mark the position of a stop codon.
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The pseudogene on clone RP11-10G12 in MR2 shows 100% identity to the 83 amino
acid protein for S27 on chromosome lq (Figure 5-19). The gene on chromosome lq
has four exons and the gene on chromosome 4 has one. The sequence of this exon on
chromosome 4 is exactly identical to the four exons of the S27 gene, but with the
intronic sequence spliced out and a genomic poly-A tail of 12 nucleotides beginning
immediately after exon 4. The pseudogene does not contain the same UTR sequence
as the gene. However, the pseudogene has a continual ORF and therefore may still be
expressed if it has been inserted in a region under the promoter of another gene.
However, I could not detect any expression from RT-PCR of the sequence in either
lymphoblastoid or universal cDNA (Section 5.5.2.2).
A second gene, Similar to RNPS1 in MR1, is also likely to be a pseudogene. The
pseudogene has two exons and possesses a poly-A tail in the genomic sequence
immediately after the second exon. The RNPS1 gene is on chromosome 16p and has
eight exons, but the first exon is non-coding. The gene on chromosome 4 codes for
the same protein as the RNPS1 gene on chromosome 16, contained entirely within its
large second exon, with a complete ORF. As with the S27 pseudogene, the retention
of the complete ORF means that it may be expressed, although this is unlikely. RT-
PCR was not performed to confirm this.
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Figure 5-19: Pseudogene S27 on chromosome 4p. A: The genomic sequence containing the
S27 gene from chromosome 1. The exons encoding the protein (blue) and the untranslated
regions (red) are highlighted. The poly-adenylation signal is boxed. B: The S27 pseudogene
on chromosome 4p codes for the same protein and shows the same exon sequence. The
sequence contained in four exons on the chromosome 1 gene are contained within one exon
on chromosome 4p. This lack of introns and the genomic poly-A tract observed immediately
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The characterisation of two susceptibility regions to psychiatric illness on
chromosome 4p is described. A combination of bioinformatics analysis, cDNA
library screening and RT-PCR has allowed the identification of four novel genes and
two processed pseudogenes, and allowed the assessment of these and the known
genes with respect to location and Giesma staining. Problems with non-specificity of
the cDNA library screening hampered the identification of genes and the majority of
STSs tested by RT-PCR were negative. However, it is impossible to conclude
anything from a negative result.
Historically, the G-banding technique helped identify the human chromosomes and
chromosomal regions and characterise GC content (Bickmore and Sumner 1989).
Low GC content is also thought to represent gene poor regions. This is upheld in
these two candidate regions, with the majority of genes positioned in a light band. In
accordance with what has been shown for other genomic regions, the majority of the
genes have a CpG island on or near exon one and the most common poly-adenylation
signal is AATAAA. Four of the genes did not have either of the two most common
poly-adenylation signals and this therefore lends support to the findings of Beaudoing
et al (2000) that rarer signals are likely to exist.
It is difficult to predict how many genes there are left to identify in MR1 and MR2.
The 23 known genes in MR1 and MR2, totalling approximately 8Mb, gives a gene
density of approximately 2.8 genes per Mb. The estimated genome wide gene density
has been found to vary between the chromosomes, from five genes per Mb on
chromosome 13 to 23 genes per Mb on chromosome 19, although these estimates of
gene number must exclude some unknown genes. Furthermore, regional differences
in gene density make predicting gene density in the relatively small minimal regions
problematic. It seems reasonable to predict however that not every gene has been
identified.
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Genes are associated with functional elements that help predict their structure.
However, exon and gene prediction programmes are not perfect. For example, the
accuracy of exon prediction is dependent on length, where very short (less than 70bp)
and very long (longer than 200bp) exons are not well predicted (Rogic et al, 2001). In
the region of 20-30% of Genscan exons are predicted incorrectly (Guigo et al, 2000;
Burge and Karlin, 1997) with the first and last exons most likely to be inaccurate
(Rogic et al, 2001). However, the training and testing methods of these programmes
have questionable applicability to the prediction of real gene structure. For example,
Rogic et al (2001) tested seven different gene prediction programmes with GenBank
gene sequences submitted after the programmes had been developed, in order to
subject them to novel sequences, but removed genes from the test set that had
unconventional splice sites. It is likely that they did this to remove incorrect
GenBank submissions, but it probably also biased the accuracy of gene prediction
programmes to well characterised gene structures. Furthermore, they measured the
accuracy of the prediction on the plus strand, the same strand as the GenBank
submission, but ignored any predictions made to the minus strand. Therefore,
predicted accuracy is again inflated since the correct absence of a prediction is not
accounted for.
A consensus between different prediction methods is desirable. Bioinformatic
evidence coupled with real transcript evidence, ESTs for example, is better evidence
for a novel gene than gene prediction programmes alone. However, there will be
many more for which there is currently no known transcript evidence. Low
expression levels of the protein or constrained expression times during development
will ensure that there are genes for which no expression data is obtained. In addition,
genes with an unusual structure will be missed by prediction programmes. Therefore,
there will be genes in MR1 and MR2 that have not yet been identified.
Annotation of full length coding features is only the first step in the characterisation
process. Regulation, tissue distribution and function pose greater challenges. A
BLAST similarity search can give some idea of a gene function. For example, the
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novel gene LOC91050 contained a characterised protein domain that strongly
suggests a function for the protein. However, this is not always the case. For
example, the LOC202025 and 74M11 genes do not possess any known protein motifs
and therefore their function remains uncertain. Furthermore, the lack of an ORF in
the 74M11 gene raises the interesting question ofwhether it might be a non-coding
RNA gene. As more and more protein coding genes are identified in the human
genome, attention will shift towards the elements of the genome largely ignored to
date, such as characterising families of non-coding RNA genes.
It is also important to define pseudogenes in the minimal regions. Pseudogenes are
generally defined by a set of characteristics including a disrupted ORF, a genomic
poly-A tail, the lack of introns and promoter sequence or the presence of evidence for
genome duplication of the original locus (Mighell et al, 2000). However, whether the
pseudogene is still functionally expressed and therefore can really be classified as a
pseudogene is harder to define. For example, the pseudogene of S27 retains the
complete original ORF. It lacks the original promoter and has a genomic poly-A tail
and has therefore arisen by retrotransposition. However, it is impossible to determine
from this evidence alone whether it is expressed and if it is expressed whether it is
functional in a complimentary or an altered way to the original protein. RT-PCR was
required to determine that it is not expressed, although it is still possible that the
pseudogene has a specific spatio-temporal expression that has not been captured in
the cDNA screened.
The identification of every gene in MR1 and MR2 is an important aim for the group
in order to direct SNP detection and association analysis. Since the aim is to identify
the susceptibility SNP in the families, directing SNP detection towards coding
regions is desirable. These results have gone some way towards completing the
transcript map of these two candidate regions for psychiatric illness.
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Genetic Analysis of the Superoxide Dismutase 3
(SOD3) Gene
6.1. Introduction
Here I describe sequence analysis and association studies of the Superoxide
Dismutase 3 (SOD3) gene. As mentioned previously, linkage analysis has identified
large regions on chromosome 4p that are inherited with psychiatric illness in four
families. I have described in Chapters 3 and 4 how these regions have been compared
and that the overlap observed permits the definition of smaller candidate regions.
However, these sub-regions are still large and contain a number of genes, as
discussed in Chapter 5. SOD3 was positioned on chromosome 4pter-q21 by
Hendrickson, et al, (1990). Today, its exact genomic position can be ascertained from
the human genome sequencing project (HGP) and it is located in MR2. MR2, the
susceptibility region ofF22, F50 and F48, covers ~4.3Mb of sequence and contains
12 other known genes.
In humans, SOD3 is expressed in the heart, brain, placenta, lung, liver, muscle,
kidney and pancreas (Folz and Crapo, 1994). In the mouse brain it has a wide
distribution, and has been observed in the cortex, the subiculum, the entorhinal
cortex, the striatum, the nucleus accumbens, the ventral pallidum, the hippocampus,
the diencephalons and hypothalamus, and a small number of scattered cells in the
midbrain, hindbrain, cerebellum and brainstem (Oury et al, 1999). This localisation
of SOD3 to discrete areas suggests that it plays a specialised role in the brain. In most
tissues it is anchored to the extra cellular matrix (ECM). However, in the brain,
SOD3 is observed in the cytoplasm of neurons and hypothalamic tanycytes and
shows a granular (possibly vesicular) distribution.
The function of SOD3 in the brain remains unknown. Mice with SOD3 knocked-out
or over-expressed have been shown to exhibit impairments on tasks involving
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hippocampal spatial learning and memory (Levin et al, 1998). This memory and
spatial learning deficit is affected by motivational state. Food restriction increased
their ability to learn but did not alter the learning rate of control mice (Levin et al,
2000). The actions of SOD3 have also been suggested to be linked to nitric oxide
(NO) signalling. SOD3 controls levels of extracellular O 2 (Oury et al, 1996), and NO
is inactivated by 0~2- Like SOD3, nitric oxide synthase is found in the neurons in the
hippocampus, and studies have found that NO is involved in behaviour, and learning
and memory functions (Hawkins, 1996).
SOD proteins are known for their antioxidant properties. Oxygen free radicals are
toxic compounds produced by cells during normal utilization of oxygen. SOD
proteins form one type of cellular protein that detoxifies oxygen free radicals by
catalysing the conversion of superoxide anion radicals to hydrogen peroxide and
molecular oxygen. It is unknown whether it is this action that lies behind SOD3's
role in learning and memory.
The SOD3 protein is encoded by a three exon gene. The protein is contained entirely
within exon three; exons one and two are non-coding (Figure 6-1). Non-coding exons
are quite common, estimated to occur in greater than 35% ofhuman genes and are
distinguished from untranslated regions (UTRs) by the presence of introns (Zhang,
1998). The gene transcribes a 240 amino acid protein. The first 18 amino acids form
the signal peptide. Amino acids 96-193 show ~50% sequence homology to the final
two thirds of all known eukaryotic SOD Is, including the amino acid responsible for
catalytic activity. Amino acids 194-222 are hydrophilic and contain nine positively
charged amino acids, which probably confers affinity to heparin (Hjalmarsson et al,
1987). This heparin binding site may anchor SOD3 to the ECM. Proteolysis of the
domain abolishes heparin affinity and results in the clearance of SOD3 from the
tissue into the serum (Hjalmarsson et al, 1987).
Only one functional variant in SOD3 has been described in the literature. Sandstrom
et al (1994) identified an arginine to glycine substitution at amino acid position 213,
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in the centre of the C-terminal cluster ofpositively charged residues that defines the
heparin binding domain. Arginine is positively charged and glycine is uncharged.
This variant was observed in 2.2% of 504 random blood donors and results in a 10
fold increase in plasma SOD3 caused by a reduction of affinity for heparin and thus a
loss of SOD3 from the ECM to the plasma. The enzymatic activity of SOD3 was not
affected. No obvious phenotype was observed with this mutation, although all
individuals tested were heterozygote.
It is prudent to study such candidate genes for SNP variation in the linked families.
Firstly, this may identify variation that alters the amino acid sequence, and potentially
the function, of the protein. Secondly, it contributes to defining the disease associated
haplotype in each family. Whilst this is interesting in itself, it also enables the
analysis of haplotype sharing between the families. A shared disease haplotype across
a gene would provide support for a common ancestral allele and point to the possible
role of the gene in the susceptibility to psychiatric illness. The number of control
chromosomes available is limited by family size, but this is generally not a problem
since two of the families are large. However, there is a maximum of only four disease
chromosomes in which to detect allele sharing. Despite this, it is still possible to
obtain a statistical measure of the difference in the frequency of control and disease
alleles and determine whether allele sharing is expected above chance.
An association study offers a complimentary approach to studying the families. It
involves comparing the variation observed on the chromosomes of a large population
of unrelated cases versus a large population ofunrelated controls. The advantage of
studying many different disease chromosomes means that many different
recombination events surround the susceptibility locus. Consequently, if a positive
association is observed it will only extend over a relatively small genomic region.
Furthermore, association analysis has the power to detect variants with small effect
sizes. Therefore, performing association analysis within the linked regions in the four
families will provide a way to study these large regions in more detail.
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In this chapter I describe the results of family and association analyses of the SOD3
gene. I have identified the disease associated SNP haplotypes of the four families
across the SOD3 gene, and describe the use of these and other SNPs in an association
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6.2.1. Sample
In order to increase the chance of identifying the SNP responsible for susceptibility to
psychiatric illness in the families, SNPs were identified by sequencing family
members on the AS DNA panel (Figure 2-5). The panel consists of 46 indivduals
with a total of45 independent chromosomes: four disease chromosomes and 41
control chromosomes. This provides a larger sample from which to identify SNPs
and also enables the assessment of allele sharing between the four families to be
carried out across the gene.
6.2.2. STS Design and SNP Detection
STSs were designed to cover the coding regions and splice sites of the gene and part
of the 3' and 5' UTRs. The aim was to capture SNPs that alter the amino acid
sequence of the protein and SNPs involed in the function of the promoter or splicing
mechanisms. STSs were designed to an optimum length of ~500bp, to overlap by at
least 50bp, and to extend at least 50bp into an intron. A PCR was optimised for each
STS on three CEPH control DNAs. The amplified product from each indivdual was
sequenced with the reverse primer and run on an ABI 377 or 3730 Genetic Analyser.
Sequence chromatograms were aligned using the phredPhrap software and visualised
with the Consed programme. Sequences were then manually for polymorphisms.
SNPs were positively identified if at least two heterozygotes were observed.
However, SNP ihl70 was positively identified in only one heterozygote, although the




Genetic Analysis of SOD3
Sequencing the SOD3 gene in individuals from the AS panel identified eight SNPs.
Four of these were in dbSNP (prefixed 'rs') and four were novel (prefixed 'ih')
(Figure 6-2).
A number of SNPs from other sources were chosen to provide an even distribution of
SNPs across the gene for association analysis. There are a number of SNPs
(September 2003) across the SOD3 gene for which an assay has been developed and
is available from Applied Biosystems. This 'Assay on Demand' service not only
provides a ready made SNP assay, but also provides frequency data from a
population of45 Caucasians. One SNP (C_2668721_10) with a Caucasian frequency
of greater than 0.1 was chosen. The database dbSNP (www.ncbi.nih.nlm.gov/SNP) is
a database in which independent researchers deposit the position of SNPs that they
have identified from a population. Therefore a SNP can be submitted a number of
times. Five SNPs that had been confirmed, at least twice, by independent research
groups (rs800399, rs800414, rs800447, rs800448, rs2324580) were chosen, on the
premise that more than one independent submission would increase the liklihood of
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6.3.1. Amino Acid Changes
Of the eight SNPs identified from sequencing the AS panel, two are located in the
peptide sequence: rs2536512 and rs8192291 (Figure 6-2). SNP rs8192291 is a c>t
change of the first nucleotide of codon 'ctg' at amino acid position 71. Both
alternative codons code for leucine. SNP rs2536512 is an a>g change of the first
nucleotide of codon 'acg'. This codes for threonine at amino acid position 58, and is
changed to an alanine if the first nucleotide is a guanine. The frequency of this
variant could provide some idea of its functional importance. As has been seen, the
SNP was identified by sequencing chromosomes from the AS DNA panel. The AS
panel gives a total of 45 independent chromosomes. The variant was observed on 18
chromosomes, which translates into a frequency of 40%. Therefore, this is a common
variant in this sample. This suggests that an alanine substitution would not have a
significant impact on protein function. However, the Common Disease/Common
Variant (CD/CV) hypothesis (Discussed in detail in Section 1.5.5) suggests that
common variants will underly the susceptibility to common complex diseases such as
psychiatric illness. Therefore, a susceptibility variant would be expected to be
common in the control chromosomes. Despite this, it is possible that assortative
mating has made the SNP is more common in the families compared to the general
population. The mutation was observed on the disease chromosome of the Celtic
families 22, 59 and 50, but not the Jewish family 48. It forms part of the most
common eight SNP haplotype observed from 32 chromosomes (Section 6.3.2).
The properties of each amino acid give some idea ofwhether a substitution would be
tolerated or not. Bordo and Argos (1991) identified the ajmmino acid substitutions
that are least likely to disturb protein structure. According to their results, threonine
and alanine can be substituted with 95% confidence. Despite this, alanine and
threonine are placed in different positions on four different hydrophobicity scales
(Janin, 1979; Wolfenden et al, 1981; Kyte and Doolittle, 1982; Rose et al, 1985).
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Alanine is positioned near the top in each scale, and is consistantly considered to be
more hydrophobic than threonine which is placed near the middle in each scale.
Therefore, this difference could alter the secondary structure of the protein because a
more hydrophobic residue may be more likely to be buried inside the protein than a
less hydrophobic residue.
Figure 6-3 displays the patial results of a Protein Identification ofUnknown
Sequences (PIX) analysis at the MRC Rosalind Franklin Centre for Genomics
Research (MRC-RFCGR, www.hgmp.mrc.ac.uk). A PIX analysis runs twelve
different types of analysis programme on a peptide sequence. I therefore ran the
analysis on the two alternative proteins to assess what impact an amino acid
substitution might have on predicted protein structure and functional domains. The
results ofmost interest displayed in the figure are the secondary structure prediction
programmes DSC and Simpa96, the protein domain predictor programmes Pfam and
BLOCKS, and the antigenicity predictor programme Antigenic. The protein with the
alanine variant (6-3: B) at position 58, due to its hydrophobicity, would be predicted
to be buried. However, it is predicted to be on the surface by Antigenic. It is also
likely to be part of a fairly continuous coil structure. The protein with the threonine
variant (6-3: A) has an inconclusive coil/beta strand structure or an alpha helix
structure for the five or six amino acids immediately 5' to it and the threonine itself is
predicted to be in a non-antigenic region, suggesting that it is not exposed on the
protein surface. This is not consistant with the findings of the four scales of
hydrophobicity mentioned above in which alanine is more hydrophobic than
threonine. The Pfam Copper Zinc superoxide dismutase protein domain prediction is
unchanged by the alternative amino acid, but a BLOCKS protein domain prediction
is created. The BLOCKS programme predicts a MADS-box domain from amino
acids 46 to 59. A MADS-box domain is a DNA-binding domain that has been
identified mostly in plants but also in several vertebrates, including humans. A
protein with a DNA binding domain might be involved in the regulation of gene
transcription. However, the domain prediction is identical at only seven out of
fourteen amino acids and is therefore not likely to be real.
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Figure 6-3: The results of a Protein Identification of Unknown Sequences (PIX) analysis
(carried out at the MRC-RFCGR: www.rfcgr.mrc.ac.uk) for the part of the Superoxide
Dismutase 3 (S0D3) protein that contains SNP rs2536512. The first line follows the RasMol
colouring scheme (The molecular graphics programmes to visualise the 3D structure of
proteins, developed by Roger Sale, University of Edinburgh, where each amino acid is a
different colour). The next seven lines show the individual properties of each amino acid.
White is the default colour. Red = acidic, blue = basic. Red = polar. Red = hydrophobic. Red
= aromatic, blue = aliphatic. Red = surface, blue = buried. Red = positive, blue = negative.
Red = tiny, green = small, blue = large. The sequence is annotated with two secondary
structure prediction programmes DSC and Simpa96, two protein domain prediction
programmes Pfam and BLOCKs, and the antigenicity predictor programme Antigenic. The
secondary structure programmes predict three structures: helix (H), coil coil (C/c) and beta
strand (E/b). The two amino acid variants created by SNP rs253652 are shown (arrow). A:
Threonine variant, B: Alanine variant.
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The poor antigenicity of the alanine variant, compared with the surface availability of
the threonine, could have an impact on protein function if the alanine is predicted to
create or abolish a functional motif. PROSITE (Bairoch et al, 1997)
(www.expasy.org/prosite) is a database ofprotein families and domains. It searches a
protein sequence for biologically relevant sites, patterns and profiles. Therefore I
used this to determine whether the two alternative proteins would differ at a
functional motif. The predictions for the normal S0D3 protein are shown in Table 6-
1. As can be seen, the threonine at position 58 (bold) is predicted to be part of an N-
myristoylation site. The alanine variant does not alter this functional motif.
Position Sequence Motif
107-110 NSSS N-glycosylation site
232-235 PRES




Protein kinase C phosphorylation site








201-204 AGRR Amidation site
112-122 AIHVHQFGDLS Copper/zinc superoxide dismutase signature 1
199-210 GNAGRRLACCW Copper/zinc superoxide dismutase signature 2
Table 6-1: Results of a PROSITE database scan (www.expasy.org/prosite) for functional
motifs in the Superoxide Dismutase 3 (S0D3) protein. The position refers to the amino acid
position in the S0D3 protein. The sequence shows the amino acid sequence that identifies
the functional motif.
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The phosphorylation of a residue in a protein is determined by its local environment.
The NetPhos version 2.0 server (www.cbs.dtu.dk/services/NetPhos/) uses a neural
network method to predict the phosphorylation of individual serine, threonine and
tyrosine residues. The results (Table 6-2) show that the threonine at position 58
(bold) is not predicted to be phosphorylated since the score of 0.240 does not reach
the threshold of 0.50.
Therefore, a functional variant at amino acid position 58 of the SOD3 protein that
replaces a threonine with an alanine is predicted to alter the secondary structure of
the amino acids immediately adjacent to it and it is predicted to be hidden from the
protein surface but leaves the phosphorylation status unchanged, does not create or
abolish a known predicted functional motif, and is a common variant in a population
of 46 individuals from four families. Therefore I conclude that it is not likely to alter
the function of the protein significantly. Functional in vitro studies would be required
to test this.
Position Context Score Prediction
4 SXDTMLAL 0.081 -
24 SDAWTGEDS 0.146 -
47 TAKVTEIWQ 0.043 -
62 DDDGTLHAA 0.240 -
74 QPSATLDAA 0.187 -
83 QPRVTGWL 0.731
108 EGFPTEPNS 0.076 -
132 GCESTGPHY 0.042 -
Table 6-2: The prediction of the phosphorylation status of the Superoxide Dismutase 3
(SOD3) protein. The phosphorylation of individual threonine residues are predicted using the
NetPhos 2.0 server. The position refers to the amino acid position in the SOD3 protein. The
context shows the nine residue sequence centred on the threonine residue being analysed.
The score ranges from 0.0-1.0. Residues for which the value exceeds the threshold value of
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As discussed previously, the genotypes for eight SNPs were obtained by sequencing
individuals from the AS DNA panel which consists ofmembers from the four linked
families. Genotyping family members allows for the unambiguous identification of
haplotypes, including that of the disease chromosome, by following the inheritance of
alleles from parent to offspring. Figure 6-4 and Table 6-3 detail the results obtained.
The AS panel defines 45 independent chromosomes. I identified 32 chromosomes for
which the data was complete and unambiguous for the entire eight SNP haplotype.
Eleven different haplotypes were observed in total. One haplotype is by far the most
common, accounting for 18, or 56%, of the 32 chromosomes. The remaining ten
haplotypes did not account for more than one or two chromosomes each (3 or 6%
respectively). Therefore ten of the eleven haplotypes could be considered rare.
The disease associated haplotypes for families 22, 50 and 59 were the most common
haplotype. Definition of the disease associated haplotype in F48 is incomplete, as it
was not possible to unambiguously determine the segregation of SNP ihl67.
Therefore, there are two possible eight SNP haplotypes in F48. One of the possible
haplotypes is observed only once out of the 32 chromosomes, the other possible
haplotype would be a novel twelth haplotype. Therefore, the disease assoicated
hapotypes for three of the four families are identical, but different to the disease
associated haplotype of F48. It is possible that the common disease haplotypes of the
Celtic families are due to a more recent common ancestor. The fact that the shared
disease haplotype is the most common haplotype observed in this study does not
support this hypothesis. However, this may be biased by the predominantly Scottish
chromosomes on the AS panel.
A Fishers exact statistical test is a non-parametric test that is similar to Chi-square
but is suitable for counts less than five. A Fishers exact test was performed using the
Analyse-it® (version 1.71) software for microsoft excel (available from
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www.analyze-it.com/). Each SNP was analysed individually for allele sharing. A
two-tailed Fishers exact test on each of the eight SNPs shows that there is no
significant difference between the allele frequency of the four disease and the non-
disease chromosomes (Table 6-4). Since the disease haplotype of family 59 does not
extend into MR2, the test was also performed without the F59 data. However, there
was still no difference in allele frequency between the disease and non-disease
chromosomes. In conclusion, there is no obvious pattern of excess allele sharing
between the families that would suggest a common susceptibility variant to
psychiatric illness.
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SNP 1 2 3 4 5 6 7 8 Frequency
Distance - 231 167 657 4744 39 595 27 no. (%)
1 g g c c a c t c 18 (56)
h 2 g a t c g t c t 2(6)
a 3 g g c c g c c t 2(6)
P 4 g g c c g t c t 2(6)
1 5 g a c c a c t c 2(6)
o 6 a g c a g c c t 1 (3)
t 7 a a c c g c c t 1 (3)
y 8 g g c c g t t c 1 (3)
p 9 g g c c g c t c 1 (3)
e 10 g g c c a c c t 1 (3)
11 g a c c g t c t 1 (3)
Table 6-3: Haplotypes identified from the Allele Sharing (AS) panel, a DNA panel compised
of members from families 22, 48, 50, 59. Eight single nucleotide polymorphisms (SNPs)
(labelled 1-8 in the table) were identified by sequencing exons of the Superoxide Dismutase
(SOD3) gene on the AS panel. Relatedness between family members means that 45
different chromosomes are represented on the AS panel. Thirty-two of the 45 chromosomes
had complete data for all eight SNPs. Eleven eight-SNP haplotypes in SOD3 are observed
from these 32 chromosomes. Haplotype 1 predominates over the others, accounting for 56%
of the variation. SNP number corresponds to the number in Figure 6-4. Distance is the
distance in base pairs between it and the preceding SNP. Frequency refers to the number
(and percentage) of the 32 chromosomes upon which the observations are based.
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D (G)3 (A) 1 1.0 0.83
ND 35 6
2
D (G)4 (A)0 1.0 1.0
ND 32 5
3
D (C)4 (DO 1.0 1.0
ND 39 1
4
D (C)3 (A)0 1.0 1.0
ND 35 2
5
D (A)3 (G)1 0.9766 1.0
ND 22 15
6
D (C)4 (DO 0.8678 1.0
ND 32 8
7
D (T>3 (0)1 1.0 1.0
ND 26 14
8
D (0)3 (T)1 1.0 1.0
ND 25 15
Table 6-4: The results of a Fishers exact test on each of the eight single nucleotide
polymorphisms (SNPs) in the Superoxide Dismutase 3 (SOD3) gene (labelled 1-8 in the
table). SNPs were identifed by sequencing SOD3 exons on the Allele Sharing (AS) panel, a
DNA panel compised of members from families 22, 48, 50, 59. Relatedness between family
members means that 45 different chromosomes are represented on the AS panel. The
number of chromosomes successfully genotyped for each allele is included in the table (with
the corresponding allele in brakets). A two-tailed hypothesis for a difference in allele
frequency between 'diease' and 'non-disease' alleles has been used. D = allele inherited with
the disease. ND = allele not inherited with the disease. The results have been calculated
including and excluding the data from Family 59.
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6.4. Association Study on Pooled DNA
As discussed in the Introduction, association analysis can provide a suitable way to
narrow down a large linkage region. However, association studies typically require
large samples numbers, especially when studying heterogeneous disorders with small
effect sizes. DNA pooling provides one way to reduce the cost and time of
genotyping in large scale association studies, and has been found to be a reliable and
quantifiable method for genotyping (Daniels et al, 1998; Breen et al, 1999; Sham et
al, 2002). Here I describe an association study on three SNPs in SOD3 using the
DNA pooling technique.
6.4.1. Sample
The DNA was pooled by S.Le Hellard (see: Le Hellard et al, 2002, for details on the
methodology). Four DNA pools were constructed according to diagnosis: 383 control
(CTL) individuals, 271 bipolar affective disorder (BPAD) patients, 192
schizophrenic (SCZ) patients and 87 recurrent major depressive (RMD) patients. A
Pools plate was constructed (Figure 2-5) which contained four replicates of each of
the four DNA pools and 16 individual control DNAs.
6.4.2. SNPs
Three SNPs, rs2536512, rs2695232 and rs2855262, that were identified in the
individuals on the AS panel (Section 6.2.3), were used in the study. At the time of
this study, the remaining five SNPs had not yet been identified from the AS panel.
6.4.3. Genotyping
Previous studies have identified the SNapShot™ method of genotyping as suitable
for estimating allele frequency from DNA pools (Le Hellard et al, 2002). The
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SNapShot™ reaction was run on the ABI PRISM® 3100 Genetic Analyser and
analysed using the GeneScan version 3.0 software.
6.4.4. Analysis
The genotype from a SNapShot™ reaction, when analysed on the ABI PRISM®
platform, is read as a peak of fluorescence. The allele frequency is determined by
measuring the peak heights of each allele and translating this into a frequency (Figure
6-5). However, when the SNaPshot™ genotyping reaction is performed on an
individual, unequal allele amplification is observed. This pattern is reproducible in
individuals, but not between individuals, and therefore has to be accounted for in the
DNA pool. Therefore, a set of 16 individual control DNAs are run with each pool to
ensure that approximately five heterozygotes are obtained for each SNP. The K ratio
measures the ratio between the allele peak heights of an individual heterozygote. This
is then subtracted from the peak heights of the DNA pools before further analysis.
Approximately five heterozygotes are needed to calculate an average measure of the
between-individual variation in the K ratio. Too much variation makes the assay
unreliable, and therefore, a standard error of the mean (SEM) of greater than 10%
was not tolerated.
Variation in the amplification of the individual DNAs in a pool will also be observed.
Therefore, each pool was replicated four times and the average variation between
replicate peak height ratios was calculated. A SEM of greater than 0.01 (1% variation
around the mean) was deemed unreliable. A SEM calculation that exceeds the
required cut off can be reduced by increasing the number of replicates of either the
heterozygotes or the pools.
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Figure 6-5: Example of the fluorograms for two DNA pools for the single nucleotide
polymorphism (SNP) rs2536512. Genotyping was performed by the SNaPshot™ method, run
on an ABI PRISM® 3730 genetic analyser and signal intensity was visualised as a fluorogram
using the GeneMapper (version 3.0) software. The coloured peaks represent each allele of
the SNP. Allele frequency in a DNA pool is assessed by comparing the signal intensity (peak
height) of each allele. A: Control DNA pool. B: Recurrent major depression (RMD) DNA pool.
In this example, the blue allele is over-represented in the RMD DNA pool compared to
controls.
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Significance was measured by the non-parametric Chi-square statistic which
measures the difference between expected and observed frequencies. In a test for
association, the expected frequency for each allele is the frequency observed in the
control group. The main problem ofusing the Chi-square statistic for pooled DNA is
that one of the requirements of the test is that real frequencies are used. To meet
these requirements, the peak heights are first translated into real allele frequencies
before inputting the figures into the equation. In addition, an adjustment factor was
included into the p-value to account for the error involved in this translation. The K
ratio, the calculation of allele frequency from peak heights and the p-value correction
factor were developed by Peter Visscher (published in Le Hellard et al, 2002).
6.4.5. Results
The results are detailed in Table 6-5 (see Appendix II for the raw data). The
difference in allele frequency of SNP rs2536512 between the RMD patient group and
the CTL group approaches significance. However, the individual heterozygote
variation (K ratio) and the RMD pool SEM are a little high. The differences in allele
frequency of SNP rs2695232 between the control and patient groups was not
significant. This SNP also displayed too much variation between pool replicates in
each of the four pools. Subsequent efforts to increase the number of replicates, in
order to reduce the SEM, failed.
The difference in allele frequency between the control and the RMD DNA pools for
SNP rs2855262 reveals a p-value of <0.003. This is a highly significant difference.
The allele frequency of the major allele in the control group is 65% compared to 37%
in the RMD patient group (Appendix II). Therefore, the minor allele is
overrepresented in the unipolar affective disorder group. However, it is impossible
from this to predict whether it might be the under representation of the major allele or
the over representation of the minor allele that is responsible for the association and
the predicted change in protein function. Unfortunately, this could be a false positive
since the unipolar group is the smallest of the four pools, containing only 87
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individuals, and, due to a genotyping failure, the result was based on only two pool
replicates (Appendix II).
6.4.6. Problems
Subsequent analysis ofDNA profiles revealed that the pools contained a number of
historical duplicate samples, meaning that the results were not reliable. This
inflexibility is an obvious disadvantage of pooling DNA. The effort required to
construct accurate pools and a decrease in genotyping cost led to the decision to carry




Het 0.12 0.01 0.02
CTL 0.004 0.02 0.002
BPAD 0.005 0.02 0.005
SCZ 0.007 0.03 0.01
RMD 0.015 0.07 0.002
P-
value
BPAD 0.37 0.82 0.63
SCZ 0.83 0.4 0.42
RMD 0.08 0.65 0.003
Table 6-5: The results of a Chi-Square test for association on pooled DNA. Three single
nucleotide polymorphisms (SNPs) in the Superoxide Dismutase 3 gene were tested. The
allele frequency of each SNP was measured in DNA pools of control individuals (CTL),
bipolar affective disorder patients (BPAD), schizophrenic patients (SCZ) and recurrent major
depressive patients (RMD). Allele frequency comparisons between the CTL group and each
of the case groups are given as a p-value. Each DNA pool, and five individual heterozygotes
(Het) are genotyped a number of times and the standard error of the mean (SEM) measures
the variation between these genotyping replications.
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6.5. Phase I Association Study on Individuals
The association study was to be carried out in two phases. The Phase I sample
consisted of a small number of individuals and was used to identify the linkage
disequilibrium (LD) between SNPs and to identify SNPs with a trend towards a
positive association to carry through to a Phase If study on a larger group.
6.5.1. Sample
The Phase I sample consisted of 95 controls, 93 BPAD patients and 95 schizophrenic
patients.
6.5.2. SNPs
Seven of the eight SNPs that had been identified by sequencing the SOD3 gene in
individuals from the AS DNA panel were tested in Phase I. SNP ihl67 was not
included in the study because the sequence quality was poor and 1 was not absolutely
sure that the SNP was real. The seven SNPs were clustered in exon one and exon
three and therefore a further six SNPs were included to ensure a more even coverage
of the gene to hopefully cover all LD blocks. One SNP was chosen from Applied
Biosystems as an 'Assay on Demand' TaqMan® assay. The Caucasian minor allele
frequency was 0.41. Five SNPs from dbSNP were also included. These were chosen
on the basis that there had been more than one independent submission to dbSNP.
The 13 SNPs included in Phase 1 gives a coverage of one SNP every ~1.75kb. This
aimed to account for potential assay failures and the unknown nature of the LD block
structure across the region.
6.5.3. Genotyping and Analysis
Twelve SNPs were genotyped at the Sanger institute by the Sequenom®
MASSARRAY™ primer extension method. The results of this analysis revealed a
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number of gaps due to assay failure. Therefore, I re-genotyped rs2536512 and
rs2324580, by SNaPshot™ and sequencing respectively, in order to provide a better
coverage of the gene. The SNP that was provided as an 'Assay on Demand' by
Applied Biosystems was genotyped by the TaqMan® method by Alison Condie.
• 9
Association was measured using Chi-square and LD was measured using D' and r .
Association, LD and Hardy-Weinberg equilibrium were calculated using the
UNPHASED software, version 2.403, developed by Frank Dudbridge (www.hgmp.
mrc.ac.uk/~fdudbrid/software/unphased/) (Dudbridge, 2003), by Naomi Wray.
6.5.4. Results
Table 6-6 details the results of the association study for each SNP. Eleven out of
twelve SNPs sent to the Sanger Institute for genotyping by the Sequenom®
MASSARRAY™ method failed. The reasons for failure were as follows. The assay
failed for four of the SNPs, the negative control was contaminated for one SNP, and
three SNPs were not polymorphic. There are possible explanations for three of the
SNPs not being polymorphic in the DNA panels used for the association study. SNP
ihl70 was observed only once on the AS panel and was therefore very rare, SNP
ihl68 was identified from bad quality sequence and therefore may not be real, and
SNP rs800448 selected from dbSNP and therefore was not known to be polymorphic
in this population. Therefore, eight SNPs were discarded at this stage. Out of the
remaining four SNPs, all four were found to be in Hardy Weinberg equilibrium.
However, an insufficient number of chromosomes were successfully genotyped for
three of the SNPs. This left one SNP for which the assay worked on a sufficient
number of chromosomes to test for association. In order to attain better coverage of
the gene and to calculate LD, I retyped rs2324580 and rs2536512 inhouse. Together
with SNP C_2668721_10 from Applied Biosystems, this produced four SNPs with
sufficiently high quality data for further analysis.
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In a cost-effective approach, the case-control study was undertaken in two phases. In
Phase I, all SNPs were genotyped on 95 cases and 95 controls. All SNPs with
association p-values of <0.2 were to be chosen for the Phase II association study, to
be performed on a larger sample. This threshold was selected based on power
calculations carried out by Dr N Wray (using an in house programme developed by
N. Wray based on standard formulas, e.g. Schaid and Rowland, 1998). Under a
multiplicative genotype relative risk (RR) model, a sample size of 95 cases and 95
controls, using a liberal type 1 error of 0.20, has over 80% power to detect an
association with a heterozygote genotype RR of 2, even when the frequency of the
associated allele is low at 0.10 and over 90% power to detect the same RR when the
allele frequency is 0.40-0.60. Therefore, despite the small sample size in Phase I, it is
very unlikely that any SNP that is truly associated will be eliminated from the list of
SNPs tested in Phase II. Moreover, the power for the Phase II sample was similar to
the power of the Phase I sample when different corrections for multiple testing based
on the full set vs a selected subset of SNPs was taken into account. In this way, a high
cost-effectiveness is achieved with little loss in overall power.
SNP haplotypes were not analysed since the case-control data precluded definitive
haplotype construction. Instead, each SNP was tested independently for association.
A bonferroni correction for multiple testing, to account for the number of SNPs
tested, was not applied to the p-value cut-off at which significance was declared
because multiple tests within the one gene are not considered to represent
independent tests if LD is maintained between them (Nyholt, 2001). A correction for
multiple testing would also be appropriate if the sample group was to be split, for
example, by gender, for further comparison. However, this was not done here.
The results of the association analysis showed that none of the SNPs showed a
significant difference in allele frequency between the control group and either the
schizophrenic or the BPAD groups or both case groups combined.
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Linkage disequilibrium is a measure of how likely two loci (in this case SNPs) will
be separated by a recombination event. Therefore, the Phase I set of individuals was
to provide a measure of LD as well as the results of association. Rather than
exhibiting a gradual decay over increasing genomic distance, LD has been suggested
to occur in a block-like structure with clustered recombination 'hotspots' (Daly et al,
2001; Jeffreys and May, 2004). The extent to which these blocks exist and whether
recombination hotspots are the mechanism by which they occur is still controversial
(Oord and Neale, 2003). However, an association study ought to be able to pick a
minimal set of SNPs to represent all or most of the haplotype diversity and therefore
provide an even coverage of the gene with respect to LD. LD can be measured in a
number of different ways, ofwhich D' and r2 are two of the most frequently used
examples. D' is a widely accepted method, however, r2, unlike D', is more sensitive
to allele frequency. For example, with D', high LD can be observed between two
SNPs if one has a rare minor allele if the rare allele is only ever observed in
combination with one allele of the second SNP. The r2 measure is a pairwise
correlation and therefore is not so influenced by allele frequency.
The results of the LD calculations show high LD between SNP 3 and 7, suggesting
that it would not be necessary to type further SNPs in between these. The D' and r2
values are very similar, reflecting the fact that the allele frequency of both SNPs is
the same. However, there is quite low LD, by both D' and r2, between SNP 7 and 10,
and SNP 10 and 13. Therefore, these three SNPs do not adequately cover the LD
landscape across this region. This level ofLD would suggest that, in contrast to the
premise used to design the study, the tests for association performed with each SNP
are independent and, therefore, criterion for declaring significance should be adjusted
accordingly. However, since no association was found, further correction for multiple
testing would be unnecessary. In addition, the lack of LD between the SNPs means
that the lack of association to psychiatric illness observed in the region of SOD3
covered by SNPs 7, 10 and 13 does not necessarily apply to the intervening regions.
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6.6. Phase II Association Study on Individuals
As discussed in the previous section, the Phase I association study was performed on
a restricted set of individuals and a high p-value threshold of <0.2 was set. This
aimed to capture all possible true association, but would also include a number of
false positive results.
6.6.1. Sample
The Phase II sample consisted of 388 controls, 331 BPAD patients and 254
schizophrenic patients. The individuals in this group did not overlap with the
individuals in Phase I. Therefore, this represented a replication study with an
independent sample, but also enabled the results from both groups to be analysed
together in one larger group.
6.6.2. SNPs and Results
None of the SNPs in SOD3 passed the threshold p-value of <0.2. Therefore none of




Genetic Analysis of SOD3
Here I describe the genetic analysis of the SOD3 gene in MR2. MR2 is a candidate
region for the susceptibility to psychiatric illness in three families that show linkage
to the region, and SOD3 is a good functional candidate gene within this region. It is
expressed in the brain, is believed to play a role in protection against damage induced
by oxygen toxicity and may be involved in learning and memory.
I identified eight SNPs by sequencing the coding and regulatory regions of the SOD3
gene in members of the four linked families. One SNP was found to alter amino acid
58 of the protein from a threonine to an alanine. Bioinformatic and frequency
analysis showed that this substitution is unlikely to significantly alter the function of
the protein.
The haplotypes of the four families were ascertained and assessed. The eight SNP
haplotype that occurs on the disease chromosome of families 22, 59 and 50 is the
same. This is the most common haplotype in the population; it is observed on 56% of
32 chromosomes. Ten other haplotypes were observed, each accounting for between
3% and 6% of the total. The eight-SNP haplotype on the disease chromosome of
family 48 was rare in the individuals sampled. However, due to the uninformative
nature of one of the SNPs it was not possible to determine whether it was unique or
was the same as one of the ten rare haplotypes observed. The haplotype sharing of
families 22, 50 and 59 might reflect the common ancestry of the three Celtic families.
In addition, the frequency of the common haplotype might be an artefact of the
predominantly Celtic chromosomes on the AS panel: 41 out of the 45 chromosomes
on the panel are from families 22, 59 or 50. Chromosomes from other ethnic groups
would need to be genotyped to test this.
There are certain limitations to analysing haplotype sharing using the AS panel.
There are only four disease chromosomes to compare and the control chromosomes
are family members which could be biased by assortative mating. However, having
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closely related control chromosomes is advantageous, and studying families enables
the unambiguous determination of haplotypes.
Three of the SNPs that had been identified in the families were tested for association
in a set of pooled DNA samples. The results revealed a significant positive
association between SNP rs2855262 and the RMD patient group compared to
controls. However, the results were deemed unreliable because the pools contained
replicate DNAs. Therefore, comparison of pooled and individual association results
is not possible. The inflexibility ofDNA pooling is an obvious disadvantage. Once
an individual is classified into a particular group he/she cannot be removed and
therefore precludes the correction of sample errors. In addition, psychiatric illnesses
are clinically and genetically heterogeneous, and diagnoses can change over a persons
lifetime. Therefore, samples that have not been pooled can be more appropriately
analysed at a later stage.
Seven of the SNPs that had been identified from the four families, and an additional
six SNPs identified from the public databases, were tested for association in a
population of unrelated individuals. This preliminary association study consisted of
95 controls, 95 schizophrenic patients and 93 BPAD patients. This preliminary
screen intended to identify SNPs which showed a trend towards a significant positive
association before testing these on a larger sample. None of the SNPs showed a
significant positive association in this preliminary screen and so none were tested on
the larger population.
There are a number of advantages to using association studies in this way. It provides
a good way to narrow down a large linkage region. In addition, using this data set it
was possible to create an LD map of the gene. This allows the assessment of the
coverage obtained in Phase I of the study and ensures that there is no unnecessary
duplication in Phase II. Due to genotyping failures, only four SNPs were included in
the LD calculations. This revealed that whilst SNP 3 and 7 appear to be in high LD,
the remaining SNPs do not. Therefore, future studies are required to analyse a higher
234
Chapter Six Genetic Analysis of SOD3
density of SNPs across SOD3 in order to be able to rule out association with
psychiatric illness completely.
Caution is required when interpreting association studies. Psychiatric illness has a
heterogeneous genetic cause. In a family, the genetic cause is likely to be the same
for all individuals. However, studying unrelated individuals significantly reduces this
likelihood and more than one genetic locus will be responsible for a clinical
diagnosis. Consequently the sample size required to detect the loci will be increased.
The effect size of the loci that contributes to susceptibility to psychiatric illness in the
four families is unknown, so the required association study sample size is unknown.
A reasonable guess would be the kinds of effect sizes shown in other studies. For
example, the results of association and haplotype analysis in the NRG1 gene and
schizophrenia have observed effect sizes in the region of 2 (Stefansson et al, 2002).
Power calculations by Dr. Naomi Wray suggest that an association with this effect
size would be detectable in the Phase I population if a p-value of <0.2 is considered.
In summary, the results of genetic analysis of SOD3 in the four families did not
reveal a mutation in SOD3 that would alter protein function and contribute to
psychiatric illness. Association studies in pooled DNA revealed a significant
association for one SNP in RMD patients. However, the sample proved unreliable.
Association studies on individuals did not reveal a significant association to
schizophrenia, BPAD or RMD. LD across the gene has not been covered and
therefore further SNPs should be tested in SOD3
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Chapter Seven
Genetic Analysis of the G-Protein-Coupled
Receptor 78 (GPR78) Gene
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Genetic Analysis of the G-Protein-Coupled Receptor
78 (GPR78) Gene
7.1. Introduction
Here I describe sequence analysis and association studies of the orphan G-protein-
coupled receptor 78 (GPR78) gene. Previously I have described how the comparison
of linkage regions in four families has prioritised two regions: MR1 and MR2. MR1
currently (February 2004) extends over ~3.8Mb of sequence and contains seven
known genes. GPR78 is positioned in MR1, and it is therefore a candidate gene for
psychiatric illness in F22, F50 and F59.
In the previous chapter, I explained the rationale of studying individual genes within
these regions for SNP variation in the families. As in the previous chapter, I have
chosen a candidate gene from MR1 to identify the haplotypes that are observed on
the family disease chromosomes, identify SNPs that potentially alter the function of
the protein and perform association studies of these SNPs in a group ofunrelated
cases and controls. 1
GPR78 is a good candidate gene to study within MR1 because it is a member of the
G-protein-coupled receptor family. G-protein-coupled receptors are involved in
cellular signalling pathways and are therefore well positioned to mediate the subtle
changes in cellular function that may be involved in psychiatric illness. GPR78 was
identified by virtue of its homology to GPR26, which itselfwas identified in human
and rat by Lee et al (2000). A human EST encoding a fragment of the G-protein-
coupled receptor GPR26 was used to screen cDNA libraries. This identified the full
length rat cDNA ofGPR26 and a partial genomic DNA fragment of human GPR26.
Rat GPR26 cDNA encoded a 317 amino acid protein distantly related to the
serotonin 5-HT5a and gastrin releasing hormone BB2 receptors. Expression of the
mRNA was identified in numerous brain regions.
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GPR78 was identified by the same group (Lee et al, 2001) by using partial GPR26
sequence as a probe to search the EST and high throughput genomic sequences
(HTGS) databases. GPR78 mRNA is expressed in the pituitary and the placenta, but
not in the brain. This places GPR78 in a good position to play a role in the
hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is involved in hormone
and stress regulation and has been found to be dysfunctional in affective disorder
patients (Pariante & Miller, 2001), and schizophrenic patients (Altamura et al, 1999).
The closest relation to GPR78 is GPR26. Both are orphan receptors with unknown
ligands, they share 65% identity in their transmembrane domain (TMD) regions and
have a similar protein structure: they lack an asparagine-linked extra cellular
glycosylation site, have a short amino terminus, have a similar intron-exon structure,
and share cationic arginine and lysine residues in transmembrane domains V and VI
respectively (Lee et al, 2001). These residues have previously been found to play a
role in purinergic binding in P2Y receptors; G-protein-coupled receptors for the
nucleotides ADP, ATP, UDP, and UDP-glucose. Therefore GPR78 belongs to
subgroup 1-C of the group 1 family ofG-protein-coupled purigenic and adenosine
receptors that use cAMP as a second messenger.
The GPR78 gene has three exons and gives rise to the classic seven transmembrane
receptor structure ofG-protein-coupled receptors, with an extracellular N-terminus
and an intracellular C terminus (Figure 7-1). Within MR1, the gene is positioned on
BAC RP11-301J10 and lies within the recombination breakpoint interval at the
telomeric end ofMR1. In chapter 4,1 described refinement of this recombination
interval, but unfortunately I could not definitively rule GPR78 in or out ofMR1.
However, even if in the future it is ruled out ofMR1 it could still be under promoter
control from within MR1, and it will still remain on the disease chromosome of F22.
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As in Chapter 6, the allele sharing (AS) DNA panel was used to identify SNPs
(Figure 2-5).
7.2.2. STS Design and SNP Detection
STSs were designed, PCR's were optimised and sequenced and SNPs were identified
as in Section 6.2.2. Every STS was sequenced with both the forward and reverse
primer to confirm the genotype obtained.
7.2.3. SNPs identified
Twenty-three SNPs were identifed from the AS DNA panel (Figure 7-2). None of
these SNPs were in the public database dbSNP at the time (February 2002). Today
(February 2004), five of these SNPs have since been submitted to dbSNP. Two of the







































7.3.1. Amino Acid Changes
7.3.1.1. ih31
SNP ih31 in exon one changes amino acid 201 from an arginine to a serine. The SNP
is an a>c variant, the third nucleotide of codon 'aga'. The mutation occurs in the
intracellular loop between TMD V and VI, just after TMD V. It changes a charged
residue to an uncharged residue in a string of charges. It could be hypothesised to
play a role in TMD anchoring, as this is thought to be under the control of such a
string of charged residues. The frequency of this variant could provide some idea of
its functional importance. The SNP was identified by sequencing the 45 independent
chromosomes from the AS DNA panel. This SNP was observed on 10 chromosomes,
which translates into a frequency of 23%. This is fairly common, and might suggest
that the alternative protein would not have a significant impact on protein function.
However, as discussed in Chapter 6, the CDCV hypothesis suggests that common
variants will underly the susceptibility to common diseases, or assortative mating
may have made the SNP more common in the families. Despite this, the variant was
only observed on the disease chromosome of F50, and not families 22, 59 or 48.
The properties of each amino acid should give some idea ofwhether a substitution
would be tolerated or not. According to Bordo and Argos (1991) these two amino
acids cannot be substituted. Four different scales of hydrophobicity place arginine at
or near the bottom and therefore is consistently considered to be more hydrophilic
than serine, which is placed near the middle (Janin, 79; Wolfenden et al, 81; Kyte
and Doolittle, 82; Rose et al, 85). Therefore, this could alter the secondary structure
of the protein because the more hydrophilic residues will tend to be exposed on the
protein surface.
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PIX analysis was described in Section 6.3.1. The results of a PIX analysis of the two
GPR78 variant proteins (Figure 7-3) shows that the serine variant (B) has extended
the region of predicted antigenicity by four residues, and slightly altered the
secondary structure of two adjacent amino acids from an alpha helix to a coil
structure in the DSC secondary structure prediction programme. However, these are
still surrounded by an extensive region of a predicted alpha helical structure. The
transmembrane domain predictions, by the programmes TMHMM, TMPRED,
TMAP and DAS, are the same in both protein variants. Therefore, structurally, the
serine variant does not appear to have a significant impact on the protein.
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Figure 7-3: The results of a Protein Identification of Unknown Sequences (PIX) analysis
(MRC-RFCGR) for part of the orphan G-protein-coupled receptor 78 (GPR78) protein
containing single nucleotide polymorphism (SNP) ih31 at amino acid position 201 (arrow).
The two amino acid variants created by SNP ih31 are shown (arrow). A: Arginine variant. B:
Serine variant. See Figure 6-3 for an explanation of the analysis programmes.
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If the variant amino acid is predicted to alter a functional motif it could be postulated
to impact upon protein function. The PROSITE database, described in Section 6.3.1,
searches for such functional motifs. The results of a PROSITE scan in the normal
GPR78 protein can be seen in Table 7-1. The arginine-serine variant at position 201
falls between two predicted protein kinase C phosphorylation sites, but does not fall
directly within any existing motif. A PROSITE search with the variant serine at
position 201 does not create any additional motifs.
Position Sequence Motif
47-50 NLSL N-glycosylation site
348-351 NGSV
355-358 NDSC






321-324 STHD Casein kinase II phosphorylation site
325-328 SSLD
353-356 TEND
286-294 KAVADPFTY Tyrosine Kinase phosphorylation site







Table 7-1: Results of a PROSITE scan for functional motifs in the orphan G-protein-coupled
receptor 78 (GPR78) protein. The position refers to the amino acid position in the GPR78
protein. The sequence shows the amino acid sequence that identifies the functional motif.
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The NetPhos 2.0 server, decribed in Section 6.3, predicts phosphorylation of
individual serine, threonine and tyrosine residues in a protein. Phosphorylation of
proteins can be an important part of cellular signalling cascades. The results of the
predicted phosphorylation status of serine residues in GPR78 are shown in Table 7-2.
As can be seen, the predicted phosphorylation status of the serine in the alternative
protein (position 201 in the table) does not exceed the threshold value of 0.5 and is
therefore not predicted to be phosphorylated.
Position Context Score Prediction
22 VALLSNALV 0.002 -
33 CCAYSAELR 0.007 -
41 RTRASGVLL 0.398 -
49 LVNLSLGHL 0.008 -
74 GRTPSAPGA 0.875 *s*
91 TFLASNAAL 0.009 -
96 NAALSVAAL 0.571 *s*
101 VAALSADQW 0.173 -
134 AWGQSLAFS 0.003 -
138 SLAFSGAAL 0.039 -
145 ALGCSWLGY 0.007 -
150 WLGYSSAFA 0.007 -
151 LGYSSAFAS 0.011 -
155 SAFASCSLR 0.006 -
157 FASCSLRLP 0.015 -
192 LCLTSLQVH 0.006 -
201 RVARSHCQR 0.059 -
223 DLHPSVRHG 0.620 *s*
279 WGILSKCLT 0.005 -
285 CLTYSKAVA 0.027 -
295 PFTYSLLRR 0.010 -
321 PRPASTHDS 0.998 *s*
325 STHDSSLDV 0.655 *s*
326 THDSSLDVA 0.428 -
345 PRPASTHNG 0.996 *s*
350 THNGSVDTE 0.045 -
357 TENDSCLQQ 0.203 -
Table 7-2: The prediction of the phosphorylation status of the orphan G-protein-coupled
receptor 78 (GPR78) protein. The phosphorylation of individual serine residues are predicted
using the NetPhos 2.0 server. The position refers to the amino acid position in the GPR78
protein. The context shows the nine residue sequence centred on the serine residue being
analysed. The score ranges from 0.0-1.0. Residues for which the value exceeds the
threshold value of 0.50 are predicted to be phosphorylated.
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Therefore, a functional variant at amino acid position 201 that changes the residue
from an arginine to a serine is unlikely to greatly alter the function of the GPR78
protein, if at all. The variant is relatively common on control chromsomes and it does
not effect the predicted phosphorylation state of the protein or the protein structure.
7.3.1.2. SNP ih34
SNP ih34 in exon three changes amino acid 342 from an arginine to a histidine. The
SNP is variant g>a , the second nucleotide of codon 'cgc'. The variant occurs in the
protein's C-terminal, and is the 23rd amino acid from the end. The C-terminal region
is situated intracellularly and is therefore in a position to be involved in intracellular
signalling cascades. This variant was observed on five chromosomes from the AS
panel; a frequency of 11.4%. This minor allele frequency is quite low and therefore
this variant is quite rare. It was observed on the disease chromosome of family 22,
but not families 59, 50 or 48.
According to Bordo and Argos (1991) these two amino acids cannot be interchanged.
Using four different scales of hydrophobicity, arginine is consistently considered to
be more hydrophilic than histidine, being positioned at or near the bottom whilst
histidine is positioned near the middle (Janin (1979); Wolfenden et al, 1981; Kyte
and Doolittle, 1982; and Rose et al, 1985).
The results of a PIX analysis at the MRC-RFCGR is shown in Figure 7-4. The
secondary structure of this region of the protein is not altered by the histidine variant.
However, the level of antigenicity is increased. This does not follow with the
observation that histidine is more hydrophobic that arginine. However, if histidine is
more exposed on the protein surface, this could alter the availability of functional
motifs to intracellular signalling molecules and en2ymes.
The PROSITE database predictions for functional motifs in the GPR78 protein have
already been shown in Table 7-1. Performing the same search with the variant
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histidine at amino acid 342 changes the motif 'TPR' to 'TPH' at position 340-342.
This would abolish a predicted protein kinase C phosphorylation site. Since the
variant histidine occurs in the intracellular C-terminal region it is well positioned for
interactions with components of intracellular signalling cascades.
Therefore, the consequence of this variant is unclear. It is possible that it disrupts an
intracellular signalling cascade. However, the programmes used are predictions only
and in vitro functional studies would be required to determine this unequivocally. It
is a rare polymorphism which therefore could indicate that it is either relatively new
or that it is under negative selection pressure. The CDCV hypothesis would not
postulate a rare polymorphism to be involved in a common illness. Furthermore, if it
does alter the function of the protein it does not play a role in the disease pathology
of families 50, 59 or 48 because the mutation occurs only on the F22 disease
chromosome. However, it is an interesting variant, and if a positive association were
found between ih34 or other GPR78 markers in LD with ih34, it might justify further
in vitro work being carried out.
Figure 7-4: The results of a Protein Identification of Unknwon Sequences (PIX) analysis
(MRC-RFCGR) for part of the orphan G-protein-coupled receptor 78 (GPR78) protein that
contains single nucleotide polymorphism (SNP) ih34. The two amino acid variants created by
SNP ih34 are shown (arrow). A: Arginine variant. B: Histidine variant. See Figure 6-3 for an





As mentioned above, the genotypes for 23 SNPs were obtained by sequencing
individuals from the AS DNA panel which consists ofmembers from the four linked
families. This allows for the unambiguous identification of haplotypes, including that
of the disease chromosome, by following the inheritance of alleles from parent to
offspring.
Figure 7-5 details the genotypes of the 46 individuals from the AS panel. SNPs ih47
and ih48 were removed from the analysis because the genotyping was unreliable
since the results did not segregate. I suspected that this was because the minor allele
amplified inefficiently in the sequencing reaction and that therefore heterozygote
genotypes were mistaken for homozygote genotypes. Thirty-six unambiguous 21-
SNP haplotypes were identified from the 45 chromosomes. These represented twelve
different haplotypes (Table 7-3). Two of the twelve haplotypes are common and
differed at only one SNP. They accounted for 10 chromosomes (28%) each, therefore
representing 56% of the observed variation. The third most common haplotype
accounts for five chromosomes (14%). Therefore, 70% of the haplotype diversity of
these 23 SNPs is represented by three haplotypes, and this can be captured by
sampling just three SNPs (for example, SNPs 1, 5 and 11). The remaining nine
haplotypes are relatively rare, accounting for between one (2.7%) and two (5.5%)
chromosomes each.
The disease associated haplotype for family 59 was one of the most common and for
family 50 it was the third most common. The disease associated haplotype for family
22 was unique and the disease associated haplotype for family 48 could not be
unambiguously determined. Therefore, the disease assoicated hapotypes of the three
families are all different. Family 50, 48 and 59 share a common 12 SNP haplotype
from SNPs 11-23, excluding 22 (Table 7-3). There are only two haplotypes that are
observed in this region. One is composed entirely of the common alleles, and the
other is composed entirely of the rare alleles, and family 22 has the rare haplotype.
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The frequency of the rare 12 SNP haplotype on the AS panel is 11.4%. In the gene
they cover a distance ofjust over lkb, from intron two to the 3' UTR. Therefore, this
is a small region with a lot of SNPs that are observed infrequently in the population
and that are all in LD with one another in this sample. I have already described that
SNP ih34 within this haplotype alters the amino acid sequence of the protein, but that
its effect on the function of the protein is unclear. The fact that this rare haplotype is
observed on the F22 disease haplotype, and that ih34, part of this haplotype, may
alter the function of the protein, is interesting. As mentioned previously, a positive
association in this region would justify further study of these SNPs.
A Fishers exact test was performed using the Analyse-it® (version 1.71) software for
microsoft excel. Since the disease haplotype of F48 does not extend into MR1, the
position ofGPR78, the analysis was carried out with and without F48. Each SNP was
analysed individually for allele sharing. A two-tailed Fishers exact test on each of the
21 SNPs shows that there is no significant difference between the allele frequency of
disease and non-disease chromosomes with or without F48 included in the analysis
(Table 7-4). Therefore, in conclusion, there is no obvious pattern of excess haplotype
sharing between the four families that would suggest the presence of a common
susceptibility variant to psychiatric illness.
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D (G)2 (A)1 1.00 -
ND 25 13
2
D (G)3 (C)1 1.00 1.0
ND 27 14
3
D (G)3 (A)1 1.00 1.0
ND 29 12
4
D (C)4 (T)0 1.00 1.0
ND 40 1
5
D (A)2 (C)2 0.8447 1.0
ND 25 12
6
D (G)3 (A)1 1.00 1.0
ND 29 12
7
D (A)3 (0)1 1.00 1.0
ND 29 12
8
D (T)3 (G)1 1.00 1.0
ND 29 11
11
D (C)3 (T)1 0.3756 0.2923
ND 36 1
12
D (A)3 (G)1 0.3756 0.2923
ND 36 1
13
D (C)3 (T)1 0.3756 0.2923
ND 36 1
14
D (G)3 (A) 1 0.3756 0.2923
ND 36 1
15
D (T)3 (0)1 0.3756 0.2923
ND 36 1
16
D (G)3 (A) 1 0.3756 0.2923
ND 36 1
17
D (A)3 (0)1 0.3756 0.2923
ND 36 1
18
D (C)3 (G)1 0.3756 0.2923
ND 36 1
19
D (G)3 (0)1 0.3756 0.2923
ND 36 1
20
D (T)3 (G)1 0.3756 0.2923
ND 36 1
21
D (T)3 (0)1 0.3756 0.2923
ND 36 1
22
D (G)4 (T)0 1.00 1.0
ND 39 2
23
D (C)3 (T) 1 0.3756 0.2923
ND 36 1
Table 7-4: The results of a Fishers exact test on 21 single nucleotide polymorphisms
identified by sequencing exons of the orphan G-protein-coupled receptor 78 gene in the
Allele Sharing DNA panel (46 members of families 22, 48, 50 and 59, totalling 45 different
chromosomes). The number of chromosomes successfully genotyped for each allele is
included in the table (with the corresponding allele in brakets). A two-tailed hypothesis for a
difference in allele frequency between 'diease' and 'non-disease' alleles has been used. D =
allele inherited with the disease. ND = allele not inherited with the disease. The results have
been calculated including and excluding the data from Family 48.
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7.4. Association Study on Pooled DNA
As discussed in the previous Chapter, association analysis can provide a suitable way
to narrow down a large linkage region, and DNA pooling provides a way to reduce
the cost and time of genotyping.
7.4.1. Sample
Pools were constructed as Section 6.4.1. The pools plate (Figure 2-5) contained six
replicates of each of the four DNA pools and 24 individual DNAs.
7.4.2. SNPs
At the time of the study on pooled DNA, 18 of the 23 SNPs (SNPs 6-23 in Figure 7-
2) had been identified from a subset of 11 chromosomes from the AS panel. Linkage
disequilibrium (LD) was calculated from these 11 chromosomes in order to
determine a smaller set to study for association. Taking each SNP in turn, I calculated
the occurrence of each of the two alleles with each allele of every other SNP. An
example of complete LD therefore would be where allele A of SNP 1 only ever
occurs with allele A of SNP 2. Based on such small numbers of chromosomes, it
would only be feasible to calculate an LD block as instances of complete LD and type
one member from this block.
Three groups of LD were identified (Figure 7-6). Group one consisted of SNPs 6 and
7, group two consisted of SNPs 9 and 10 and group three consisted of SNPs 11-13,
excluding SNP 22. Therefore, six SNPs were chosen for the association study: SNP 7
from group one, SNP 9 from group two, SNPs 13 and 16 from group three, and SNPs
8 and 22. Despite the lack of segregation of SNPs 9 and 10 in the larger AS panel, at
this time, the genotypes did segregate in these eleven chromosomes, and therefore
they were included in the study.
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s 6 7 8 9 10 11 12 13 14 15
Al. G A A C T G C G G A c T A G c T G A T c
6 G 7 0
iff | A 0 4
7 A 7 0 7 0
C 0 4 | 0 4
8 T 6 1 6 1 7 0
G 1 3 1 3 0 4
9 C 6 2 6 2 6 2 8 0
G 1 2 1 2 1 2 0 3
10 G 6 2 6 2 6 2 8 0 8 0
A 1 2 1 2 1 2 0 3 0 3
11 C 6 4 6 4 6 4 7 3 7 3 10 0
T 1 0 1 0 1 0 1 0 1 0 0 1
12 A 6 4 6 4 6 4 7 3 3 10 0 10 0
G 1 0 1 0 1 0 1 0 1 0 0 1 0 1
13 C 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0
T 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1
14 G 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0
A 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1
15 T 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
C 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
16 G 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
A 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
17 A 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
C 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
18 C 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
G 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
19 G 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
C 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
20 T 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
G 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
21 T 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
C 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
22 G 6 4 6 4 6 4 7 3 3 9 1 9 1 9 1 9 1 9 1
T 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0
23 C 6 4 6 4 6 4 7 3 3 10 0 10 0 10 0 10 0 10 0
T 1 0 1 0 1 0 1 0 1 0 0 1 0 1 0 1 0 1 0 1
Figure 7-6 (continued overleaf): Linkage disequilibrium (LD) calculations of 18 single
nucleotide polymorphisms (SNPs) in the orphan G-protein-coupled receptor 78 (GPR78)
gene. Eleven chromosomes were used to calculate the occurrence of each allele of each
SNP with each allele of every other SNP. Three groups of complete LD (where two of the
four possible genotypes are seen) are shown (yellow, blue and purple). S=SNP, Al.=allele
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16 17 18 19 20 21 22 23
G A A c c G G c T G T c G T C T
10 0
0 1
10 0 10 0
0 1 0 1
10 0 10 0 10 0
0 1 0 1 0 1
10 0 10 0 10 0 10 0
0 1 0 1 0 1 0 1
10 0 10 0 10 0 10 0 10 0
0 1 0 1 0 1 0 1 0 1
10 0 10 0 10 0 10 0 10 0 10 0
0 1 0 1 0 1 0 1 0 1 0 1
9 1 9 1 9 1 9 1 9 1 9 1 10 0
1 0 1 0 1 0 1 0 1 0 1 0 0 1
10 0 10 0 10 0 10 0 10 0 10 0 9 1 10 1





As described in the previous chapter, the SNaPshot™ method of genotyping was
used to esitmate the allele frequency from DNA pools. The SNaPshot™ reaction was
run on the ABI PRISM® 3100 DNA sequencer and analysed using the GeneScan
version 3.0 software.
7.4.4. Results
Section 6.4.4 describes in detail how the allele frequency of each DNA pool is
determined and how Chi-square is calculated. The results can be seen in Table 7-5.
The minor allele for SNP 22 was not visible. This was thought to be because it is too
rare in the population. This was supported by the fact that the minor allele frequency
of the SNP from the AS DNA panel was only 4.4% (or two chromosomes). The assay
for SNP 8 failed. The SEM for SNP 9 is a little high for the control, BPAD and RMD
groups, so that the significant association observed in the SCZ group is not reliable.
A significant association was also found for ih34 between the control and RMD
groups. This is interesting in the light of the previous observations about the amino
acid change in the protein caused by this SNP, and its occurrence on the disease
chromosome of the family that segregates affective disorder (F22). An almost
significant association was also found in SNP 16 between the BPAD and control
groups. The different results obtained for SNPs 13 and 16 do not follow with the fact
that, based on 11 chromosomes from the AS panel, they are in complete LD with
each other. Upon genotyping the entire AS panel, the two SNPs were still in
complete LD (Figure 7-5). Since the association results suggest that the two SNPs are
not in LD in that population, it would appear that 45 or less chromosomes is not
enough from which to calculate LD reliably. An alternative explanation is that the





AS mentioned in chapter 6, a subsequent discovery that the pools contained
duplicated samples meant that work on pools had to be stopped. Therefore, I did not
attempt to further reduce the SEM for SNP 9 or get the assay to work for SNP 8 and
unfortunately the positive associations observed were not reliable. I therefore moved
on to readdress the question ofwhether any of the SNPs showed significant
association by undertaking a study on individuals.
SNP
7 8 9 13 16
SEM
Het 0.09 - 0.09 0.03 0.06
CTL 0.009 - 0.04 0.005 0.005
BPAD 0.009 - 0.06 0.003 0.004
SCZ 0.007 - 0.01 0.004 0.004
RMD 0.01 - 0.03 0.002 0.01
p-value
BPAD 0.6 - 0.9 0.3 0.06
SCZ 0.7 - 0.03 0.95 0.7
RMD 0.6 - 0.3 0.05 0.1
Table 7-5: The results of a Chi-Square test for association on pooled DNA. Five single
nucleotide polymorphisms (SNPs) in the G-protein-coupled receptor gene were tested. The
allele frequency of each SNP was measured in DNA pools of control individuals (CTL),
bipolar affective disorder patients (BPAD), schizophrenic patients (SCZ) and recurrent major
depressive patients (RMD). Allele frequency comparisons between the CTL group and each
of the case groups are given as a p-value. Each DNA pool, and five individual heterozygotes
(Het) are genotyped a number of times and the standard error of the mean (SEM) measures
the variation between these genotyping replications.
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7.5. Phase I Association Study on Individuals
7.5.1. Sample
The Phase I sample consisted of 95 controls, 93 BPAD patients and 95 schizophrenic
patients.
7.5.2. SNPs
Twenty-two of the 23 SNPs that had been identified by sequencing individuals from
the AS DNA panel were tested in Phase I. Three additional SNPs were chosen from
Applied Biosystems as an 'Assay on Demand' TaqMan® assay. SNPs were chosen
that had a causacian minor allele frequency greater than 0.1. SNPs C_1221917_10
and CI 1352300_10 are 8.8kb and 2.9kb from the 5' end of exon one respectively,
and SNP C_1221895_10 is 3.6kb from the 3' of exon 3 (not shown on Figure 7-2).
Therefore, a total of 25 SNPs across GPR78 were included. The 25 SNPs included in
Phase 1 gave one SNP every ~870bp. The structure of LD was unknown since it was
with these SNPs that LD was to be determined. Therefore, a SNP every 800bp,
accounting for potential assay failures, was predicted to cover LD across the region.
7.5.3. Genotyping and Analysis
The 22 SNPs identified from the AS DNA panel were sent to the Sanger Institute for
genotyping by the Sequenom® MASSARRAY™ primer extension method. The
three SNPs that were provided as an 'Assay on Demand' by Applied Biosystems
were genotyped by the TaqMan® method by Alison Condie on an ABI PRISM®
3730 Genetic Analyser.
As Chapter 6, association was measured using Chi-square method and LD was





Table 7-6 details the results of the association analyses. Fifteen SNPs could not be
used in the association analysis for the following reasons. Three SNPs failed the
primer design stage of the assay, the assay failed for five of the SNPs and one SNP
was not polymorphic in this population. Six SNPs were not in Hardy-Weinberg
equilibrium. One of these five also had a minor allele frequency that was too low and
another did not have enough chromosomes genotyped. The fifteenth SNP had a
minor allele frequency that was too low. Therefore, nine SNPs were suitable for LD
calculation. Section 6.5.4 describes how and why LD was measured. The results
show that the D' measurements between each SNP show moderate to high LD (>0.6)
except between SNPs ih31 and oh34, where LD is low (D'=0.37). The r2
measurements are more variable, but show high LD between ih33 and 31 and high to
moderate LD between ih40 and ih36. Based on the D' measurements, if an LD block
is defined by a continuous stretch ofpairwise LD exceeding the threshold of 0.60, the
nine SNPs form two LD blocks (SNPs c_1221917_10 to ih31 and ih34 to
C_1221895_10). The D' values within the blocks (> 0.64) exceed the D' value
between the blocks (0.37). Therefore, this suggests that the intervening region
between SNPs ih31 and ih34 has not been covered in terms of the LD observed, and
further association analysis might want to be undertaken. Furthermore, it also
suggests that the Phase I association analysis constituted two independent tests for
association (Nyholt, 2001).
Section 6.5.4 also describes how SNPs with a p-value <0.2 were to be chosen for the
Phase II association study. The results of the Chi-square test for association on the
Phase I sample revealed that one SNP, ih31, is significantly associated with
schizophrenia and BPAD and schizophrenia combined. Therefore, only one SNP
from the two LD blocks was chosen for study on the Phase II sample.
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7.6. Phase II Association Study on Individuals
As discussed in the previous section, the Phase I association study was performed on
a restricted set of individuals and a high p-value threshold of<0.2 was set. Power
calculations suggested that this would capture all true association.
7.6.1. Sample
As discussed in Section 6.6.1., the Phase II sample consisted of 388 controls, 331
BPAD patients and 254 schizophrenic patients.
7.6.2. SNPs and Genotyping
One SNP, ih31, showed a significant association to schizophrenia (p < 0.08) and
schizophrenia and BPAD combined (p <0.15) (Table 7.6) and was therefore tested on
this larger sample. Genotyping was performed the Sequenom® method, carried out
by the Sanger Institute.
7.6.4. Results
The results showed that SNP ih31 was not associated with either schizophrenia,
BPAD in the Phase II sample (Table 7-7).
p-value
SNP HW MAF. No. Ch's (CTL) BPAD SCZ
Ih31 0.41 35 766 0.67 0.46
Table 7-7: The Phase II association study results. SNP ih31 in the orphan G-protein-coupled
receptor 78 gene was genotyped in 388 controls (CTL), 331 bipolar affective disorder (BPAD)
and 254 schizophrenic (SCZ) patients. The table details the test for Hardy-Weinberg (HW)
equilibrium (p<0.05 not tolerated), the minor allele frequency (MAF) in the CTL group, the
number of CTL chromosomes genotyped and the results (p-value) of the Chi-square test for





Here I describe the genetic analysis of the GPR78 gene in MR1. MR1 is a candidate
region for the susceptibility to psychiatric illness in three families that show linkage
to the region. GPR78 is expressed in the placenta and the pituitary and is therefore
positioned to play potential roles in the HPA axis and during pregnancy. The HPA
axis plays an important role in stress regulation and has been shown to be
dysfunctional in patients suffering from schizophrenia and affective disorders
(Pariante and Miller, 2001; Altamura, 1999). The effect ofmaternal factors, such as
stress hormones, on an unborn child has also been suggested to be involved in
psychiatric pathology (Weinstock, 1997).
I identified twenty-three SNPs by sequencing the gene in members of the four linked
families. Two SNPs alter the amino acid sequence of the protein. SNP 8 (ih31)
changes amino acid 201 from an arginine to a serine, and SNP 12 (ih34) changes
amino acid 342 from an arginine to a histidine. Bioinformatic and frequency analysis
showed that these substitutions are unlikely to significantly alter the function of the
protein.
Despite this, predicting the relationship between protein sequence, structure and
function is inexact. Many tools (e.g. Pfam) rely on homology to known protein
sequences and functional domains whilst others use algorithms extrapolated from
past in vitro studies (e.g. NetPhos). Experimentally determined structures are only
available for a limited number ofproteins, and computational methods with varying
degrees of accuracy are required to model the structures of the rest (Kopp and
Schwede, 2004). Biological and biochemical data is still needed to reliably go from a
sequence to function. For example, a cysteine to arginine amino acid mutation at two
residues of the apolipoprotein E protein (residues 112 and 158) creates three common
isoforms: E2 (cys/cys), E3 (cys/arg) and E4 (arg/arg) (Weisgraber et al, 1981). The
E4 allele confers a susceptibility risk to late onset Alzheimer's disease (LOAD)
(Corder et al, 1993) and is associated with an increase in the amount in beta-amyloid
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deposition in the post-mortem brains of LOAD patients (Lambert et al, 2001).
Subsequent in vitro work has shown that the E4 allele binds with significantly higher
affinity to beta amyloid than the E3 allele (Sanan et al, 1994). However, it is
unknown how an arginine at residue 112 should influence this, and without
biochemical analysis it might not have been predicted. Therefore, prediction of the
likely effect of an amino acid variant on protein function when very little is known
about the protein, as is the case for GPR78, is very difficult.
The haplotypes of the four families were ascertained and assessed. The twenty-three
SNP haplotype that occurs on the disease chromosomes of the families are different
to each other. Thirteen haplotypes were observed in total, with three that are
common. The disease haplotype of families 48, 50 and 59 are common and the
disease haplotype of F22 is rare. A Fishers exact test revealed that there was no
significant allele sharing between the four families and therefore a susceptibility
haplotype could not be determined. As discussed in the previous chapter, there are
certain limitations concerning the number of disease chromosomes and the potential
for assortative mating. However, a Fishers Exact test is more suited to low numbers
and efforts have been made to rule out assortative mating is unlikely since there is a
disease associated risk haplotype inherited from one side in each family.
Six of the SNPs that had been identified in the families were tested for association in
a set of pooled DNA samples. The results revealed a significant positive association
between SNP 9 and the schizophrenic patient group, SNP 16 and the BPAD patient
group, and SNP 13 and the RMD patient group compared to controls. However, the
results were deemed unreliable because the pools contained replicate DNA's. For this
reason, comparison ofpooled and individual association results is not possible.
Twenty-two of the SNPs that had been identified from the four families and an
additional three SNPs identified from the public databases were tested for association
in a population of unrelated individuals. This preliminary association population
consisted of 95 controls, 95 schizophrenic patients and 93 BPAD patients. A relaxed
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p-value cut off of<0.2 was chosen to pick SNPs for a second round of association
analysis on a larger population. SNP 8 (ih31) showed a significant positive
association in this preliminary screen (p<0.08) and so was tested on the larger
population. In addition, this data was used to measure LD across the region. It is not
possible to do this with the AS DNA panel because the number of chromosomes is
too few to be reliable. This was supported by the fact that the complete LD seen
between some of the SNPs on the AS panel was not observed in the Phase I control
population (inferred from the differences in allele frequency of the SNPs). Pairwise
LD between the nine SNPs suggested the presence of two blocks (SNPs
c 1221917_10 to ih31 and ih34 to C_1221895_10), in which D' values within the
blocks (> 0.64) exceeded the D' value between the blocks (0.37). Therefore, this
suggests that the intervening region between SNPs ib.31 and ih34 has not been
covered in terms of the LD observed, and further association analysis might want to
be undertaken.
The results of the Chi-square test of SNP 8 on the Phase II sample did not find an
association between this SNP and psychiatric illness. Using a high p-value cut off
(p<0.2) for Phase I means that a large number of false positives would be expected
(20%). The lack of association in SNPs apparently in LD with SNP 8 and the lack of
replication of the Phase I finding in the larger Phase II population, suggests that the
positive association of SNP 8 to schizophrenia was a false positive. A 20% false
positive rate for nine SNPs would mean that 1.8 positive associations would be
expected by chance. Therefore, one positive association cannot be considered
unexpected.
An interesting haplotype was observed in family 22 between SNPs 11 and 23. The
minor allele of SNP 22 was extremely rare (4.4%) and the minor alleles of the
remaining 12 were moderately rare (11.4%) in the AS panel. There are two
interesting things about this region. Firstly, it is a highly polymorphic region, with 12
SNPs in just over 1 kb. Secondly, the minor allele was observed only in F22, and
only two haplotypes were observed. One haplotype is composed of the rare alleles
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and the second haplotype is composed of the common alleles. The small distance and
the presence of only two haplotypes suggests that they are so tightly in LD that they
are never separated by a recombination event, but also that they occurred together in
one founding individual. However, it might simply be that the AS panel does not
contain enough chromosomes to sample all possible haplotypes. Evidence for this
comes from the association study results. As mentioned previously, the fact that the
Phase I sample consists of unrelated individuals means that haplotypes can only be
inferred. However, the finding that the minor allele frequency of a subset of SNPs
from the 12-SNP haplotype are different, suggests that more than two haplotypes
exist in this larger population. Since a positive association was not identified between
any SNPs in this haplotype and schizophrenia or BPAD in Phase I, the haplotype was
not studied further.
In summary, the results of genetic analysis ofGPR78 in the four families did not
reveal a mutation that would unambiguously alter the function of the protein and
contribute to psychiatric illness. However, the amino acid change caused by SNP
ih34 is interesting because it is rare, located on the disease haplotype of F22, and
abolishes a predicted intracellular protein kinase C phosphorylation site. However,
the lack of a positive association between SNPs in the gene and psychiatric illness










This thesis describes the genetic analysis of candidate regions implicated in the
susceptibility to psychiatric illness. Linkage in four families has previously identified
a region of chromosome 4p linked to psychiatric illness. The focus of this thesis has
been on MR1 and MR2, two candidate sub-regions within the linkage region. I have
successfully refined the recombination breakpoint intervals ofMR1. The refinement
of the telomeric end ofMR1 was aided by the positioning of four BAC clones in this
region. I have also carried out analysis to identify novel genes within MR1 and MR2,
and analysed two candidate genes for association to psychiatric illness.
It has become accepted that the identification of disease genes in complex disorders
such as psychiatric illness will require the implementation of a number of
complimentary approaches (Evans et al, 2001b). This reflects the approach taken
here.
8.2. Families
The results of linkage analysis in four families have been used to guide the work
done here. There are a number of advantages of studying large families to identify
genes in complex disease. A single gene ofmajor effect is more likely to underlie the
cause and should be common to the majority of affected members (Blackwood et al,
2001). The advantage of studying multiple linked families is that they allow the
determination of a common shared haplotype between the families. However,
reduced pentrance means that the disease susceptibility variant will also be present in
family members without the illness.
A possible caveat of studying large families with relatively high disease penetrance
is that the causative variant could be rare and may not generalise to the population of
patients. However, even if this is the case, the identification of susceptibility genes
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may highlight cellular pathways involved in the pathophysiology of psychiatric
illness, and thus identify further candidate genes. Another caveat is that there may be
more than a single gene operating in single families via mechanisms of genetic
heterogeneity or assortative mating, where multiple genes are inherited from both
parents (Blackwood et al, 2001). In these four families, the presence of only one
disease associated haplotype, inherited from only one side of the family, makes
assortative mating unlikely. Furthermore, genetic heterogeneity, at least in F22,
ought to be limited. The genetic effect of the disease associated haplotype in F22 is
large. Using the data from Blackwood et al (1996), there are 95 individuals in F22
for which the haplotype data (ascertained or inferred) and diagnostic status are
known. In these 95 family members, the disease associated haplotype occurs in
100% ofBPAD patients, 87.5% ofRMD patients and 22% of the remaining non-
affected family members. Therefore most of the genetic liability in this family is
likely to come from this one genetic locus. It is, however, more difficult to make this
kind of assumption about the smaller families.
8.3. Minimal Region One
8.3.1. Minimal Region One Contig
In order to study the linked regions in the future for genes and association, it is
necessary to have the continuous sequence of the region. The production of high
quality human genome sequence is of considerable value to the mapping of complex
disease genes. The complete sequence not only lends itself to gene identification, but
has also led to large scale projects to facilitate the identification of the variants
underlying complex disease. For example, the efforts of dbSNP and the SNP
consortium to identify SNPs in the human genome, and of the HapMap, which aims
to characterise patterns ofLD between SNPs and identify 'tagSNPs' that capture
haplotype diversity, aim to provide the tools necessary for researchers to design and
implement the appropriate study.
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The complete human sequence at both Ensembl and the UCSC Golden Path were
published in July 2003. The Sanger Institute, the curators of the Ensembl genome
database, reports that 93.22% of the genome has been sequenced, of which 88.99% is
finished, whilst the international human genome sequencing committee (IHGSC),
curators of the UCSC Golden Path genome database, reports that 99% of gene
containing regions have been sequenced. However, the quality of the draft sequence
across the genome has been variable during its production, and even with the
announcement of the finished product, gaps and inconsistencies are still evident. This
was observed with the STS stl75378snp (Section 3.3.2). Whilst it amplified a region
of chromosome 15, it did not produce a match to any chromosome 15 clone after a
BLASTn similarity search.
One of the gaps in the genome sequence lies within MR1, the minimal region formed
by the overlapping disease haplotypes of families 22, 59 and 50. A contig gap within
the recombination breakpoint interval ofMR1 is flanked on one side by a region of
low representation in genomic libraries, and on the other side by a region of highly
repetitive sequence. The contig flanking the gap on the repetitive side has been
highly unstable in previous releases of the UCSC Golden Path. It is preferable for our
purposes to have unequivocal evidence for clone position. Bioinformatic alignment
alone does not prove that two clones overlap, since it is not possible to rule out
sequencing or clone labelling errors, or the alignment of repetitive clones from
different chromosomal regions. The HGP is a large scale project that does not carry
out detailed manual curation of the data, therefore making such errors more likely
than the small scale work undertaken here. The colony PCR results described in
Chapter three provided an extra layer of analysis to the HGP.
Positioning novel clones in the gap, and eventually closing the gap is a continuing
aim of the project. It is important to understand the genomic landscape in this region,
since it is within or around just such repetitive regions that chromosomal duplication,
deletions or rearrangements are predicted to occur and that might affect gene
expression or function (Cheung et al, 2003). The region will also be a source of
novel SNP and microsatellite markers to refine the telomeric end of MR1. The
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refinement of the recombination breakpoint interval is important in order to rule out
genes from MR1, and novel markers are required to do this. Furthermore, the region
may be a source of novel genes.
The predicted repetitive nature of the intervening sequence in the gap might be one
reason that has precluded its identification, or its inclusion into a BAC in the
genomic libraries, and contributed to the variability of the HGP contigs. The
evidence for low copy number of the clones immediately telomeric to the gap might
be further evidence of this. The possibility of using the chromosome 4 specific repeat
sequence to probe BAC libraries has not been investigated and might prove
worthwhile. However, several copies of the tandem repeat has also been identified on
chromosome 8p (Gondo et al, 1998).
Using the Golden Path, it is possible to obtain clones for which the sequence is not
yet finished and/or which cannot be placed with certainty at a specific position on the
chromosome (http://genome.ucsc.edu/goldenPath/hgl6/chromosomes/). It is likely
that the reason they have not been positioned is because they are repetitive or that
they are under represented in libraries. A future experiment may be to inspect these
clones on an individual basis to design specific STSs to test whether any of them
map to this region ofMR1.
8.3.2. Minimal Region One Recombination Breakpoints
Typing SNP and microsatellite markers in the families enabled the successful
refinement of both recombination breakpoint intervals ofMR1 (Chapter 4).
However, the resolution was not sufficient to rule in or out two candidate genes from
the telomeric end ofMR1. Since candidate genes cannot be identified by function
alone, and association analysis is required to analyse MR1 further, ruling genes out
ofMR1 is desirable to reduce the future work load. Therefore, future work should




Refinement of the telomeric recombination breakpoint of MR1 was precluded by an
extensive region of homozygosity in the transmitting parent F50-3. This highlights a
problem with this type of experiment; the fact that you are relying on chance to
identify heterozygosity in parents transmitting the recombination breakpoint.
Furthermore, recombination breakpoint mapping relies on random recombination
events around the disease gene and since recombination only occurs at meiosis and
once or rarely twice per chromosome per generation, the disease locus identified by
recombinants is likely to be large.
Combining data from four families effectively increases the number of meioses and
the chance of recombination events defining a smaller disease gene region. However,
the fact that the four families show linkage to the same chromosomal region is
encouraging but is not evidence that they share the same ancestry or disease gene. If
the same gene and the same variant underlie the susceptibility in the families, the
variant might have arisen in a single, relatively recent, common ancestor, (e.g. with
the Celtic families) meaning that some or all of the families will share a common
haplotype around this variant. Alternatively, the hypothetical common ancestor
might be sufficiently far back in evolutionary time that recombination has degraded
the surrounding haplotype (they will be the same within the LD block that the variant
is in but this will be a substantially smaller region). A further scenario would be
where the same variant arose independently in different ancestors (convergent
evolution) or different variants arose in the same gene in different ancestors (allelic
heterogeneity). Convergent evolution or allelic heterogeneity could have arisen on
the same background haplotype (if this background haplotype is older than the
variants), or different background haplotypes.
The highly significant Lod score obtained in F22 defines a region that is extremely
likely to contain a susceptibility variant for psychiatric illness. The Lod score in F48
is also significant and, used in conjunction with the region defined by F22, defines a
smaller overlapping linkage region. However, allelic heterogeneity might still
operate. The Lod scores obtained in the two small families, F50 and F59, are much
more likely to be spurious, but, if they are real, allelic heterogeneity is still a
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possibility. Therefore, the use of families 48, 50 and 59 should be viewed as a way of
prioritising the search for a functional susceptibility variant in F22, rather than
searching exclusively for a common susceptibility variant in the four families.
A project such as this cannot rely on using linkage and recombination breakpoint
mapping alone to identify the candidate gene and the susceptibility variant to a
complex disorder. It simply does not produce the desired resolution and other
complimentary approaches are needed. The refinement of linkage regions is really
just the beginning of the process for the identification of the disease gene.
8.4. Allele Sharing
Analysis of the family haplotypes in the genie regions provides a complimentary
approach for narrowing down this large linkage region and SNPs were identified
from members of the four families with this aim. The AS panel was constructed to
have enough control chromosomes to compare the frequency of allele sharing
between the families compared to controls. A region of increased haplotype sharing
would support the common ancestor hypothesis. If this concurred with the results of
association analysis then this would provide compelling evidence for the
identification of the susceptibility region. However, the marker haplotypes are
currently biased by the focus of SNP discovery in coding and regulatory regions and
by the natural uneven spread of those SNPs that are identified within these regions.
Within a gene this is not so much of a problem, but between all genes within MR1
and MR2 this results in vast regions of 'empty' space.
Allele sharing was not observed in GPR78 or SOD3, as measured by the Fishers
exact test on a marker-by-marker basis (Sections 6.3.2 and 7.3.2). An alternative
application of the Fishers exact test would be to study the allele frequency of a
sliding window of two or more marker haplotypes since this may be more
informative than marker alleles alone. For example, it has been seen that the
association observed between a haplotype in the NRG1 gene and schizophrenia is not
observed for each of the individual alleles that comprise the haplotype (Stefansson et
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al, 2002). The analysis of haplotype sharing across the whole extent ofMR1 and
MR2 is a worthwhile future task and highlights the advantage of this project by being
able to study several families that show linkage to the same region.
8.5. Identification of Genes
Without the HGP, the task of identifying the disease gene operating in these families
would be significantly harder. It is vital to have a map of all the genes in the linked
region since any one of them might harbour the disease variant and the production of
finished human sequence is a critical component to the identification of genes. The
current release of Ensembl (version 19.34b.2) reports the identification of 31,609
gene transcripts. It is unknown what the final gene count will be, but the early
estimates of 100,000 have been curbed dramatically to the order of 30,000 or less
since the completion of the human genome (Claverie, 2001; Pennisi, 2003).
It is an important aim of the group to have a catalogue of all the genes within the
linked region. Abundantly expressed genes are readily identified due to the presence
of vast numbers of ESTs and other transcript evidence. The majority of currently
known genes constitute such abundant transcripts, for example, GPR125 in MR2.
However, it is more problematic to identify genes with low expression levels and/or
that are expressed at specific developmental time points or where expression is
restricted to specific spatial regions. An example of this is the identification of the
74M11 gene in MR1 (Section 5.6.2.1). This gene had limited EST evidence
supporting it and to only some of the exons. The 74M11 ESTs were not remarkably
different to others in MR1 for which RT-PCR or cDNA library screening has not yet
been performed. It is therefore entirely possible that other low level expressed genes
have been missed. Furthermore, there is no reason to suppose that these rare or
restricted genes are not of relevance for psychiatric illness.
To further complicate gene identification, some expression evidence is spurious. For
this reason it is necessary to be cautious when performing RT-PCR or library
screening based on a single line of evidence. A consensus ofmore than one line of
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evidence is preferable. The more genes that are identified, the more it will be
possible to learn about the characteristics that predict genes. However, this highlights
the circularity of gene prediction, since prediction methods can only be based upon
the known characteristics of confirmed genes.
Most of the results from RT-PCR and library screening were negative (Sections
5.5.1.6 and 5.5.2.2). This could be because the transcript evidence is spurious, but it
could also be due to assay failure. It is difficult to draw definite conclusions from a
negative result. A significant proportion of the RT-PCR assays were optimised
before screening and therefore negative results are more likely to reflect an absence
of expression. However, the library screening assays were also optimised before
screening, but this did not preclude vast numbers of non-specific products being
amplified. Despite this, the importance of prior optimisation can be seen with the
RT-PCR attempted in order to extend the GPR125 transcript (Section 5.6.2.2). RT-
PCR failed to link the first five exons with the last 14 exons, despite the fact that
others subsequently published confirmation of the link in the UCSC Golden Path.
Despite an optimal assay, a negative result can always be attributed to the rarity of
the transcript, as mentioned above. Attempts to address this were made by the use of
universal cDNA (Clontech), a mixture of 37 human tissues to provide a wide range
of cDNAs, in addition to the lymphoblastoid cDNA extracted inhouse.
A number of alternative techniques might be employed for future transcript mapping.
5' RACE (rapid amplification of cDNA ends), and other cDNA based techniques,
would be subject to the same limitations as RT-PCR and cDNA library screening.
Northern blotting would provide an alternative method for transcript verification and
would also immediately identify the size of the transcript and give an idea of the
existence of alternative transcripts. However, this would be relatively time
consuming and costly to apply to large regions such as these. Real time PCR would
be a good method for detecting genes with low expression levels. However, this
would depend on the availability of human tissue, or the identification of the
homologue in other species. An interesting transcript identification technique
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described by Li et al (2004a) involved the construction of a microarray using short
segments of genomic sequence that represented the chromosome 4q22-24 region.
The genomic sequence is then used to identify novel genes from mRNA. This would
provide a possible way to identify rare transcripts or genes with a structure that
would not normally be predicted by prediction programmes.
For the purposes of this study, it is vital to have a complete transcript map of the
candidate region in order to be able to direct and interpret future association analysis.
There are advantages in the level of individual inspection of the transcript evidence
that is possible from working as an individual experimenter. However, with the
advent of the finished genome sequence, there are a number of large scale gene
identification projects underway, for example Ota et al (2004) that may provide
valuable data for this and other projects. Such large scale approaches might also
dissuade the individual from carrying out the work his- or herself. However, in the
same way that the production of the genome sequence, in the absence of detailed
examination of the sequence assemblies, leads to errors, not every gene will be
captured in a high throughput project and individual inspection of the region might
still be productive.
The identification of genes is not trivial and will remain a challenge in the future.
However, it is an essential endeavour for the aim of the project and for other groups
attempting to identify susceptibility variants in complex disorders. It is interesting to
wonder, from the point of view of the HGP, whether one can ever be sure that every
human gene has been identified.
8.6. Identification of Association
Association studies were used here as another approach to narrow down the large
regions of linkage in the families. SNPs were identified in the families to ensure that
they were relevant to the population, and were identified around the coding and
regulatory regions of known genes. Based on position and function, two candidate
genes were studied for association.
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DNA pooling has been suggested to be a powerful tool to reduce the time and cost
involved with the large scale genotyping required to detect variants with small to
moderate effect size in common complex diseases (Shaw et al, 1998; Daniels et al,
1998; Breen et al, 1999; Sham et al, 2002). Allele frequency estimation of SNPs is
not significantly affected by genotyping technique (SNaPshot™ or primer extension
measured with dHPLC or mass spectrometry), DNA pool size and the natural
unequal amplification that occurs for a SNP is not affected by the allele frequency in
a pool (LeHellard et al, 2002). However, the biggest disadvantage, not discussed in
most papers, is their lack of flexibility. This was seen in this study when it was
identified that the pools contained a number of sample ID errors (Section 6.4.6).
Simple human error, where samples of the wrong diagnosis were included in the
pool, could have been avoided by better methods of sample labelling, for example
barcoding. However, the pools also contained individuals where the diagnoses
changed over time. This type of error cannot be planned for, and is unfortunately not
unusual in psychiatric illness. A second limitation ofDNA pooling is the inability to
construct haplotypes, although there are a number of programmes available that can
estimate them. The decreasing price of individual genotyping meant that it was
considered more reliable to perform association studies on individuals.
Association analysis on individuals was divided into two phases. The smaller Phase I
population aimed to calculate association but also to identify LD between SNPs.
Based on this, a non-redundant set of SNPs that are associated with psychiatric
illness and that represent LD blocks can be chosen for Phase II. A relaxed threshold
for significance aimed to capture all true association in the small sample, accepting
that a greater number of false positives will also be taken through. The importance of
LD in association analysis is two fold. Firstly, it is a way of reducing marker
redundancy and secondly, it ensures that the gene has been adequately covered. The
rationale of the two phases was based on a set of power calculations performed by
Dr. Naomi Wray. However, these power calculations assume that the causal SNP is
being studied, and therefore, the power reduces if it is not.
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Consequently, splitting association analysis into two phases saves time and money,
an important consideration in large projects such as this. Association analysis of two
genes, SOD3 and GPR78, involving a total of 38 markers, involved a great deal of
time and effort. Genotyping this entire set on the Phase I and Phase II sample
combined would be costly, especially if every gene known in MR1 and MR2
(currently 23) is to be tested in a similar manner. In the future, a several tiered
approach seems sensible, where regions within MR1 and MR2 that show positive
association are followed up with a higher density ofmarkers to cover LD more
adequately and confirm results.
The results of the phase I and II association studies on two genes in the minimal
regions, SOD3 (Section 6.5.4) and GPR78 (Sections 7.5.4 and 7.6.4), found that
there was no positive association between SNPs in the genes and psychiatric illness.
However, the LD calculations suggested that neither gene fully covered all LD
blocks and future studies may want to test more SNPs in these genes.
8.7. Identifying the Causal Variant
A positive association between markers within or near a gene and psychiatric illness
is really only the first stage in the process of identifying the causal variant. A number
of factors could complicate the implementation and interpretation of association
analysis in the future for the group. This is mainly because an associated SNP is not
likely to be the causative SNP itself, making the identification of the disease variant
more difficult. Alternative splicing, the mechanism by which protein diversity is
increased, is a highly complex and poorly understood process (Caceres and
Kornblihtt, 2002; Cartegni et al, 2002). Alteration in splicing machinery has been
shown to operate in human disease, such as in cancer and cystic fibrosis, resulting in
changes in the relative levels of alternative spliced isoforms (Nissim-Rafinia and
Kerem, 2002). These types ofmutation are harder to identify by sequence analysis.
The search for disease genes has traditionally centred on identifying differences in
protein sequence. Here I analysed the potential effects of the SNPs in SOD3 (Section
6.3.1) and GPR78 (Section 7.3.1) which resulted in an altered protein sequence.
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However, the causative variant in psychiatric illness is likely to cause subtle
alterations in protein function, as exhibited by amino acid substitutions that have
non-significant impact on protein function as assessed by conventional programmes,
or by subtle effects on splicing or promoter machinery.
Epigenetic factors are heritable changes in the methylation status of genes and the
structure and methylation, phosphorylation, acetylation, ubiquitination and ADP-
ribosylation status of chromatin that affect gene expression, but do not involve a
change in DNA sequence (Nakao, 2001). The differential expression of paternal and
maternal genes by the mechanism of CpG methylation is thought to be important for
the regulation of reproduction, placentation, energy homeostasis, lactation and
behaviour (Surani, 2001). In psychiatric illness, there is some evidence from linkage
and association studies for epigenetic control of inheritance, such as paternal or
maternal inheritance or evidence for the effects of imprinting on gene expression
(Petronis, 2000). Such effects would mean that an association might be missed. For
example, it might be necessary to characterise differential expression of imprinted
alleles when interpreting the results of allelic association studies. Sex differences
were not analysed here and might be worth considering for future analysis if no
association is found in the minimal regions. This is another reason why performing
association analysis on individuals rather than pools is perhaps preferable. At the
beginning of a study, it is not necessarily possible to account for all the ways a case
sample is to be divided up and analysed in the future.
The premise of this work assumes that the causal variant lies within or near a gene in
this region of chromosome 4p and that the variant affects this genes functioning.
However, long distance gene regulation has been identified in vertebrates (Kluppel et
al, 1997) and, therefore, it is possible that a causal variant a considerable distance
away in a different part of the genome regulates a gene in the chromosome 4p region,






Association studies and haplotype analysis are currently being performed on all the
known genes in MR1 and MR2, and MR1 and MR2 wide haplotype and LD maps
are being constructed as a result. However, SNP discovery is focused on genes and
the genes are unevenly spaced and therefore there will be an uneven coverage of
markers across these regions. It might be that a variant affecting gene expression or
function operates a large distance away from the gene. In this situation, analysis of
the intergenic regions would be desirable.
The public HapMap project (www.hapmap.org/) has recently published the results of
its measurements of LD across the genome (March 2004). Using the SNPs that make
up the HapMap across MR1 and MR2, 442 SNPs would be required to capture all
haplotypes with a frequency of greater than 10%, or 271 SNPs would be required to
represent one SNP per haplotype block (S. Le Hellard, personal communication). In
order to minimise the cost of sequencing intergenic regions in the families, the
HapMap will be useful in the future in order to close LD gaps formed after SNP
discovery in the families and genotyping in the phase I population.
Biochemical approaches will be the next step in testing for altered gene function in
affected versus non-affected family members. As mentioned previously, association
studies in themselves will not necessarily identify the causative variant and the
causative variant will not necessarily be obvious. Furthermore, an area of association
may not be identified at all. Therefore, complimentary methods for identifying the
causative polymorphism form an important adjunct to association analysis.
Protein and RNA expression profiling by microarray is becoming a popular
technique in complex diseases (Bunney et al, 2003), and could be considered in the
future for this project. The microarray assay is able to reflect the complexity of the
disease process by identifying multiple differences in a hypothesis free manner. This
technology could be utilised to detect a difference in the protein expression profiles
of disease haplotype and non-disease haplotype carriers in the four families. The
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ultimate aim would be to identify differential expression of a protein that resides in
one of the minimal regions, or that functions in the same cellular pathway as a
protein in one of the minimal regions. If the results of protein expression profiling
point to the same genomic region as the results of association and/or haplotype
analysis, this would provide compelling evidence for the location of the
susceptibility gene.
Other protein expression profiling techniques that could be used include mass
spectrometry using SELDI-TOF or MALDI-TOF. In a similar way to microarrays,
they identify differences in protein expression on the basis of protein mass rather
than mRNA or protein sequence, in a hypothesis free manner.
The ultimate aim of the association analyses and/or protein or mRNA expression
profiling will be to highlight sub-regions or individual genes within MR 1 and MR2
that are associated with psychiatric illness. Hypothesis driven biochemical analysis
of particular candidate genes could then provide information about altered protein
function in affected and non-affecteds. For example, quantitative RT-PCR in patients
versus controls would provide information on relative protein expression levels,
whereas quantitative RT-PCR in mouse tissue at different developmental time points
would provide information on developmental expression. In situ hybridisation or
immunohistichemistry in mouse or human post-mortem samples could highlight the
regional distribution of the mRNA or protein. Therefore, a whole array of future
experiments will become possible as association and haplotype analysis proceed.
8.9. Findings Genes in Psychiatric Illness
Identifying genes in psychiatric illness is proving quite difficult. This is due to the
problems discussed concerning the application of linkage and association analyses to
complex disorders and the problem of extracting the real data from the false positives
and false negatives (Merikangas and Risch, 2003).
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This group is well positioned to identify the causal variant or variants on
chromosome 4p predisposing to psychiatric illness in these families. The linkage
findings are convincing and have been replicated. However, considerable effort is
required in the future to continue with haplotype refinement, continue the search for
allele sharing between the families and implement association and functional
analyses across the entire region in order to pinpoint the gene involved. This is not
trivial, and puts other research groups without the advantages of strong linkage
families and the availability of large association populations at a distinct
disadvantage. The emerging picture from this research is the importance of the use of
complimentary techniques and the convergence of data and evidence. An exciting
future prospect is the convergence of association and functional evidence to a gene or
genes within one of the minimal linkage regions.
There is much work left to be done, but these are exciting times for psychiatric
genetics. The accumulation of linkage, association and haplotype data is beginning to
appear for certain candidate genes, for example NRG1 on chromosome 8 (Collier
and Li, 2003). It won't be long before this group is in a similar position. As candidate
genes become well established and confirmed and even susceptibility variants are
identified, it is possible to envisage an explosion of findings in the field with the
consistent implication of biochemical pathways and as methodologies become
refined.
8.10. Conclusions
In conclusion, the work carried out here has contributed to the refinement of linkage
regions for psychiatric illness on chromosome 4p, contributed to the identification of
novel genes in these regions and analysed two positional and functional candidate
genes for allele sharing in the families and association in a population of unrelated
cases and controls. Whilst no positive association was identified, this has contributed
to the analysis of the entire minimal regions, which contain a number of other
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Appendix 1
Appendix I: Primer Sequences
Primer Sequences
The following tables detail the STSs used in each chapter with their primer
sequences, the resultant STS size, the optimal PCR cycling annealing temperature,
the optimal PCR buffer, the additives included in the PCR and any further comments.
PCR cycling that utilised the touch down technique is prefixed 'TD\ PCR cycling of

































































































































































































































































































Chapter 5 cDNA library screening
Primer Sequences
224 cgaatcgtaaccgttcgtacgagaatcgct


















































































St106M4pt40 CTTGGCTGTGTTTTCCTTCG 543 TD50
312

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix IV Phase I and II Raw Data
Appendix IV: Raw Data of the Phase I and Phase II
Association Study
SOD3
Raw data for four SNPs tested in Phase I (1: C-2669721_10, 2: 2536512, 3:
rs2855262, 4: 2324580). Table shows sex (0: unknown, 1: male, 2: female),
diagnosis (0: control, 1: BPAD, 2: SCZ) and genotype (1: A, 2: C, 3: G, 4: T) of each
chromosome (a or b).
Sample Sex Diag 1a 1b 2a 2b 3a 3b 4a 4b
413 0 0 2 2 3 3 2 2 2 2
424 0 0 1 1 1 1 4 4 2 2
428 0 0 1 2 1 3 4 4 2 2
431 0 0 1 1 1 3 4 4 2 2
433 0 0 1 1 1 3 2 4 2 2
444 0 0 1 2 1 3 2 4 2 4
445 0 0 1 2 1 3 4 4 2 2
447 0 0 1 1 1 1 4 4 2 2
450 0 0 1 1 1 1 4 4 2 2
452 0 0 1 2 1 3 4 4 2 2
456 0 0 1 1 1 1 4 4 2 2
457 0 0 1 1 1 1 4 4 2 2
458 0 0 1 1 1 1 4 4 2 2
459 0 0 1 1 1 1 4 4 2 2
460 0 0 1 2 1 3 2 2 2 2
461 0 0 1 2 3 2 4 2 2
462 0 0 1 1 1 1 4 4 2 2
464 0 0 1 2 1 3 2 4 2 4
465 0 0 1 1 1 1 4 4 2 2
467 0 0 1 2 1 3 2 4 2 2
472 0 0 2 3 2 4 2 2
485 0 0 1 1 1 1 4 4 2 2
486 0 0 1 2 1 1 4 4 2 2
487 0 0 1 1 1 1 4 4 2 2
488 0 0 1 2 1 3 4 4 2 2
489 0 0 1 1 1 1 2 4 2 2
490 0 0 1 2 1 3 2 4 2 2
491 0 0 1 2 1 3 4 4 2 2
492 0 0 1 1 1 1 4 4 2 2
493 0 0 1 2 1 3 4 4 2 2
494 0 0 1 2 1 3 4 4 2 2
495 0 0 1 2 1 3 2 4 2 2
496 0 0 1 1 1 1 4 4 2 2
497 0 0 2 3 4 4 2 2
498 0 0 1 2 1 3 0 0 2 4
500 0 0 1 1 1 1 4 4 2 2
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501 0 0 1 2 1 3 4 4 2 2
502 0 0 1 2 3 3 4 4 4 4
503 0 0 1 1 1 1 2 4 2 4
504 0 0 1 2 1 3 4 4 2 4
505 0 0 1 2 1 3 4 4 2 2
506 0 0 1 1 1 1 4 4 2 4
521 0 0 1 1 1 1 4 4 2 2
531 0 0 1 2 1 1 2 4 2 2
532 0 0 2 3 4 4 2 4
533 0 0 1 2 1 3 0 0 2 2
535 0 0 1 1 1 1 0 0 2 4
536 0 0 2 0 4 4 2 2
537 0 0 1 1 1 1 4 4 2 2
545 0 0 1 1 1 1 2 4 2 2
554 0 0 1 2 1 1 4 4 2 4
556 0 0 1 2 1 3 2 4 2 2
561 0 0 1 2 1 3 2 4 2 2
570 0 0 1 1 1 3 4 4 2 4
572 0 0 1 1 1 1 4 4 2 4
580 0 0 1 1 1 1 4 4 2 2
587 0 0 2 0 4 4 2 2
588 0 0 1 1 1 1 4 4 2 2
591 0 0 1 1 1 3 4 4 2 2
592 0 0 1 1 1 1 2 4 2 2
595 0 0 1 2 3 2 4 2 2
598 0 0 1 1 1 1 4 4 2 2
599 0 0 1 2 1 3 4 4 2 2
600 0 0 1 1 1 1 4 4 2 2
603 0 0 1 1 1 1 2 4 2 2
604 0 0 1 2 1 3 4 4 2 2
607 0 0 1 1 1 1 4 4 2 2
610 0 0 1 1 1 1 4 4 2 2
613 0 0 1 2 1 3 4 4 2 2
615 0 0 1 1 1 1 4 4 2 2
616 0 0 1 1 1 1 4 4 2 2
618 0 0 1 1 1 1 4 4 2 2
619 0 0 1 1 1 3 2 4 2 2
621 0 0 1 1 1 3 2 4 2 2
622 0 0 1 2 1 3 2 4 2 2
624 0 0 2 3 2 4 2 4
625 0 0 2 3 2 4 2 2
627 0 0 1 2 1 1 4 4 2 2
633 0 0 1 2 1 1 0 0 2 2
634 0 0 1 1 1 1 0 0 2 2
635 0 0 2 1 3 2 4 2 4
639 0 0 1 2 1 3 0 0 2 2
640 0 0 1 2 1 3 0 0 2 2
641 0 0 1 1 1 1 4 4 2 2
644 0 0 1 1 1 1 4 4 2 2
645 0 0 1 2 1 3 4 4 2 2
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648 0 0 1 2 1 1 4 4 2 2
650 0 0 1 2 3 3 4 4 4 4
651 0 0 1 1 1 3 2 4 2 4
653 0 0 1 1 1 1 4 4 2 2
655 0 0 1 1 1 1 4 4 2 2
656 0 0 1 2 1 3 0 0 2 2
657 0 0 1 2 1 1 0 0 2 2
659 0 0 2 3 4 4 2 4
682 0 0 1 1 1 1 2 4 2 4
243 1 1 1 1 1 1 0 0 2 2
297 1 2 1 1 1 1 4 4 2 2
302 1 1 1 2 1 3 4 4 2 2
319 2 1 1 2 1 3 4 4 2 4
323 2 2 2 3 4 4 2 2
346 2 1 2 3 2 4 2 4
358 1 2 1 2 1 3 2 4 2 2
404 1 1 1 2 1 3 4 4 2 2
462 2 2 1 2 1 3 2 4 2 4
774 2 2 1 2 1 3 2 4 2 2
899 2 2 1 2 1 3 4 4 2 2
1080 1 2 1 2 1 3 2 2 2 2
1085 1 2 1 2 1 3 4 4 2 2
1190 2 1 1 1 1 1 4 4 2 2
1325 2 1 1 1 1 1 4 4 2 2
1326 1 1 1 1 0 4 4 2 2
1475 1 2 1 2 1 3 4 4 2 2
1548 1 1 1 1 1 1 2 4 2 2
1563 2 1 1 2 1 3 2 4 2 4
1567 1 1 1 1 1 1 4 4 2 2
1645 2 1 1 1 1 3 4 4 2 2
1646 1 2 1 2 0 4 4 2 2
1695 1 2 1 1 1 3 0 0 2 2
1705 2 1 1 1 1 1 0 0 2 4
1725 1 1 1 1 1 1 4 4 2 2
1758 2 1 1 2 1 1 4 4 2 4
1767 2 1 1 2 1 3 0 0 2 2
1780 1 2 2 3 4 4 2 2
1797 1 2 1 2 1 3 4 4 2 2
1961 1 2 1 1 1 3 2 2 2 2
2075 1 2 1 2 1 3 4 4 2 2
2086 1 2 1 1 1 1 4 4 2 2
2092 1 1 2 3 2 4 2 2
3000 2 1 1 2 1 3 4 4 2 2
3016 2 1 1 2 0 4 4 2 2
3042 2 1 1 2 1 3 4 4 2 2
3049 1 1 1 1 1 1 2 4 2 2
3071 1 2 1 2 1 3 4 4 2 2
3109 2 1 1 2 1 3 4 4 2 2
3133 1 1 1 2 1 3 4 4 2 2
3136 1 2 1 2 1 1 4 4 2 2
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3141 1 2 1 1 1 3 4 4 2 2
3150 2 1 1 2 1 3 2 4 2 4
3159 2 1 2 3 4 4 2 2
3162 1 1 2 3 4 4 2 4
3165 1 1 1 1 1 1 4 4 2 2
3183 2 1 1 1 1 1 4 4 2 2
3193 1 1 1 1 1 1 4 4 2 2
3194 1 1 1 1 1 2 4 2 2
3195 1 1 1 1 1 1 2 2 2 4
3196 2 1 1 1 0 4 4 2 2
3205 2 2 1 2 1 3 4 4 2 2
3206 1 2 1 1 1 1 4 4 2 2
3207 2 2 1 1 1 1 4 4 2 2
3208 1 2 1 2 1 3 4 4 2 2
3209 2 2 1 1 1 1 4 4 2 2
3223 2 1 1 2 1 1 2 4 2 2
3339 1 2 2 3 4 4 2 2
3340 2 2 1 2 1 3 2 4 2 2
3347 1 1 1 1 1 1 4 4 2 2
3389 2 1 1 1 1 1 2 4 2 2
3422 1 2 1 2 1 3 0 0 2 4
3435 2 1 2 3 2 4 2 2
3458 1 1 1 1 1 3 4 4 2 4
3467 2 1 1 2 1 3 4 4 2 4
3477 2 1 1 2 1 3 4 4 2 4
3489 2 1 1 1 1 1 4 4 2 2
3505 2 2 2 3 3 4 4 2 2
3537 1 2 2 1 3 4 4 2 4
3542 1 1 1 2 3 3 4 4 4 4
3545 1 2 1 2 3 3 4 4 2 2
3559 1 2 1 1 0 0 4 4 2 2
3570 1 1 2 0 0 4 4 2 2
3572 1 2 1 2 1 3 4 4 2 2
3581 1 2 1 1 1 1 4 4 2 2
3590 1 1 1 2 0 0 0 2 2
3594 1 2 1 1 1 1 2 4 2 2
3596 1 1 1 2 0 4 4 2 2
3622 1 2 1 2 1 3 2 4 2 4
3623 1 1 1 1 1 4 4 2 2
3639 1 1 1 2 1 3 4 4 2 2
3640 1 2 1 2 1 3 4 4 2 2
3647 1 2 1 2 1 3 4 4 2 2
3652 2 2 2 3 4 4 2 2
3655 2 1 1 1 1 1 4 4 2 2
3664 2 1 1 1 1 3 4 4 2 2
3684 2 1 1 1 1 1 4 4 2 2
3685 1 2 1 1 1 1 4 4 4 4
3695 2 1 1 1 1 1 4 4 2 2
3705 2 1 1 1 1 1 2 4 2 4
3742 1 2 1 1 1 1 4 4 2 2
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3743 1 2 1 2 1 3 4 4 2 2
3756 2 2 1 1 1 1 4 4 2 2
3766 1 2 1 1 1 1 4 4 2 2
3782 2 2 0 1 3 2 4 2 2
3783 1 2 1 1 1 1 2 4 2 4
3787 2 2 0 0 4 4 2 2
3791 2 2 1 1 1 1 4 4 2 2
3793 1 1 1 2 1 1 4 4 2 2
3800 1 2 1 1 1 3 2 4 2 4
3802 2 2 1 2 1 3 4 4 2 2
3805 1 2 1 2 1 3 4 4 2 4
3845 2 2 1 1 1 1 4 4 2 2
3867 1 1 2 3 4 4 2 2
3880 2 1 1 1 1 1 4 4 2 2
3889 1 2 1 2 1 3 2 4 2 2
3895 1 2 1 2 1 3 4 4 2 2
3900 1 1 1 1 0 4 4 2 2
3911 2 2 1 2 1 3 4 4 2 4
3918 2 1 2 0 2 4 2 2
3919 2 2 1 1 1 1 4 4 2 4
3920 2 1 1 1 1 1 4 4 2 2
3921 1 2 1 2 1 3 4 4 2 2
3938 1 1 1 1 1 1 2 4 2 4
3944 1 2 1 1 1 3 4 4 0 0
3945 2 2 1 2 1 1 4 4 2 4
3953 2 2 1 2 1 3 4 4 2 4
3969 1 2 1 1 1 1 2 4 2 2
4000 2 1 1 1 1 1 4 4 2 2
4008 1 2 1 2 1 3 2 4 2 2
4012 1 1 1 1 1 1 4 4 2 2
4018 2 1 1 1 1 3 4 4 2 4
4020 2 1 2 3 2 4 2 2
4042 2 2 1 2 1 3 2 4 2 2
4052 2 1 1 1 1 1 2 4 2 2
4058 1 2 1 2 1 3 0 0 2 2
4066 1 1 1 1 1 1 4 4 2 2
4067 1 1 1 2 1 3 4 4 2 2
4068 2 1 1 2 1 3 4 4 2 4
4101 1 2 1 2 1 1 2 4 2 4
4102 1 2 1 1 1 1 4 4 2 2
4106 1 2 1 2 1 1 2 2 2 2
4111 1 2 1 1 1 1 4 4 2 2
4112 2 2 1 1 1 1 4 4 2 2
4157 2 1 1 1 0 4 4 2 2
4171 2 1 1 1 1 1 4 4 2 4
4178 2 1 1 1 1 1 4 4 2 2
4179 1 2 1 2 1 3 2 4 2 2
4206 2 1 1 2 3 4 4 2 2
4277 2 1 1 2 1 3 4 4 2 2
4344 2 1 1 1 1 1 4 4 2 2
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4355 2 2 1 1 1 3 4 4 2 2
4358 2 1 1 2 1 3 2 4 2 2
4387 1 1 1 2 1 3 2 4 2 2
4403 1 1 1 2 1 3 2 4 2 2
4421 1 1 1 1 1 4 4 2 2
4424 1 2 1 1 1 1 2 4 2 2
4428 1 1 1 2 3 4 4 2 4
4441 1 2 1 2 1 3 4 4 2 2
4443 2 1 1 1 1 4 4 2 2
4460 1 2 1 2 1 1 4 4 2 2
4463 1 2 1 2 1 3 4 4 2 2
4512 1 2 1 1 1 1 2 4 2 2
4571 2 1 1 1 1 3 4 4 2 4
4577 2 1 1 2 0 4 4 2 2
4620 2 1 1 1 1 3 4 4 2 2
4622 2 1 1 2 1 3 4 4 2 2
4683 1 1 1 1 1 1 2 4 2 2
4694 1 2 1 2 1 3 2 4 2 2
4698 1 2 1 1 1 1 2 4 2 4
4706 1 2 1 1 1 1 4 4 2 2
4707 1 2 1 1 1 1 4 4 2 4
4710 1 2 1 1 1 1 2 4 2 4
4715 1 2 1 1 1 1 4 4 2 4
4716 1 2 1 1 0 2 4 2 2
4721 2 1 1 2 1 3 2 4 2 2
4731 2 2 2 3 2 2 2 2
4748 1 2 2 1 1 4 4 2 2
4753 2 1 1 1 0 4 4 2 2
4762 2 1 1 1 1 1 2 4 2 2
4775 1 1 2 3 4 4 2 2
4793 1 1 1 2 1 3 0 0 2 2
5302 2 1 1 2 1 3 4 4 2 2
5315 1 1 1 1 1 1 2 4 2 2
5337 2 2 1 1 1 1 4 4 2 2
5338 1 2 1 1 1 1 4 4 2 2
5350 1 2 1 1 3 2 4 2 4
5363 2 1 1 1 1 1 4 4 2 2
5367 1 2 1 1 3 4 4 2 4
5376 1 2 1 1 1 1 4 4 2 2
5379 1 2 1 1 1 1 2 4 2 4
5390 1 2 1 2 1 1 2 4 2 2
5423 1 1 1 1 0 4 4 2 4
5452 1 2 1 1 0 4 4 2 2
5463 1 1 1 2 1 3 4 4 2 2
5484 1 1 1 2 1 3 4 4 2 2
5487 1 2 1 2 0 0 4 4 2 4
6057 2 1 1 2 1 3 4 4 2 4
334
Appendix IV Phase I and II Raw Data
GPR78
Raw data for nine SNPs tested in Phase I (1: C_122191710, 2: C_11352300 30, 3:
ih63, 4: ih33, 5: ih31, 6: ih34, 7:ih40, 8: ih36, 9: C_1221895 10). Sa = sample
number. Se = sex. Codes are as previous table.
Sa Se D 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b 7a 7b 8a 8b 9a 9b
413 0 0 2 2 4 4 3 3 4 4 2 2 3 3 3 3 2 2 4 4
424 0 0 2 4 2 2 2 2 2 2 1 1 0 0 3 3 2 2 2 4
428 0 0 2 2 2 4 2 3 2 4 1 2 0 0 2 3 2 3 4 4
431 0 0 2 2 2 2 2 2 2 2 0 3 3 3 3 2 2 4 4
433 0 0 2 2 2 2 2 3 2 2 1 1 3 3 3 3 2 2 2 4
444 0 0 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
445 0 0 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
447 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
450 0 0 2 4 2 2 2 2 2 2 1 1 3 3 2 3 2 2 2 4
452 0 0 2 2 2 4 2 2 2 2 1 1 3 3 3 3 2 2 4 4
456 0 0 2 2 2 4 2 2 2 2 1 1 3 3 3 3 2 2 4 4
457 0 0 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
458 0 0 2 2 2 2 2 2 2 2 0 0 3 3 3 3 2 2 4 4
459 0 0 4 4 2 2 2 2 2 2 0 0 3 3 3 3 2 2 2 4
460 0 0 2 4 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
461 0 0 2 4 2 4 3 3 4 4 2 2 3 3 3 3 2 2 4 4
462 0 0 2 2 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
464 0 0 2 2 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
465 0 0 2 2 2 4 3 3 2 4 0 0 1 3 2 3 2 3 2 4
467 0 0 2 4 2 2 2 2 2 2 0 0 1 3 2 3 2 3 2 4
472 0 0 2 2 2 2 2 2 2 2 0 0 1 3 3 3 2 2 2 4
485 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 2
486 0 0 2 2 2 2 2 2 2 2 0 0 3 3 3 3 2 2 4 4
487 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
488 0 0 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
489 0 0 2 2 2 2 3 3 2 4 1 2 3 3 3 3 2 2 2 2
490 0 0 2 2 2 4 3 3 2 4 1 2 3 3 3 3 2 2 2 4
491 0 0 4 4 2 2 3 3 4 4 2 3 3 3 3 2 2 2 4
492 0 0 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
493 0 0 2 2 2 2 2 3 2 2 1 1 3 3 3 3 2 2 4 4
494 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
495 0 0 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
496 0 0 2 4 2 2 2 3 2 4 1 2 1 3 2 3 2 3 2 4
497 0 0 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
498 0 0 2 4 2 2 2 2 0 0 0 0 0 0 0 0 0 0 2 4
500 0 0 2 2 2 2 2 2 2 2 0 0 3 3 3 3 2 2 4 4
501 0 0 2 2 2 2 2 2 2 2 0 0 3 3 3 3 2 2 4 4
502 0 0 2 2 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 2
503 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
504 0 0 2 4 2 2 2 3 2 4 1 2 1 3 3 3 2 2 4 4
505 0 0 2 4 2 4 2 3 2 4 1 2 1 3 2 2 2 3 2 2
506 0 0 2 2 2 2 2 3 2 2 0 0 0 0 3 3 2 2 4 4
521 0 0 2 4 2 2 2 3 2 4 1 2 1 3 3 3 2 2 4 4
335
Appendix IV Phase I and II Raw Data
531 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
532 0 0 2 4 2 2 2 3 2 4 1 2 0 0 3 3 2 2 4 4
533 0 0 2 4 2 2 2 3 0 0 0 0 0 0 0 0 0 0 4 4
535 0 0 2 4 2 2 2 3 0 0 0 0 0 0 0 0 0 0 4 4
536 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
537 0 0 2 2 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
545 0 0 2 2 2 2 2 3 2 2 0 0 1 3 3 3 2 2 4 4
554 0 0 2 2 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
556 0 0 2 2 2 4 3 3 2 4 0 0 1 3 2 3 2 3 2 4
561 0 0 2 4 2 2 2 2 2 2 0 0 1 3 3 3 2 2 2 4
570 0 0 4 4 2 2 3 3 4 4 2 2 3 3 3 3 2 2 2 4
572 0 0 2 2 2 2 2 2 2 2 0 0 1 3 3 3 2 2 2 4
580 0 0 4 4 2 2 2 2 2 2 0 0 3 3 3 3 2 2 2 4
587 0 0 2 2 2 2 2 2 2 2 0 0 1 3 3 3 2 2 4 4
588 0 0 2 4 2 4 2 3 4 4 2 2 3 3 3 3 2 2 4 4
591 0 0 2 2 2 2 2 2 2 2 0 0 3 3 3 3 2 2 2 4
592 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 2
595 0 0 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
598 0 0 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
599 0 0 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
600 0 0 2 4 2 2 2 3 2 4 1 2 1 3 2 3 2 3 2 4
603 0 0 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 4
604 0 0 2 4 2 4 2 3 2 4 1 2 1 3 2 3 2 3 2 4
607 0 0 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 2
610 0 0 2 2 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
613 0 0 2 4 2 4 2 2 2 4 1 2 3 3 3 3 2 2 4 4
615 0 0 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
616 0 0 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
618 0 0 2 4 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 4
619 0 0 4 4 2 2 3 3 4 4 2 2 3 3 3 3 2 2 2 2
621 0 0 4 4 2 2 2 2 2 2 0 0 1 1 2 2 3 3 2 2
622 0 0 4 4 2 2 3 3 4 4 2 2 3 3 3 3 2 2 4 4
624 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
625 0 0 2 4 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 4
627 0 0 2 2 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 4
633 0 0 2 4 2 2 2 2 0 0 0 0 0 0 0 0 0 0 4 4
634 0 0 4 4 2 2 2 2 0 0 0 0 0 0 0 0 0 0 2 4
635 0 0 2 2 2 4 2 3 2 4 1 2 1 3 2 3 2 3 2 2
639 0 0 2 2 2 2 2 2 0 0 0 0 0 0 0 0 0 0 2 4
640 0 0 2 2 4 4 3 3 0 0 0 0 0 0 0 0 0 0 2 4
641 0 0 2 4 2 2 2 3 4 4 2 2 3 3 3 3 2 2 4 4
644 0 0 2 2 4 4 3 3 4 4 2 2 3 3 3 3 2 2 2 4
645 0 0 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
648 0 0 2 4 2 2 2 3 2 4 0 0 3 3 3 3 2 2 4 4
650 0 0 2 2 2 4 2 3 2 4 1 2 1 1 2 2 3 3 2 2
651 0 0 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
653 0 0 2 4 2 4 3 3 4 4 2 2 3 3 3 3 2 2 2 4
655 0 0 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
656 0 0 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 2 4
657 0 0 2 2 2 2 2 3 0 0 0 0 0 0 0 0 2 2 2 4
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659 0 0 2 2 2 2 2 3 2 4 0 0 3 3 3 3 2 2 4 4
682 0 0 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
243 1 1 2 4 2 2 2 3 0 0 1 2 3 3 3 3 2 2 4 4
297 1 2 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
302 1 1 2 4 2 2 2 3 2 4 0 3 3 3 3 2 2 4 4
319 2 1 2 2 2 4 2 3 2 4 0 3 3 3 3 2 2 2 4
323 2 2 2 2 2 2 2 2 2 2 1 2 3 3 3 3 2 2 2 4
346 2 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
358 1 2 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
404 1 1 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
462 2 2 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 2
774 2 2 2 4 2 2 3 3 2 4 1 2 3 3 2 3 2 2 2 2
899 2 2 2 4 2 2 3 3 4 4 2 3 3 3 3 2 2 2 4
1080 1 2 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
1085 1 2 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 4 4
1190 2 1 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
1325 2 1 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
1326 1 1 2 2 2 2 2 2 2 2 0 1 3 2 3 2 3 2 4
1475 1 2 2 4 2 2 2 3 2 2 1 1 0 0 3 3 2 2 2 4
1548 1 1 2 4 2 2 3 3 2 4 1 2 3 3 3 3 2 2 2 4
1563 2 1 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
1567 1 1 4 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
1645 2 1 4 4 2 2 2 3 2 4 1 2 1 3 2 3 2 3 2 2
1646 1 2 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
1695 1 2 4 4 2 2 2 2 2 2 1 1 1 3 3 3 2 2 4 4
1705 2 1 2 4 2 4 3 3 0 0 0 0 0 0 0 0 0 4 4
1725 1 1 2 2 2 4 2 3 2 4 1 2 1 3 2 3 2 3 2 2
1758 2 1 2 2 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
1767 2 1 2 4 2 4 2 3 0 0 0 0 0 0 0 0 0 4 4
1780 1 2 2 4 2 2 2 3 2 4 1 2 1 3 2 3 2 3 2 2
1797 1 2 2 4 2 2 3 3 4 4 2 3 3 3 3 2 2 4 4
1961 1 2 2 2 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
2075 1 2 0 0 2 4 3 3 4 4 2 3 3 3 3 2 2 4 4
2086 1 2 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 4
2092 1 1 2 2 2 2 2 2 2 2 0 1 3 2 3 2 3 2 2
3000 2 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3016 2 1 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3042 2 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
3049 1 1 2 4 0 0 3 3 2 4 1 2 3 3 3 3 2 2 4 4
3071 1 2 2 2 2 2 2 3 2 2 1 1 3 3 3 3 2 2 2 4
3109 2 1 2 2 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 2
3133 1 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
3136 1 2 2 2 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 4
3141 1 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3150 2 1 2 4 2 4 2 3 2 4 1 2 1 3 2 3 2 3 4 4
3159 2 1 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3162 1 1 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
3165 1 1 4 4 2 2 3 3 4 4 2 3 3 3 3 2 2 4 4
3183 2 1 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3193 1 1 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
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3194 1 2 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3195 1 1 2 2 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
3196 2 1 2 2 4 4 3 3 4 4 2 3 3 2 3 2 2 2 4
3205 2 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3206 1 2 2 2 2 4 2 3 2 4 1 2 1 3 2 3 2 3 2 4
3207 2 2 2 4 2 2 2 2 2 2 0 3 3 3 3 2 2 2 4
3208 1 2 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
3209 2 2 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3223 2 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
3339 1 2 4 4 2 2 3 3 4 4 2 3 3 3 3 2 2 4 4
3340 2 2 0 0 2 4 2 2 2 2 1 1 3 3 3 3 2 2 4 4
3347 1 1 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3389 2 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3422 1 2 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3435 2 1 2 2 2 4 3 3 2 4 1 2 1 3 2 3 0 0 2 4
3458 1 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3467 2 1 2 4 2 2 2 2 2 2 0 0 1 3 2 3 2 3 2 2
3477 2 1 2 2 2 4 2 3 2 4 0 0 3 3 3 3 2 2 4 4
3489 2 1 2 2 2 2 2 2 2 2 0 0 1 3 2 3 2 3 2 4
3505 2 2 2 2 2 4 2 3 2 4 1 2 0 0 3 3 2 2 4 4
3537 1 2 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3542 1 1 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3545 1 2 2 2 2 4 0 0 2 4 1 2 0 0 3 3 2 2 4 4
3559 1 2 2 4 2 2 3 3 4 4 2 2 3 3 3 3 2 2 4 4
3570 2 1 2 4 2 4 2 3 2 4 0 0 1 3 3 3 2 2 4 4
3572 1 2 4 4 2 2 3 3 4 4 2 2 3 3 3 3 2 2 4 4
3581 1 2 2 4 2 2 2 3 2 2 1 1 3 3 3 3 2 2 2 4
3590 1 1 2 2 2 4 0 0 0 0 0 0 0 0 0 0 0 0 2 4
3594 1 2 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3596 1 1 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3622 1 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3623 2 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3639 1 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3640 1 2 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 2
3647 1 2 2 2 2 2 2 3 2 4 1 2 1 3 2 3 2 3 2 4
3652 2 2 2 2 2 4 2 3 2 4 1 2 1 3 3 3 2 2 4 4
3655 2 1 2 2 2 4 3 3 4 4 2 2 3 3 3 3 2 2 4 4
3664 2 1 2 4 2 2 2 3 0 0 0 0 3 3 3 3 2 2 2 4
3684 2 1 2 2 4 4 3 3 4 4 2 2 3 3 3 3 2 2 4 4
3685 1 2 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
3695 2 1 2 2 2 4 2 3 4 4 2 2 3 3 3 3 2 2 4 4
3705 2 1 2 4 2 2 2 3 2 4 1 1 3 3 3 3 2 2 2 4
3742 1 2 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
3743 1 2 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
3756 2 2 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3766 1 2 2 4 2 2 2 2 2 2 1 1 1 3 3 3 2 2 4 4
3782 2 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3783 1 2 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 2
3787 2 2 0 0 0 0 2 2 2 2 1 1 1 3 3 3 2 2 0 0
3791 2 2 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
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3793 1 1 2 4 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3800 1 2 2 2 2 2 2 2 2 2 1 1 0 0 3 3 2 2 2 4
3802 2 2 2 2 2 2 2 2 2 2 1 1 1 3 3 3 2 2 4 4
3805 1 2 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 4 4
3845 2 2 2 4 2 4 2 2 2 2 1 1 3 3 3 3 0 0 2 4
3867 1 1 2 4 2 2 2 3 2 4 2 1 3 2 3 2 3 2 4
3880 2 1 2 4 2 2 2 2 2 2 1 1 0 0 3 3 2 2 2 4
3889 1 2 2 2 2 2 2 2 2 2 1 1 1 3 3 3 0 0 4 4
3895 1 2 2 2 2 2 3 3 4 4 2 3 3 3 3 2 2 2 4
3900 1 1 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 4 4
3911 2 2 4 4 2 2 2 3 2 4 1 2 3 3 3 3 0 0 4 4
3918 2 1 2 4 2 2 3 3 4 4 2 3 3 3 3 2 2 4 4
3919 2 2 2 4 2 4 0 0 2 4 1 2 0 0 3 3 2 2 2 4
3920 2 1 2 4 2 2 2 2 2 2 0 3 3 3 3 2 2 4 4
3921 1 2 2 4 2 2 2 2 2 2 1 1 1 3 3 3 2 2 4 4
3938 1 1 2 4 2 4 3 3 4 4 2 3 3 3 3 2 2 4 4
3944 1 2 2 2 2 2 2 3 2 4 1 2 1 3 2 3 2 3 4 4
3945 2 2 2 2 0 0 2 2 2 2 1 1 3 3 3 3 2 2 2 4
3953 2 2 2 4 2 2 2 2 2 2 0 3 3 3 3 2 2 2 2
3969 1 2 2 2 2 4 2 3 2 4 1 2 3 3 3 3 2 2 2 4
4000 2 1 2 4 2 2 2 2 2 2 1 1 0 0 3 3 2 2 2 2
4008 1 2 2 4 2 2 3 3 2 4 1 2 3 3 3 3 2 2 2 4
4012 1 1 2 4 2 2 2 3 2 2 1 1 1 3 2 3 2 3 2 4
4018 2 1 4 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
4020 2 1 2 2 2 2 3 3 4 4 2 3 3 3 3 2 2 4 4
4042 2 2 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4052 2 1 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
4058 1 2 2 4 2 2 0 0 0 0 0 0 0 3 3 0 0 2 4
4066 1 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
4067 1 1 2 4 4 4 3 3 4 4 2 3 3 3 3 2 2 4 4
4068 2 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4101 1 2 2 2 2 4 2 3 2 4 1 2 3 3 2 3 2 2 2 4
4102 1 2 2 2 2 2 2 3 2 2 1 1 3 3 3 3 2 2 4 4
4106 1 2 4 4 2 4 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4111 1 2 2 4 2 4 2 3 2 4 1 2 1 3 2 3 2 3 4 4
4112 2 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
4157 2 1 2 2 2 4 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4171 2 1 4 4 2 2 2 3 2 2 1 1 1 3 2 3 2 3 2 2
4178 2 1 2 4 2 2 2 2 2 2 1 1 0 0 3 3 2 2 2 4
4179 1 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4206 2 1 2 4 2 2 2 2 2 2 1 1 3 3 3 3 2 2 2 4
4277 2 1 2 2 2 2 0 0 2 2 1 1 0 0 3 3 2 2 2 4
4344 2 1 2 4 2 2 2 2 2 2 1 1 1 3 2 3 2 3 2 4
4355 2 2 4 2 2 3 3 2 4 1 2 3 3 3 3 2 2 2 4
4358 2 1 2 2 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
4387 1 1 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 2 4
4403 1 1 2 2 2 2 2 2 2 2 1 1 3 3 3 3 2 2 4 4
4421 2 1 2 4 2 2 2 3 2 2 1 1 0 0 2 3 2 3 2 4
4424 1 2 2 4 2 2 2 3 2 4 1 2 3 3 3 3 2 2 4 4
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